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ABSTRACT OF DISSERTATION 
ROLE OF PI3K-AKT PATHWAY IN THE AGE ASSOCIATED DECLINE IN TLR 
MEDIATED ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES 
Immunosenescence results in reduced immune response to infections with Streptococcus 
pneumoniae as well as to pneumococcal polysaccharide vaccines. The antibody response to the 
capsular polysaccharide (CPS) provides protection against S. pneumoniae infection. CPS 
immunoresponse is T cell independent and needs the macrophage-derived cytokines such as IL-
12, IL-6 and IL-1β to elicit an antibody response. We showed a cytokine dysregulation, i.e. a 
decrease in IL-12, IL-6 and TNF-α but an increase in IL-10, in the aged (18-24 months old 
comparable to >65 years in human) compared to young adult mouse (8-12 weeks less than 65 
years old) splenic macrophages (SM) or bone marrow derived macrophages (BMDM) activated 
via TLR4, TLR2 or TLR9 as well as heat killed Streptococcus pneumoniae (HKSP). There is 
also an age-associated defect in splenic B cells in the production of IgG3 upon stimulation with 
these ligands. A microarray analysis in SM followed by validation by both qt-RTPCR and 
western blots indicated that this age-associated defect in aged SM, BMDM and B cells was due 
to a heightened activity of the PI3K-Akt signaling pathway.  We hypothesized that the 
senescence of immune responses in macrophages and B cells is due to an increase in activity of 
PI3K/Akt and decrease in the activity of GSK-3, the downstream kinase. Inhibition of the PI3-
kinase with either LY294002 or Wortmannin restored the TLR2, 4, 9 and HKSP induced 
cytokine phenotype of the aged to that of the young adult in both the SM and BMDM and an 
enhanced IgG3 production in aged mice.   
We also showed that inhibition of glycogen synthase kinase-3 (GSK-3) the downstream 
target of the PI3K-Akt signaling pathway with SB216763 in SM, BMDM and B cells resulted in 
an enhancement in production of IL-10, IL-6 and IL-1β by macrophages and in B cell activation. 
Treatment of B cells with SB216763 in the presence of ligands for TLR-1/2, 4 or 9 as well as 
HKSP under in vitro conditions led to enhanced production of IgG3 and IgA, plasma cell 
formation and a slight increase in the proliferation of the B-cells with no adverse effects on the 
viability of the cells. Therefore, targeting the PI3K-AKT-GKS-3 signaling pathway could rescue 
the intrinsic signaling defect in the aged macrophages, increase IL-12 and IL-6, and enhance 
anti-CPS antibody responses.  
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                                                                                                                           Mosoka P. Fallah 
 
                                                                                                                              June 30, 2011                                                               
 
 
 
 
 
 
 
 
 
 
 
ROLE OF PI3K-AKT PATHWAY IN THE AGE ASSOCIATED DECLINE IN TLR 
MEDIATED ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES 
 
BY 
MOSOKA P. FALLAH 
 
                                                                                                 Subbarao Bondada, PhD 
                                                                                               Director of Dissertation 
 
                                                                             Beth Garvy 
                                                                                                       Director of Graduate Studies 
 
                                                                                               June 30, 2011 
                                                                                               Date 
 
 
 
 
 
RULES FOR USE THE OF DISSERTATIONS 
Unpublished dissertation submitted for the Doctor’s degree and deposited in the University of 
Kentucky Library are as a rule open for inspection, but are to be used only with due regard to the 
rights of the authors. Bibliographical references may be noted, but quotations or summaries of 
parts may be published only with the permission of the author, and with the usual scholarly 
acknowledgements. 
Extensive copying or publication of the dissertation in whole or in part also requires consent of 
the Dean of the Graduate School of the University of Kentucky. 
A library that borrows this dissertation for use by its patrons is expected to secure the signature 
of each user. 
Name                                                                                                                                          Date 
 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
 
 
 
 
 
DISSERTATION 
 
 
 
 
MOSOKA P. FALLAH 
 
 
 
 
The Graduate School 
University of Kentucky 
2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROLE OF PI3K-AKT PATHWAY IN THE AGE ASSOCIATED DECLINE IN TLR- 
MEDIATED ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES 
 
 
 
_______________________________ 
DISSERTATION 
_______________________________ 
 
 A dissertation submitted in partial fulfillment of the of the requirements for the  
degree of Doctor of Philosophy in the College of Medicine at the University of Kentucky  
 
By 
Mosoka Papa Fallah 
 
Lexington, Kentucky 
 
Director: Dr. Subbarao Bondada 
Professor of Microbiology, Immunology and Molecular Genetics 
 
Lexington, Kentucky 
2011 
Copyright © Mosoka Papa Fallah 
 
 
 
 
 
 
 
DEDICATION 
I dedicate this dissertation to my DEAR FATHER, MR. KAMANO FALLAH, who taught me and my 
siblings that education was a sure escape route from poverty. A few months ago he was struck with a 
massive stroke and became paralyzed and speechless back home in Liberia. He passed away on Father’s 
day, June 19, 2011. The memories of his desire to give us an education forever remains fresh in my heart. 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
The following dissertation, while an individual work benefited from insights and direction of 
several people. First, my dissertation Chair, Dr. Subbarao Bondada, provided guidance in my scientific 
development and taught me how far we can go if we push ourselves. He gave me an opportunity of a 
lifetime. He exemplified for me the virtue of a true scientist during my years with him and in guiding me 
through this dissertation. Next, I wish to thank my dissertation committee members, Dr. Charlotte 
Kaetzel, Dr. Beth Garvy, Dr. John D’Orazio and Dr. Charles Snow, who all contributed towards this stage 
of my career. I want to thank my outside reader, Dr. David Feola. 
I also want to thank our beloved department Chairman, Dr. Alan Kaplan for his tireless support. I 
want to thank Dr. Jane Harrison for all the moral support she provided over the years and Dr. Maria 
Bruno who helped me got started with the real time PCR. I benefited from the guidance of several past 
and present people in my laboratory, Dr. R. Lakshman Chelvarajan, Darrel Robertson, Diana Popa, Dr. 
Vishal Sindhava, Dr. Vikram Dasu, Michael Baker and Beth Gachuki.  
I want to thank Dr. Don Cohen for helping me with the L929 cell line; Dr. Francesc Marti for 
numerous antibodies; Drs. Anthony Sinai and Robert Geraghty for motivation to succeed in my scientific 
work. Also I want to thank Ms. Jennifer Strange and Dr. Greg Bauman from the FACS core facilities. 
Finally, I want to thank my friend, Dr. Christopher L. Tokpah, for helping me to come to the USA and 
explore opportunities. I want to thank others who supported me morally and/or financially, Jack and 
Angene Wilson, Dr. Jim Balz, Dr. Dougbeh Nyan, Ernest Frank, Andrew Stefka and Rachel Lewis. Last 
and personally, I want to thank my parents for helping me develop into the person that I became. I also 
want to thank my siblings for being there for me. 
 
 
iv 
 
TABLE OF CONTENTS 
Acknowledgments ......................................................................................................... iii 
List of Table ................................................................................................................. viii 
List of Figures ................................................................................................................ ix 
Chapter One: Literature review .................................................................................... 1 
 Immunosenescence ........................................................................................... 1 
 T cells and aging ....................................................................................... 2 
 B cells and aging ....................................................................................... 4 
 Age-associated bone marrow mediated defects affect  
 B cells in aging.......................................................................................... 6 
 Signaling mechanism governing the impaired humoral response in  
  the elderly...................................................................................... 7 
 The microenvironmental and intrinsic signaling defects in 
   bone marrow hematopoietic stem cells (HSC) affect B  
   lymphopoiesis ............................................................................... 8 
 Aging and dendritic cells .......................................................................... 9 
 Aging and Macrophages ...........................................................................9 
             Streptococcus pneumoniae as a model pathogen to study the effect of  
 aging to infection with gram positive bacteria ............................................... 11 
     History of S. pneumonia, infection and pneumococcal vaccine .............11 
 Ecology, Epidemiology and pathogenesis of S.pneumoniae ..................12 
 Epidemiology ..........................................................................................13 
 Invasive pneumococcal disease ..............................................................14 
 Risk factors for Invasive pneumococcal disease ....................................14 
 Cell Surface and virulence Factors and host defense ..............................14 
 Polysaccharide capsule ...........................................................................14 
 The cell wall ............................................................................................15 
 Lipoteichoic acid (LTA)  ........................................................................15 
 Phosphocholine .......................................................................................15 
v 
 
 Pneumolysin ............................................................................................15 
 Innate Immune response and Streptococcus pneumonia ................................15 
 Host Response to S. pneumonia ..............................................................15 
 Toll like receptors ...................................................................................16 
 TLR signaling .........................................................................................20 
 Role of TLR in mediating Immune response to S. pneumonia ...............21 
 Pro-inflammatory cytokines are critical for the clearance 
 of S. pneumonia ..........................................................................21 
 The adaptive immune response to S. pneumoniae, the role of B cells ...........25 
 T cell independent B cell mediated response to 
 capsular polysaccharides .............................................................26                         
 T cell dependent antibody response ........................................................27 
 Concept of signals 1 and 2 in the context of immune response 
  to PS from S. pneumonia ............................................................28 
 Antibiotics, success and failures in treating S. pneumoniae ...........................28 
 Evolution of polysaccharide vaccine as a viable and cost efficient  
 alternative to antibiotics .................................................................................32 
 The 23-valent capsular polysaccharide vaccine (PPSV23) ....................32 
 Immunological basis for the poor response of children less 
 than 2 years to the polysaccharide vaccine .................................33 
 Immunological basis for the impaired antibody response 
 of the elderly to PPS23 vaccine ..................................................34 
 The Shift to conjugate vaccine ................................................................ 35 
 The seven valent conjugate vaccine (PCV-7) ......................................... 35 
 The 13-valent conjugate vaccine ............................................................ 36 
 Prime boost effect of PCV-7 and PPS-23 ............................................... 37 
 Pneumococcal proteins as vaccine candidates ............................................... 37 
 Cytokines as a potential polysaccharide vaccine enhancing adjuvant ........... 39 
 Challenges with the use of exogenous cytokines .................................... 43 
 
vi 
 
 Endogenous enhancement of cytokines is a biologically relevant  
 alternative adjuvant ..................................................................... 43 
 Role of PI3K-AKT-GSK-3 signaling pathway in Macrophage  
 activation ........................................................................................................ 45 
 Role of PI3K-AKT in regulating B-cell activation ................................. 49 
 Role of GSK-3 in modulating B cell responses ...................................... 50 
 In vitro mouse model ...................................................................................... 53 
 
Chapter Two:  Methodology ........................................................................................ 55 
 
Chapter Three: Role of phosphoinositide 3-kinase – Akt signaling  
pathway in the age-related cytokine dysregulation in splenic macrophages 
stimulated via TLR2 or TLR- 4 receptors .................................................................. 64 
 Introduction .................................................................................................... 64 
 Results ............................................................................................................ 68 
 Discussion ...................................................................................................... 79 
 
Chapter Four: Intrinsic defect in the phosphoinositide 3-kinase – Akt  
pathway plays a role in cytokine dysregulation in aged  
macrophages stimulated with TLR  ligands or heat killed  
Streptococcus pneumoniae receptors ......................................................................... 100 
 Introduction .................................................................................................. 100 
 Results .......................................................................................................... 104 
 Discussion .................................................................................................... 110 
 
 
Chapter Five:  Novel role of glycogen synthase kinase-3 in secretion  
of IL-10 and Pro-inflammatory cytokines activated via TLR2 and  
TLR4 receptors ........................................................................................................... 125 
 Introduction .................................................................................................. 125 
vii 
 
 Results .......................................................................................................... 127 
 Discussion .................................................................................................... 131  
 
   
Chapter Six:  Role of PI3K-AKT-GSK-3 pathway in TLR induced  
B cell activation and differentiation .......................................................................... 146 
 Introduction .................................................................................................. 146 
 Results .......................................................................................................... 148 
 Discussion .................................................................................................... 155 
 
 
Chapter Seven: Overall conclusion and discussion ................................................. 174 
 
Appendices ................................................................................................................... 185 
Appendix A: Purity of splenic macrophages ................................................................ 185 
 
Appendix A: Abbreviations ........................................................................................ 186 
 
References .................................................................................................................... 188 
Vita ................................................................................................................................ 217 
 
 
 
 
 
 
 
 
 
viii 
 
 
 
 
 
LIST OF TABLES 
Table 1.1. Some Cytokines and their effects on modulating the humoral 
                         response to S.  Pneumoniea ................................................................... 38 
 
Table 5.1.  Inhibition of GSK-3 with SB216763 enhances both 
                         pro- and  anti-inflammatory cytokines in aged BMDM ...................... 132 
 
Table 5.2.   SB216763 upregulates both pro- and anti-inflammatory  
                        cytokines in young BMDM just like the aged BMDM ........................ 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
 
 
 
 
 
LIST OF FIGURES 
Figure 1.1 S. pneumoniae morphology displaying virulence factors ....................... 16 
Figure 1.2 The TLR signaling pathway.................................................................... 21 
Figure 1.3 Concept of signals 1 and 2 in the immune response to   
 S. pneumoniae ......................................................................................... 28 
Figure 1.4 The PI3K-Akt-GSK-3 signaling pathway in macrophages .................... 44 
Figure 1.5 The PI3K-Akt-GSK-3 signaling pathway in B cells............................... 48 
Figure 3.1 Age-associated changes in cytokine production and levels of PI3K 
 subunits in splenic macrophages stimulated via TLR-4 ......................... 82              
Figure 3.2 The age-associated increase in phosphorylation of AKT and  
 GSK-3 in TLR-4 stimulated macrophages ............................................. 83 
Figure 3.3 Age-associated increase in PI3K activity is not due to changes 
 in the levels of PTEN .............................................................................. 84 
Figure 3.4  TLR-2 and HKSP-mediated cytokine dysregulation in young and  
 aged splenic macrophages....................................................................... 85 
Figure 3.5  Age-related cytokine dysregulation in response to stimulation of  
 macrophages with TLR2 ligands ............................................................ 86 
Figure 3.6 Age-related increase in activation of AKT and GSK-3 in splenic  
 macrophages stimulated with TLR2 ligands........................................... 87 
Figure 3.7  PI3K inhibitors partially rescue the age-associated defect in  
 TLR-4 induced cytokine production by inhibiting phosphorylation  
 of Akt and GSK-3 ................................................................................... 89 
Figure 3.8  Cytokine dysregulation in aged splenic macrophages stimulated 
 with TLR2 ligands can be partially rescued by inhibiting PI3K ............ 90 
x 
 
Figure 3.9  The cytokine dysregulation in TLR1/2 stimulated aged  
 macrophages can also be reversed with PI3K inhibition ........................ 91 
Figure 3.10   The inhibition of PI3K by either LY294002 or wortmannin  
                         enhanced the HKSP-mediated induction of pro-inflammatory 
 cytokines in aged  splenic  macrophages ................................................ 92 
Figure 3.11   Age-associated cytokine defect in TLR-2 and HKSP 
                         activated macrophages is due to a defect in the AKT-GSK-3 
 signaling axis .......................................................................................... 93 
Figure 3.12   The effect of PI3K inhibition on IL-1 β induced cytokine production 
 in splenic macrophages ........................................................................... 95 
Figure 3.13  Schematic model of differing roles of PI3 Kinase and P38 MAP 
                        kinase pathways in cytokine secretion by young and aged  
 splenic macrophages ............................................................................... 96 
Figure 4.1       The purity, recovery, morphology and activation status of  
 BMDM is similar between the aged and young .................................... 111 
Figure 4.2       Cytokine production by young and aged BMDM stimulated with  
 TLR2, 4 and 9 ligands ........................................................................... 113 
Figure 4.3       Cytokine production by young and aged BMDM stimulated  
 with HKSP ............................................................................................ 114 
Figure 4.4       Age-associated changes in expression of mRNA for p110δ  
 subunit of PI3K and activation of AKT in TLR4 
 activated BMDM .................................................................................. 115 
Figure 4.5 PI3K inhibitors partially rescue the age-associated defects in  
 TLR-4 induced cytokine production ..................................................... 116 
Figure 4.6 PI3K inhibitors alter the pattern of cytokine secretion by aged  
 BMDM stimulated with ligands for TLR-2 heterodimers .................... 117 
Figure 4.7 The inhibition of PI3K by either LY294002 or wortmannin  
                        differentially regulates the HKSP-mediated induction of anti- and  
 pro-inflammatory cytokines in BMDM ................................................ 118 
Figure 4.8 PI3K inhibitors reduce activation of Akt but enhance nuclear 
xi 
 
 translocation of p65 NF-κB .................................................................. 119 
Figure 5.1 Pharmacological inhibition of GSK-3 results in increase  
                        production of  IL-10 and the pro- and anti-inflammatory cytokines  
 in aged splenic macrophages ................................................................ 130 
Figure 5.2 GSK-3 inhibition enhances both IL-10 and IL-12 in young  
 splenic macrophages ............................................................................. 131 
Figure 5.3 Kinetics of cytokine production in BMDM treated with  
 GSK-3 inhibitor .................................................................................... 134 
Figure 5.4   The ability of GSK-3 inhibitors of GSK-3 to induce higher  
                        production of pro-inflammatory cytokines is independent  
 of IL-10 ................................................................................................. 135 
Figure 5.5   GSK-3 inhibitors enhance IL-10 but inhibit IL-12 production 
 by BMDC .............................................................................................. 136 
Figure 5.6   The PI3K-Akt signaling pathway modulates the ability of GSK-3 to 
 regulate cytokine production in macrophages ...................................... 137 
Figure 5.7    GSK-3 upregulates cytokine production in macrophages  
 via p65NF-ĸB........................................................................................ 138 
Figure 5.8    Schematic model for GSK-3 inhibition in the regulation of IL-10 
 and pro-inflammatory cytokines production in splenic and  
 bone marrow macrophages via p65Nf-ĸB and CREB .......................... 139 
Figure 6.1  Age-associated decrease in IgG3 production by activated  
 splenic B cells activated via TLR2, 4 and HKSP ................................. 153 
Figure 6.2       Age-associated increased activation of Akt without changes 
 in PTEN  in splenic B-cells ................................................................... 154 
Figure 6.3       Inhibition of PI3K activity increases the production of  
 IgG3 in both the aged and young adult splenic B cells ......................... 156 
Figure 6.4  Wortmannin, a PI3K inhibitor, enhances AID expression 
 in B cells ............................................................................................... 157 
Figure 6.5       GSK-3 inhibition induces higher production of IgG3 and IgA  
 in young splenic B cells stimulated via TLR-4 ..................................... 158 
xii 
 
Figure 6.6       Inhibition of GSK-3 enhances secretion of IgM, IgA, IgG1 and  
 surface expression switched isotypes of young mouse  
 B cells stimulated with   Pam3CSK4, a TLR2/1 ligand ....................... 159  
Figure 6.7       GSK-3 inhibition leads to increase in production and expression  
 of surface IgA and IgG3 in young splenic B cells stimulated  
 with CpG, a TLR-9 ligand .................................................................... 160 
Figure 6.8 HKSP activates young splenic B cells in the presence of SB216763 
 to increase the production of IgG3 as well as surface expression  
 of IgA and IgG3 .................................................................................... 162 
Figure 6.9       SB216763 induces increased plasma cell formation in TLR-2,-4,-9  
 and HKSP stimulated splenic B-cells ................................................... 163 
Figure 6.10  SB216763 is not toxic to young splenic B cells activated via  
 TLR-2, 9 and HKSP .............................................................................. 164 
Figure 6.11  SB216763 inhibits GSK-3β phosphorylation and enhances  
 expression of AID in young splenic B cells activated via TLRs .......... 165 
Figure 6.12    Schematic model for PI3K-Akt and GSK-3 inhibition in positively  
 modulating B cell immune functions .................................................... 166 
Figure 7.1  Age-related cytokine dysregulation provides a less robust support 
 for B cell humoral response to S. pneumoniae ..................................... 176 
  
 
 
 
 
 
 
 
 
1 
 
 Chapter 1: LITERATURE REVIEW 
Introduction 
Immunosenescence: In humans and rodents it is known that the potency and vitality of 
life takes a downward trend with age resulting in increased neurological, metabolic and 
infectious diseases, as well as higher incidence of cancer as a result of defects in their 
immune system (15, 187, 288). This population of people becomes a candidate for 
vaccines to help them mount effective defenses against common pathogens that have the 
propensity to cause them to have higher hospitalization, morbidities and mortalities. 
Frustratingly, the vaccine response in this more vulnerable population is less efficacious 
than in their young counterpart. But an additional challenge is the fact that with the 
advent of modern technology and an improved health system, we see an ever increasing 
number of elderly people who are susceptible to these debilitating age-associated 
conditions. Mathematical modeling and other studies predict that 40% of the population 
in both in the USA and Europe will be above 65 years of age by 2050 (214). In spite of 
scientific efforts to improve the vitality and health conditions of this population,  an 
increase in incidence of infectious diseases is expected  (376). 
The elderly are more susceptible to diseases and mount impaired vaccine response to 
infections, such as Streptococcus pneumoniae, because there are defects in both their 
innate and adaptive immune systems. This generalized decline in innate and adaptive 
immunity is referred to as immunosenescence (15, 197). Aging affects the immune 
functions of innate cells like macrophages and dendritic cells which are critical for the 
early detection and clearance of infectious agents through early non-specific immune 
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response like phagocytosis and inflammatory mediated clearance of pathogens (5, 63, 
120). The age-associated defects in the innate cells, which are crucial for initiating the 
delayed but more specific adaptive immune system, result in defects in both the B cell 
and T cell mediated responses in the elderly (40, 92, 182, 234).  
T-cells and aging 
It is generally accepted that the T-cell arm of the adaptive immunity is seriously affected 
by aging due to thymic involution, which begins around late teens and, thus, negatively 
affects both humoral and cell mediated responses (236, 327).There is an age-related 
decrease in the naïve T cells but an increase in the memory T cells (92, 190). The 
memory T cells in the aged have impaired proliferation and IL-2 secretion, which 
associates with a defect in the MAP kinase pathway. These memory T cells have limited 
repertoire and thus are not able to repond to new pathogen (58, 370). Another mechanism 
for the age-related defect in T cells, especially the CD4 T compartment, is the formation 
of a weakened immunological synapse resulting in reduced proliferation, differentiation 
and cytokine production (136-138). 
In the frail elderly, when peripheral blood monocytes (PBM) are stimulated with 
Staphylococcus aureus Cowan (SAC) there is a predilection for the development of Th2 
cells (138) . Defects in Th1 development results in impaired delayed type hypersensitivity 
(DTH) reaction and higher incidence of intracellular infections, such as tuberculosis (TB) 
in the elderly (138). More recent studies show that the age-related defective polarization 
results in a reduction in the proliferation of both Th1 and Th2 subsets, with an 
enhancement of Th17 cells (138, 155). The age-associated increase in Th17 cells is due to 
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rapid production of these cells by memory T cells. The increase in Th17 cells is not due to 
any influence from dendritic cells as demonstrated by co-culture experiments. The most 
important finding is that Th17 cells (CD4+ CD45Rbhi ) from the aged upon transfer into 
Rag knockout mice induce more severe colitis than those from young mice (274). This 
could contribute to the increase in autoimmunity observed in the elderly. Another 
common feature in aged T cells is the decrease in the expression of CD28 costimulatory 
molecules with aging (57, 58). Aging is also associated with an overproduction of 
regulatory T cells (Treg) and a change in the T cell receptor (TCR) repertoire usage. The 
age-associated increase in Treg is considered another factor responsible for the 
suppression of immune response to pathogens and tumors, and for reactivation of chronic 
infections (138, 193, 364). Because of these defects in the helper T cells population in the 
aged, the T cells have a reduced ability to help B cells, which then negatively impinges 
upon antibody responses, both quantitatively and qualitatively,  and the eventual poor 
vaccine response (50, 138, 251). This may partly explain why the current conjugate 
vaccines or the improved pneumococcal conjugate vaccines may only have partial 
efficacy in the elderly as both vaccines function under the T-cell dependent mode to 
support B-cell mediated humoral responses (92). 
Aging also affects the immune potency of CD8 T cells. There is a reduction in CD8 TCR 
repertoire diversity and a shift in recognition of immunodominant viral epitopes. Because 
the naïve T cells in the aged have a limited T cell diversity there is a lack of robust 
response to infections and vaccines. This may be due to the lack of fresh T cell emigrant 
pool from the thymus, causing the T cell population in the periphery to increase by 
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homeostatic expansion. Thus, there will be an increase in T cells that have a limited 
repertoire (11, 138). 
B-cells and aging  
The two major changes that affect B cell immune function in the aged are changes in the 
B cell compartment and the impaired responsiveness of the peripheral B cells. While the 
total numbers of B cells remain constant, the follicular B cells are reduced which is 
compensated for by an increase in antigen experienced B cells. As a result, there is a 
restriction in naïve B cells with receptor repertoire diversity to respond to new and 
different antigens irrespective of the strain of mice (117, 165, 228).  
The  alteration in the peripheral B cell compartment which leads to impaired humoral 
response  associates with increased B cell longevity and decreased emigration of B cells 
from the bone marrow hematopoietic stem cell (HSC) compartment (182).  The 
peripheral B cell pool can exhibit homeostatic expansion and, thus, increase their 
population without migration of newly generated B cells to the periphery. In addition to 
these factors, the restricted B cell pool in the periphery can undergo clonal expansion 
leading to a restricted B cell repertoire (164, 234). Plausible mechanisms include defects 
in the pre B-cell compartment or inability of new B cells that are normally produced in 
the bone marrow to migrate to the periphery due to the presence of long-lived mature B-
cells in the periphery (165). During aging the B-cell repertoire changes from BCR with 
specificities for foreign antigens to autologous antigen as a result of shift in B-cell 
population from B-2 to B-1 cells.  There is also a reduction in the quality of the antibody 
response as measured by affinity and avidity (40, 394) (163, 327, 377). The B1 cells are 
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innate cells that constitutively produce natural antibodies in the absence of antigen. They 
are located in specialized areas like the spleen and peritoneal cavity unlike the B2 cells 
that circulate and initiate antibody response upon activation by antigens (91). These 
changes lead to such humoral defects as a reduction in the duration and protective 
abilities of the antibodies produced in the aged compared to the young.  The anti-
pneumococcal polysaccharide response upon vaccination of the elderly humans is found 
to be reduced in the elderly compared to the young. A study of both the healthy old and 
elderly nursing home residents compared to young adults shows that there is an age-
associated decrease in the memory B cell compartment compared to the young (40). Not 
only that, but there is a persistently higher IgM concentration in the aged that is attributed 
to impaired class-switching to other isotypes with specific effector functions (103, 220, 
256).  
Another consequence of this shift in peripheral B cell pool in the aged from young naive 
follicular B cells to antigen experienced B cells is the increase in auto-antibodies in the 
sera from aged mice and humans. However, the levels of auto-antibodies do not always 
correlate with autoimmunity probably due to a decrease in their binding affinity (164, 
183). This is validated in classic experiments in which lupus prone, autoimmune NZB 
and MRL/lpr mice are compared with normal Balb/c over a period of different ages 
(183). At eight months of age, the autoimmune mice have a repertoire biased towards 
autoantibodies production and indeed produce autoantibodies, while the nomal Balb/c 
mice do not exhibit any of these phenotypes. However, by 20 months, the NZB 
autoimmune mice have an accelerated autoimmune repertoire and autoantibody 
production and this is comparable to the normal, aged Balb/c mice.  
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 Studies from the Cancro laboratory highlight an exciting factor that may influence the B 
cell homeostatic regulation in response to the low emigration of B cells from the bone 
marrow. They show that the competition among various B cells for BAFF/BLYS, which 
is normally secreted by activated macrophages, dendritic cells or some subtypes of B 
cells greatly, influences the homeostatic process (232, 235). The ability of BAFF to 
influence this process is dependent on its specific binding to the BAFF receptor (BAFFR) 
expressed by transitional B cells. This specific interaction has  dual effects of guiding the 
B cell developmental process and  influencing the longevity of both marginal zone and 
mature B cells (133). The negative selection process of autoreactive B cells is efficient in 
young rodents and humans. As a result of this elimination process, there are adequate 
amounts of BAFF available for normal B cell development. With aging there is a 
reduction in the emigration of B cells from the bone marrow leading to a reduction in the 
competition for BAFF. This creates  favorable conditions  for the production and 
maintenance of autoreactive B cells in the peripheral B cell pool (235). The aged B cells 
become hyper responsive to the limited amounts of BAFF. Thus, they are able to bind 
more potently to BAFF which increases their survival, further enhancing these B cells 
with limited repertoire over naïve B cells (234). 
Age-associated bone marrow mediated defects affect B cells in aging 
The bone marrow is the site for antigen-independent development of  B cells, including 
pro- and pre-B cells. If the pro-B cell has a productive heavy chain rearrangement then it 
can proceed to the pre-B cell stage. During aging, the low production of pro-B cells and 
the impaired transition of Pro-B cells to pre-B cells is one of the factors responsible for 
the low emigration of B cells from the bone marrow (182, 233). The decrease in the 
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transition of the pro to pre- B cell is due to an age-related defect in productive V-DJ 
heavy chain rearrangements as a result of a defect in the E2A-encoded E12 and E47 
transcription factors. These transcription factors are known to regulate this process (104, 
345). Another mechanism for the impaired pro- to pre- B cell transition is attributed to 
the decreased production of IL-7 by the aged bone marrow stromal cells, as well as an 
impaired IL-7 receptor signal transduction (164, 233).  
Signaling mechanism governing the impaired humoral response in the elderly 
A critical hallmark of the humoral responses to pathogens is the ability to class switch to 
non IgM isotypes with functions more suitable to eliminate the pathogen. However, 
studies show that this ability to undergo class-switching is impaired in aged humans and 
mice. The Bloomberg laboratory showed that there is impaired class-switching to the 
typical Th2 –cell dependent isotypes IgE and IgG1. They further show a defect in class 
switching to the typical T-cell independent isotypes, IgG2a and IgG3 in senescent mice 
(105). Further they show that the impaired class switching in the elderly mice can be 
correlated with a decrease in activation-induced cytidine deaminase (AID), and E47, one 
of its transcriptional regulators. The enzyme AID is critical for both class switch 
recombination and somatic hypermutation which are necessary for enhancing both the 
effector function and increased affinity of antibodies produced by B cells (248). When 
the study is extended to human peripheral blood, there is a similar decrease in both AID 
and E47 in B cells recovered from aged compared to the young. Hence, they conclude 
that the impaired ability of the B cells to class-switch in response to  antigen and 
cytokines or CD-40 mediated signaling is due to an intrinsic signaling defect involving an 
age-associated decrease in both AID and E47 (103, 105). Other intrinsic signaling defects 
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in B cell signaling include  lower expression of costimulatory molecules like  CD86 
(396). Another study in human B cells  showed that the enzymatic activity of  protein 
tyrosine kinases and protein kinase C, major upstream signaling molecules of B cells, are 
impaired in the aged compared to the young (379).  
The microenvironmental and intrinsic signaling defects in bone marrow hematopoietic 
stem cells (HSC) affect B lymphopoiesis   
Aging also affects HSC which are the progenitors of lymphoid and myeloid cells. As a 
result of the age-related defects in the HSC, there is a decrease in lypmphopoiesis 
resulting in an increase in myelopoiesis (179, 305). Studies to date, point to a dual 
regulation of HSC by factors intrinsic to individual HSC and cues from the bone marrow 
microenvironment or stromal niches.  For example, age-related defects in both types of 
signals affect generation of B cells and macrophage lineage cells (33, 54, 170, 372, 386). 
Age-associated intrinsic signaling defects can affect HSC such as loss of the integrity of 
the genome. This is due to accumulation of DNA damage and downregulation of genes 
involved in maintaining the integrity of the genome as a result of epigenetic 
dysregulation at the chromatin level (59, 304, 372). The alteration in the expression of 
crucial genes in the long-term HSC sets the stage for the downstream defects observed in 
lymphoid and myeloid cells (305). Aging leads to a remodeling of the bone marrow, with 
a decrease in osteoblasts, which constitutes the stromal niche, but increase in adipocytes 
and osteoclasts (303). The age-related alterations in bone marrow microenvironemnt 
result in a decrease in B cell production and immunoglobulin diversity, due in part to an 
impaired expression of Rag2 at the level of the pro-B cells (192).   
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Aging and Dendritic cells (DC) 
DCs are crucial sentinel innate cells that bridge the innate and adaptive immunity via 
antigen presentation to T cells and expression of costimulatory molecues that are needed 
for T cell activation and cytokine production. Aging-related defects in DC function 
contribute to age-related impairment in T cells. Aged DCs exhibit reduced antigen 
processing, costimulatory molecules and IL-12 production leading to reduced capacity 
for antigen presentation (6). This is even more prominent in the frail elderly humans 
(354). However, studies in human blood monocyte derived DC via GM-CSF and IL-4 
show that the DCs from the aged and young are equally efficient in antigen presentation 
and inducing T cell activation (212). The migration of DCs in the aged is impaired as a 
result of their failure to upregulate chemokine receptors, such as CCR7, and due to 
reduced production of chemokines such as CCL19 and CCL21 in their microenviroment 
upon immunization. As a result there is decreased accumulation of DCs in draining 
lymph nodes in aged mice (187, 209).  Aged plasmacytoid dendritic cells (pDC) show a 
dysregulation (lower) in the secretion of type I interferon in response to CpG and HSV-2, 
which signal via TLR-9 and 7 respectively, and thus accounts for the higher incidence of 
viral and bacterial infections in the elderly (187, 211) . 
Aging and Macrophages: 
Resident tissue macrophages are affected in multiple ways in the aged which could 
account for age-related increases in viral and bacterial infections, as well as increase in 
cancers incidence. Aged peritoneal macrophages exhibit a decrease in adherence, 
opsonization, chemotaxis, phagocytosis and  antibody-dependent cytoxicity involved in 
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the killing of tumors when compared to similar macrophages recovered from the young 
(5, 77, 187, 264, 288). Liver macrophages (Kupffer cells) also exhibit age-associated 
reductions in respiratory burst and endocytotic capacity (288, 363).  A body of literature 
intimates that cytokine secretion is dysregulatated in both splenic and peritoneal 
macrophages activated through engagements of different TLRs. There is a decrease in 
pro-inflammatory cytokines like IL-6, IL-12, TNF-α, and an enhancement in the anti-
inflammatory cytokine, IL-10 by aged macrophages (34, 63, 65, 187). Both humans and 
rodent macrophages exhibit reduced expression of MHC-II (143, 288). While studies in 
human monocytes demonstrate similar number of cells between the aged and young, 
some studies indicate a reduction in the precursor cells in the bone marrow of the aged 
(264, 288).   
Several studies have investigated the signaling mechanisms governing the age-associated 
defect in macrophages. In this regards, studies in rodents and humans show age-
associated decreases in TLR expression (187). In contrast others including our laboratory, 
show no differences in TLR-2 and TLR4 expression by macrophages recovered from 
aged and young (63, 187, 298, 359). Another possible mechanism for the cytokine 
dysregulation and other aging defects is enhanced production of cycloxyenase-2 (COX-2) 
due to an increase in prostaglandin E2 (PGE). The enhanced COX-2 suppresses the pro-
inflammatory cytokines and enhances IL-10 secretion; and it is also known to suppress 
MHC-II (120, 289, 384). Studies which investigate the TLR-mediated signaling 
mechanism by aged phagocytic cells have come to different conclusions, and this may be 
due to the type of macrophages, purity, and experimental conditions. We show that 
increases in phosphorylated and total p38 MAP kinase levels have a role in cytokine 
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dysregulation which could be rescued with p38 MAP kinase inhibitors; however, others 
show an age-associated reduction in the activation of p38 MAP kinase (34, 65). We and 
others show a decrease in the NF-κB signaling pathway in the aged as a possible 
mechanism (34, 35, 65). In this thesis we tested the importance of PI3K pathway, since 
our microarray analysis showed an increased expression of PI3 kinase subunits in aged 
macrophages and since the pathway is known to have negative regulatory effects on 
macrophage-derived cytokines (107, 194). In summary, aging affects macrophages and 
may be a major player in the increased susceptibility of these individuals to infections 
and impaired immune response to vaccines. 
Streptococcus pneumoniae as a model pathogen to study the effect of aging on 
infection with gram positive bacteria 
History of S. pneumonia infection and pneumococcal vaccine  
The gram positive bacterium S. pneumoniae was independently isolated by Louis Pasteur 
and George Miller Sternberg in 1881 (373). Not long after that, the Klemperers made the 
startling discovery that serum from patients infected with S. pneumoniae could confer 
protection against homologous organisms (19, 369, 373). The first attempt to use the 
existing knowledge about S. pneumoniae in vaccine development was done by Sir 
Almroth E. Wright in 1911, when he showed that the use of killed whole pneumococci 
could confer some protection (369). However, the protection was suboptimal due to 
limited knowledge on serotype specific responses and the dosage. The evolution of the 
current pneumococcal polysaccharides vaccine is a result of the work of Felton and 
Bailey in 1926, who isolated pure pneumococcal polysaccharide for the first time (369). 
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As a result the first pneumococcal polysaccharide vaccine was developed from purified 
polysaccharides in 1931 and was shown to avert the spread of  pneumococcal infections 
(329). However, upon the development of antibiotics and the realization that they can 
serve as effective treatments for pneumococcal infections, the polysaccharide vaccine fell 
out of favor for almost forty years (20, 37). Renewed interest in the use of polysaccharide 
vaccine came from the seminal work of Robert Austrian and colleagues in the 1960s and 
1970s, which resulted in their creation of the 14-valent pneumococcal polysaccharide 
vaccine in 1977. Less than 10 years later, the vaccine was expanded to the current 23-
valent polysaccharide vaccine that contains the most common 23 serotypes that account 
for greater than 80% of pneumococcal infections (19, 21, 37). 
Ecology, Epidemiology and pathogenesis of S. pneumoniae 
Humans are the only natural reservoir for S. pneumoniae and the bacteria is found in the 
nasopharyngeal cavities (352). The carriage rate is between 30 to 40 percent in normal 
humans. There is a horizontal transfer from person to person by close contact, and this 
transfer is limited by competition with other microbial occupants of the nasopharyngeal 
flora, as well as the innate host defense mechanisms. The carriage and colonization rates 
has been associated  with the extremes in age, that is higher in children less than two 
years and elderly above 65 years (352, 357). There are other factors in addition to age 
that contribute to increases in colonization and carriage, which are considered 
precipitating factors for spread of the infection and invasive pneumococcal disease (IPD). 
Some of these factors among children less than 5 years include having young siblings, 
attendance at day care centers and for adolescent and young adults,  preexisting 
respiratory tract infections, primary or secondary smoke and being asthmatic (124, 148, 
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217, 260). If the  natural commensal relationship between the pneumococcal bacteria and 
the host is compromised due to breach in the host natural defense, then disease ensues 
and the bacteria migrate from the nasopharynx  to normally sterile sites in the upper or 
lower respiratory tracts. This results in infections, such as otitis media (if migration is to 
the middle ear), sinusitis (to the sinuses) and pneumonia (if migration is to the lungs). 
When the bacteria migrate from the middle ear or sinuses or through the blood stream to 
the meninges of the  brain it results in meningitis (281). This makes S. pneumoniae an 
etiological agent for meningitis, and bacteremia in adults and children, especially in 
people with comorbidities or impaired immune systems (180, 250, 312). 
Epidemiology 
S. pneumoniae  is the most common cause of bacterial pneumonia and other associated 
diseases like pleural effusion and emphysema (pus in the pleural space) (281). It affects 
people of all ages and all geographical regions, as well as those with chronic and 
immunocompromising diseases (156, 263). S. pneumoniae-related infections are the 
leading cause of death in the world (WHO, 2000). S. pneumoniae is a pathogen that 
associates with community acquired pneumonias both in the United States and the world. 
Pneumoccocal infections account for the most upper respiratory tract infections and otitis 
media in children (218).  Pneumococcal infections account for 20-70% of hospitalizations 
per year in the United States, 915,000 cases of community acquired pneumonia in the 
elderly and 4,600 deaths per year in adults greater than 50 years old. Other consequences 
include neurologic sequelae common among survivors (96, 218, 273).  
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 Invasive pneumococcal disease (IPD) 
Invasive pneumococcal disease (IPD) is defined as the presence of S. pneumoniae in 
normally sterile sites like the blood, cerebrospinal fluid, surgical sites, and lungs. It is a 
major cause of morbidity and mortality both in the United States and globally. In the 
United States, pneumococcal IPD is responsible for increased incidence of hospitalization 
due to bacteremia with 15-40 per 100,000 overall hospitalizations (16, 300, 380).  
Risk factors for IPD: The most common risk factors are genetic defects, such as defects 
in the classical complement pathway, the extremes of age, patients with comorbidities, 
defective immune defenses, living in crowded places like prisons or long term care 
facilities; abuse of alcohol and cigarettes and asthma (148, 149, 217, 300, 310, 357). 
Cell Surface and virulence Factors and host defense: 
Some of the virulence factors are polysaccharide capsule (CPS), cell wall and 
pneumolysin which are depicted in Figure 1.1. 
Polysaccharide capsule (CPS): The most important virulence factor of S. pneumoniae is 
the polysaccharide capsule, which encircles the cell wall and resists phagocytosis 
conferring greater survival of the bacteria (129, 218, 253, 352). The polysaccharide 
capsule is found in serotypes that are mostly pathogenic, resulting in colonization, 
invasion and causing IPD. It is used to determine the sereotypes of the various strains. 
There are about 91 different serotypes, each of which elicits a specific anti-capsular 
polysaccharide (CPS) antibody response. The global IPD are caused by 20% of these 
serotypes, which is the basis for their inclusion in the 23-valent polysaccharide vaccine. 
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These IPD causing serotypes include serotypes: 14, 4, 1, 6A, 6B, 3, 8, 7F, 23F, 18C, 19F 
and 9V (142, 273). 
The Cell Wall: The cell wall of S. pneumoniae is also a strong virulence factor as it 
recruits polymorphonuclear leukocytes to the lungs and enhances permeability of the 
alveolar epithelial cells. During progression of the infection, the cell wall is degraded 
releasing inflammatory materials leading to massive inflammation and this aggravates the 
disease condition, as well as the mortality (272). Lipoteichoic acid (LTA) is a component 
of the cell wall  and plays a major role in inducing inflammation (281). The cell wall also 
contains a polysaccharide called C-polysaccharide that is distinct from capsular 
polysaccharide. Phosphocholine is a major component of the C-polysaccharide. Naturally 
present antibodies expressing the T15 idiotype in many species react with C-
polysaccharide. Passive administration of the natural antibodies that express the T15 
idiotype protects against pneumococcal infection in animal models (43) 
Pneumolysin: Pneumolysin exhibits endotoxin-like properties and is found in all 
pathogenic strains. It is released during autolysis and becomes a pore forming cytotoxin. 
It is thought to stimulate macrophages via TLR4 and induce secretion of pro-
inflammatory cytokines. Once released by autolysis it lyses the host epithelial cells, 
inhibits mucociliary action, and impairs phagocytosis resulting in massive inflammation 
leading to morbidity and mortality associated with infection of S. pneumoniae (147, 357). 
Innate Immune response and Streptococcus pneumonia: TLRs and cytokines 
Host Response to S. pneumoniae: The lungs and the spleens are two of the most 
important organs in the clearance of infection by this normally commensal bacterial 
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organism, but deadly under disease conditions (37, 48). The first line of  defense in a 
normal host is the mucociliary movement, cough, sneeze and epiglottis reflexes which 
help to prevent the pathogen from penetrating beyond the superficial epithelium in the 
respiratory tract (281). The second layer of defense is by the host phagocytes, especially 
alveolar macrophages in the lungs and the neutrophils recruited by the inflammatory 
response. The alveolar macrophages have a critical role in the removal of bacteria via 
phagocytosis and intracellular killing. The phagocytic response is promoted by serotype 
specific antibodies, like IgA, IgM, and complement that bind the bacteria and allow for 
efficient clearance by a mechanism known as opsonophagocytosis.  
Toll like receptors (TLR) 
Toll like receptors (TLR) are the major class of receptors by which innate cells recognize 
microbial pathogens. The basis for recognition of microbial pathogens is recognition of 
specialized structures that are unique to the invading pathogens. These are known as 
pathogen associated molecular patterns (PAMP) and are recognized by the pattern 
recognition receptors (PRR) on the innate immune cells like macrophages, dendritic cells 
and other type of cells like epithelial cells (162, 174). These PRRs help in the recognition 
of germline encoded PAMPs that are associated with viruses, bacteria, yeast, fungi and 
even damaged tissues (288).  
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Figure 1.1: S. pnenmoniae morphology displaying virulence factors  
Streptococcus pneumoniae has a cell wall comprising of teichoic acid and is capsulated 
by by a polysaccharide. The capsular polysaccharide and other component of the cell wall 
constitute the virulence factors that are associated with the pathogen. 
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Figure 1.1 
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Once the PRR recognizes PAMP it initiates an intracellular signaling pathway that 
culminates in induction of cytokines, chemokines and interferons. This same intracellular 
signaling drives the maturation of dendritic cells which ushers in the adaptive immunity 
(174). 
Though Drosophilia lack an adaptive immunity, they elicit responses to fungal infections 
via toll like receptors. This supports the concept that toll like receptors are evolutionarily 
conserved across simple to more complex species (152). 
The TLRs have amino terminal leucine-rich repeats which are used to recognize PAMPs. 
The C-terminal domain which contains the Toll/interleukin-1 (IL-1) receptor homology 
(TIR) domain induces the intracellular signaling (348). As of now 11 TLRs have been 
discovered and each has specificity for distinct PAMPS, as well as self molecules under 
different conditions (174). The TLR-1/ 2 and TLR-2/ 6 heterodimers are activated by cell 
wall component of Gram positive bacteria while TLR4 is  recognized by 
lipopolysaccharide (LPS), a component of Gram negative bacteria, and endogenous heat 
shock proteins (31, 288). TLR-3, 5 and 9 receptors interact with double stranded RNA 
(PolyI:C), bacterial flagellin and CpG DNA motifs respectively (288).  Murine TLR-7 
and human TLR-8 recognize uracil-rich single stranded RNA present in many viruses 
(141). TLR-11 can be ligated by ligands from uropathogenic bacteria in mice but is 
nonfunctional in humans. TLR-10 is present in humans but has no known ligand. 
Currently, there are no TLR-10 homologs in mouse (347, 392). TLR-1, 2 and 4 are 
surface receptors while TLR-3,7, 8 and 9 are intracellular, residing on endosomes (347). 
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TLR signaling 
Ligand-mediated activation of TLRs results in intracellular signaling by means of their 
TIR domains which associate with the TIR domains of adaptor molecules such as 
MyD88, TIRAP–(MAL), TRIF–(TICAM1), and TRAM–(TICAM2).  All TLRs signal 
via MyD88 with the exception of TLR3.  This interaction further induces other adaptor 
molecules, such as TIRAP-MAL, TRIF-TICAM, depending on the specific type of TLR. 
The TLR-MyD88 interaction sequentially recruits IRAK-4 and IRAK1. IRAK-4 
undergoes autophosphorylation and then phosphorylates IRAK-1 leading to its 
disengagement from the MyD88 complex and association with TRAF-6 (162). This 
complex then activates TAK, which in turn activates intermediate molecules, like IKK. 
Upon activation IKK phosphorylates IκB, which inhibits the translocation of NF-κB. The 
phosphorylated IκB is degraded leading to an eventual nuclear translocation of NF-κB. 
This pathway also works via the MAP kinase pathway to activate both NF-κB and AP-1 
trancription factors (162, 174, 348). The activation of these transcription factors results in 
induction of pro-inflammatory cytokines like TNF-α, IL-12 and IL-6. If TLR 2 and 4 are 
activated then the TIRAP-Mal adaptor molecules will associate with MyD88 (174, 
387)(Figure 1.2). While MyD88 may be dispensable to TLR4 signaling , TLR9 signaling 
totally depends on it (162). TLR4 has a MyD88-dependent and independent pathway. 
The MyD88 dependent pathway is dependent on an interaction of MyD88 with TIRAP-
MAL. The MyD88-independent pathway signals via TRIF-TRAM heterodimers and is 
activated via both the TLR4 and 3 pathways. The latter pathway activates IRF3 leading to 
production of type-1 interferon (162, 347). 
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Role of TLR in mediating Immune response to S. pneumonia 
 TLRs are some of the major PRRs necessary to sense S. pneumoniae and activate 
phagocytes to clear the pathogen via phagocytosis (185). TLR-2 is critical in the 
recognition of S. pneumoniae since its cell wall components contain peptidoglycan, 
lipoteichoic acid and other lipopeptides that are ligands for TLR2. 
TLR-2 knockout mice have impaired responses to infection with S. pneumoniae though 
the lethality is not greater; this is thought to be due to the role of other TLRs in immune 
response to S. pneumoniae (177, 184, 240). When the TLR-2 knockout mice are 
challenged with polysaccharide from serotype 3 and 14 bacteria and the 23-valent 
pneumococcal polysaccharide (PPS23) vaccine or the pneumococcal conjugate vaccine 
the anti-PPS IgG response disappears while the IgM response is much lower compared to 
the wild type. These studies show that both the PPS23 and the conjugate vaccine contain 
a TLR-2 ligand (317). Similarly, PPS23 vaccine is also reported to contains a ligand for 
TLR-4  (317). TLR-4 is important in the clearance of S. pneumoniae because of its ability 
to recognize pneumolysin (222, 240). Because of the existence of CpG motifs in the 
bacterial DNA, it is possible that TLR-9 is also critical for the recognition and clearance 
of S. pneumoniae. Thus, TLR-9 knockout mice exhibit an enhancement in susceptibility 
to S. pneumoniae (14). 
Pro-inflammatory cytokines are critical for the clearance of S. pneumoniae. 
The critical role of cytokines in protecting the human host from S. pneumoniae-mediated 
pathogenesis is highlighted in human genetic defects involving both the pro-
inflammatory cytokines and the inflammatory signaling pathways. A recurrence of 
22 
 
pneumococcal disease occurs in humans who are deficient in IL-12 (132). In animal 
studies a critical role of cytokines such as IL-1, TNF-α and IL-6 in the clearance of S. 
pneumoniae is seen (262, 398).  Mutations in IRAK4 and NF-κB result in  recurrent 
pneumococcal infections in the affected individuals emphasizing an important role for 
pro-inflammatory cytokines (286).  
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 Figure 1.2:  The TLR signaling pathway. 
The toll-like receptors are pattern recognization receptors that serve as sensors of both 
endogenous and external danger. The TLR mediated signaling culminates in the 
activation of crucial transcription factors like NF-ĸB and AP1 which regulate cytokine 
production. 
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 Figure 1.2 
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Some studies show that the anti-inflammatory cytokine, IL-10, either precipitates or 
attenuates the infections with S. pneumoniae depending on the stage of the infection and 
the level of the host immune response (358). IL-10 is an immunomoduatory cytokine that 
is known to suppress LPS-induced pro-inflammatory cytokines. If given exogenously, it 
suppresses the pro-inflammatory cytokines and increases the lethality of S. pneumoniae 
infection by inhibiting NF-κB activation and secretion of IL-12 and TNF-α by 
macrophages (358). Low levels of IL-10  induce resting and activated B-cells to switch 
from IgM to IgG3 (325). IL-10 can also inhibit B cell proliferation induced by TLR 
ligands (328). The ability to stimulate macrophage response when pathogens are 
encountered is partly dependent upon differential expression of IL-10 and pro-
inflammatory cytokines like IL-12. Interleukin-12 (IL-12) is produced mainly by 
macrophages and DCs and directly or indirectly (via IFN- γ) acts on B-cells and induces 
increased production of IgG2a and IgG3 (42). IL-12 is tightly regulated by several 
cytokines, including IFN-γ which enhances its production and IL-10 which is inhibitory 
(17, 203, 231).  
The adaptive immune response to S. pneumoniae: the role of B cells:  
The adaptive immune response to S. pneumoniae involves both humoral and cell 
mediated responses. There is a delicate interplay among the monocytes/macrophages, T 
cells, PMN and anticapusular  polysaccharide  antibodies produced by B-cells (352). The 
humoral response is directed against the capsular polysaccharide on the whole S. 
pneumononiae and is serotype specific (232, 352). The adaptive immune response is 
often initiated in situations where the pneumococcal bacteria are more virulent or the 
immune clearance mechanism is breached due to comorbidities (48). As a result, the 
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pathogen can escape this protective mechanism, penetrate the lung interstitium and 
become systemic via the blood or lymphatic system and, thus, result in the often-fatal 
condition known as bacteremia (48, 374). The spleen plays an important role in 
mediating adaptive responses to this latter stage of the pneumococcal infection. The 
indispensability of the spleen to the clearance of Streptococcus pneumoniae is clearly 
demonstrated in splenectomized patients from surgery or auto-infarction. In these patients 
there is an increase in bacteremia and sepsis due to S. pneumoniae (70, 366). Patients 
who have functional and anatomical aspleenia also show increased incidence of invasive 
pneumococcal disease (IPD) (142, 202). The spleen is basically divided into the red pulp, 
the white pulp and the marginal zone (MZ) (which is the specialized area between the red 
pulp and the white pulp and contains the marginal zone B cells and the marginal zone 
macrophages). TI-2 antigens localized exclusively within the marginal zone where they 
associate with the MZ macrophages and MZ B-cells (127, 360). When MZ macrophages 
engage S. pneumoniae via receptors such as SIGNR1, both the MZ macrophages and B-
cells migrate to the red pulp where they interact leading to rapid differentiation of the 
pre-primed B-cells to antigen forming cells (AFC) and subsequent rapid production of 
anti-pneumococcal antibodies by a mechanism that is still not delineated (169, 171, 224). 
T-cell independent B- cell mediated response to capsular polysaccharides 
B-cell responses to capsular polysaccharide can be elicited in nude mice that lack mature 
T cells, suggesting that these antigens did not need T-cell help to elicit an antibody 
response. This conclusion is supported more rigorously by Nemazee et al. using TCR β-/- 
and α-/- mice   (241, 254, 336, 368). Hence, the capsular polysaccharide is classified as a 
T cell independent (TI) antigen. These antigens can cross-link the B cell receptor and 
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induce B cell proliferation, but are incapable of inducing immunoglobulin (Ig) secretion 
or isotype switching. When the proliferating B cells are exposed to exogenous or 
macrophage derived cytokines such as IL-1, IL-6 or IL-12, or T cell derived cytokines 
such as IL-4 or IL-5, they could now differentiate into antibody producing B cells (38, 
63, 317, 331). However, there are studies that showed that TI antigen responses may be 
modulated by T-cells either directly or indirectly, but this is not an absolute requirement 
(73, 336). 
 Studies of TI antigens identified a subset of Ti antigens which included polysaccharides 
and haptenated-Ficoll that do not elicit antibody responses in mice with an X-linked 
imunodeficiency (XID), neonatal mice and human infants. These are referred to as TI-2 
antigens and are high molecular weight polymers with repeating antigenic determinants 
for which immune responses appeared after a year or so of age in humans. These are 
distinguished from the TI-1 antigens that can elicit responses in both the XID and 
neonatal mouse model and are characterized by their ability to activate B cells 
polyclonally. TI-antigens are often components of bacterial products with lipids attached 
and included groups like LPS, TNP-LPS and TNP coupled to inactivated bacteria like 
Brucella abortus (241, 244, 331, 336). 
T cell dependent antibody response:  B-cells can bind soluble antigens or whole bacteria 
via their membrane immunoglobulin receptor a resulting in the internalization processing 
and presentation of antigenic determinant to T-cells in the context of MHC-II. The 
resultant cognant interaction between B-cells and T-cells activates B-cell expansion and 
differentiation into plasma cells. Hence, the B-cell interaction with the antigen via its B 
cell receptor (BCR) is considered as signals 1 while the cognate T-cell interaction is 
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considered signal 2. Therefore, the activation and effector functions of the B cells are 
dependent on T-cells and such antigens are designated T-cell dependent (TD) (279, 336, 
368).  
Concept of signals 1 and 2 in the context of immune response to PS from S. pneumoniae 
 In a typical TD response the antigen binding by the BCR elicits the first signal for 
activation of B cell, but the second signal is derived from the cognate B cell: T cell 
interaction. However, in the context of the B cell mediated response to PS from S. 
pneumoniae, the T-cell signal 2 is either absent or not very critical. The capsular 
polysaccharide (CPS) of  S. pneumoniae contains  repetitive epitopes that provide 
maximum cross-linking with the B-cell receptor (BCR) and activate  B-cells, without  the 
participation of  T cells help, and thus engenders low isotype switching, low affinity 
antibody and no memory (38, 79, 207, 241, 336). But where does the second signal come 
from (49, 65) ? In this case the signal 2 is provided either by (1) stimuli that directly 
target the B-cell or (2) stimuli that indirectly target B-cells via induction of stimulatory 
cytokines like IL-1β, IL-6, IL-4 or IL-5 (Fig. 1.3). Such cytokines can be produced by 
phagocytes like splenic or alveolar macrophages, when the S. pneumoniae or some of its 
cell wall components like LTA, the bacterial DNA or peptidoglycan, engage the toll like 
receptors (Figure 1.2)  (65, 100, 325). Activation of T cells by bacterial proteins may also 
provide such cytokines. 
Antibiotics, success and failures in treating S. pneumoniae: 
The first recorded incidence of penicillin resistance by S. pneumoniae was reported in 
Australia in 1967 with additional episodes reported in North America in 1974. In 1992 
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there was about 69% resistance to penicillin in Hungary. Between 1988 and 1990, there 
was a report of 15-20% resistance in the United States. In 1977, the first reports of multi-
antibiotic resistant strains were reported in South Africa which were followed by reports 
of rapid global spread of antimicrobial resistance (216, 217).  Some strains of S. 
pneumoniae  have resistance to tetracycline, erythromycin, chloremphenicol, 
clindamycin, streptomycin and the beta-lactam antibiotics (281).  
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Figure 1.3:  Concept of Signal 1 and signal 2 in the immune response to 
Streptococcus pneumoniae.  
Upon engagement of the BCR by the repetitive epitopes of the capsular PS of S. 
pneumoniae (signal 1) there is B-cell proliferation, but the proliferating B cells require  
pro-inflammatory cytokines (signal 2) derived from macrophages, activated via S. 
pneumoniae engagement of TLRs, to  differentiate  into cells that secrete anti-capsular Ig. 
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Figure 1.3 
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The mechanism of resistance includes point mutations in genes encoding key bacterial 
proteins, such as penicillin binding protein (PBP) (281) (216, 217). As a result, it is 
crucial to develop effective vaccine adjuvants to confer greater efficacy of the current 
pneumococcal polysaccharide and conjugate vaccines in the elderly. Thus, this thesis 
attempted to explore potential signaling pathways that would enhance immune response 
to the current vaccines. 
Evolution of polysaccharide vaccine as a viable and cost efficient alternative to 
antibiotics 
The 23-valent capsular polysaccharide vaccine (PPSV23) 
A combination of increased antibiotic resistance and the differences in the degree of 
severity of the pneumococcal infections in different hospitalized patients led to the 
evolution of the polysaccharide vaccine as an efficacious alternative (21, 46) (20, 21). 
Hence, there is an advocacy for the reintroduction of the polysaccharide vaccines 
resulting in the approval of the 23-valent pneumococcal polysaccharide vaccine. The 
United States Food and Drug Administration (FDA) approved the 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) in 1983 to be used in the elderly, 
children greater than two years who are at risk of the infection due to chronic diseases 
(like sickle cell anemia), and the immunocompromised (due to lymphoma, aspleenia and 
HIV/AIDS) and all adults at risk for chronic diseases. The PPSV23 vaccine is composed 
of purified capsular polysaccharides from 23 of the most common clinical serotypes. 
These serotypes account for 89% of all IPD (19, 46, 281). 
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Following the introduction of the (PPSV23) vaccine, post vaccine efficacy studies 
conducted in South Africa and other countries discovered that the vaccine elicits a robust 
response in the young, but only has a 60% efficacy in the elderly. The functional activity 
of the antibodies for the vaccine, and the ability to promote opsonophagocytosis is 
impaired in the elderly (>65) compared to the young (<45) (200). Another finding is that 
the vaccine can not elicit potent protective antibody response in children less than 24 
months old (46, 74, 321). A meta-analysis and systematic review of studies  of 19 trials 
comprising 82,665 participants from diverse settings in Western Europe, North America, 
Russia, Papua New Guinea and the Caribbean concludes that PPS23 offers little 
protection in the elderly over 65 years old and people in the ages from 2 to 64 years old 
with chronic respiratory illnesses (156). The vaccine elicits no memory and the serum 
antibodies did not last long (39, 69, 218, 272, 321, 357).  Since the vaccine confers 
protection in a serotype specific antibody response, it can not offer protection against 
serotypes not covered in the vaccine, i.e., serotype restriction which is dependent on the 
geographical region of the world (4, 18). Finally, revaccination with PPS23  is not 
recommended as it results in reduced antibody production (159). 
Immunological basis for the poor response of children less than 2 years to the 
polysaccharide vaccine 
A commonly held theory is that there is a selective and developmental disadvantage in 
eliciting an anti-polysaccharide response in young children (46, 93). A second concept is 
that in children and neonates there are tissue polysialylated glycoproteins that are capable 
of eliciting cross-reacting antibody responses in a similar manner as the bacterial 
polysaccharides and thus could be deleterious to the infants. Thus, there is a form of 
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tolerance to the polysaccharide antigens. These polysialated glycoproteins were found in 
human embryonic brains, new born rat kidney, heart and muscle, but not in the similar 
tissues in adults (98, 99). Another plausible explanation for the impaired response in 
children is the fact that the polysaccharides bind the complement factor C3d generated 
via the alternate pathway and form complexes which bind the complement receptor CD21 
on marginal zone B cells, and this is known to enhance BCR signaling. However, in 
children less than two years old, there is reduced expression of CD21 which may have a 
role in the impaired response to the polysaccharide vaccine due to a lack of CD21 
mediated amplification of the BCR signal. But with the conjugate vaccine this need for 
CD21 is overcome at least in the rat model (41). The defective antibody responses of  the 
human infants to model TI-2 antigens and pnemococcal polysaccharides is closely 
mimicked in the murine model (195). Our laboratory has shown that neonatal 
unresponsiveness to PS antigens is due to an inability of neonatal macrophages to 
produce adequate levels of IL-1, IL-12 and IL-6 (195). 
Immunological basis for the impaired antibody response of the elderly to PPS23 vaccine 
 A major factor that predisposes the elderly to increased infection with S. pneumoniae or 
impaired antipolysaccharide vaccine response is attributed to a compromised immune 
function as a result of the normal aging process (75). For example the naturally acquired 
IgG and IgM to six of the of the most common IPD causing serotypes (3, 4, 6B, 9V, 14 
and 23F) are impaired in the elderly compared to the young (327). Not only that, but the 
natural IgG and IgM antibodies to some common pneumococcal surface proteins 
including PspA are impaired in the elderly compared to the young (327).  Hence, this 
age-related defect can also account for the impaired PPS vaccine response in the elderly. 
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There are also studies that indicate that aging affects B cell immune functions and 
specificities, such as class switching to Ig Isotypes to IgG3 in mice and IgG2 in humans 
(43, 105, 227, 278). Since, the immune responses to S. pneumoniae and PPS vaccine are 
mainly B cell mediated, such age-associated defects in B cells can account for the lower 
vaccine efficacy in this population. Aging is also associated with a decrease in cytokines 
such as IL-12, IL-6 which are needed for the induction of antibody response to the TI 
antigens, like the PPS vaccine (38, 63). 
The shift to conjugate vaccine:  
The seven valent conjugate vaccine (PCV-7) 
 Because the immune response to the PPS23 was late onset and thus could not protect 
children less than two years from pneumococcal pneumonia or acute otitis media (AOM), 
the conjugate vaccine was developed by coupling some of the PS to a protein carrier to 
make the PS, a T dependent antigen. It was approved for use in the USA in 2000 by the 
FDA (218, 319). It is recommended for children within the first 6 months of their lives 
and children greater than 2 years who are at higher risk for IPD due to HIV/AIDS and 
sickle cell anemia (261, 357). The conjugate vaccine, designated PCV-7, is made up of 
the purified capsular polysaccharides of seven of the most common clinical isolate 
serotypes, which are 4, 6B, 9v, 14, 18C, 19F and 23F and they are conjugated to a protein 
carrier, such as tetanus-toxoid. As a result of this composition the antibody response is 
now shifted to a T-cell dependent response. The carrier protein is able to activate T-cells 
that are specific for the protein and thus provide help for the polysaccharide specific B-
cells. As a result B-cells can undergo affinity maturation, Ig class-switching and 
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induction of memory B-cells. The 7 serotypes  contained in the conjugate vaccine 
account for  more than 80% of all IPD in North America in  children less than two years 
of age and the elderly (69, 261). PCV-7 vaccine protects children less than two years old 
from IPD and offers some protection from otitis media, and also indirectly protects adults 
and elderly as a result of herd immunity (154, 218, 319).  
Upon the introduction of the conjugate vaccine it became obvious that non-clinical 
serotypes that are not included in the vaccine have emerged and are leading to increased 
incidence of IPD. For example, serotype 19A that is not included in the 7-valent 
conjugate vaccine began to emerge, thus reversing the initial gain in the reduction of 
otitis media in children (26, 218, 319). The heptavalent conjugate vaccine lacks a global 
appeal as the seven serotypes selected for inclusion are geographically restricted to North 
America. For instance, it will not work in sub-Saharan Africa because the predominant 
IPD causing S. pneumoniae consists of serotypes 1 and 5. The cost of producing the 
conjugate vaccine is too high and can not be afforded by poorer countries (2, 76, 79, 
276).  It also requires multiple immunizations to elicit long lasting protective antibody 
responses (69, 297). Five of the serotypes included in the PCV-7 vaccine are known to 
contribute to 80% penicillin resistance and thus with the introduction of the PCV-7 
vaccine there is an overall reduction in the IPD caused by the erythromycin and multiple 
drug resistant  strain through herd immunity (191, 283). 
The 13-valent conjugate vaccine 
 The 13-valent conjugate vaccine after some field testing is finally approved by the FDA 
on February 24, 2010. This new vaccine has broader serotype coverage and is expected to 
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prevent IPD among infants and children, and to help in the reduction of otitis media (32, 
261). The new 13-valent vaccine is made of serotypes from the initial PCV-7 conjugate 
vaccine along with six new serotypes (1, 3, 5, 6A, 7E, and 19A). Note that there is an 
inclusion of the newest nonclinical serotype that has become prominent, serotype 19A 
and the target population is for infants 2 – 59 months old and children between the ages 
60 to 71 months old who present with underlying medical condition or children who 
received only a single dose of the PCV-7 vaccine (242, 261, 287).  
Prime boost effect of PCV-7 and 23-PPSV 
 Studies show that an enhanced response can be elicited in a prime-boost immunization 
with the conjugate vaccine and with the 23-valent polysaccharide vaccine. If the priming 
is done with the PCV-7 vaccine followed by a boost with the PPSV23 vaccine there is an 
enhanced anti-capsular response (263). This prime-boost response is further potentiated 
with highly active antiretroviral therapy (HAART) treatment in HIV/AIDS children and 
infants (3). This latter regimen shows some promise in the elderly and the 
immunocompromised young adults (1, 160, 261). However, if the priming is done with 
the PPSV23 vaccine it results in hyporesponsiveness, even if the conjugate vaccine is 
used as a boost. 
Pneumococcal proteins as vaccine candidates 
 Due to the current disadvantages of both the polysaccharide and the conjugate vaccines, 
there have been efforts made to utilize the pneumococcal proteins that confer cross-
protection and, thus, are independent of any particular serotypes. There are many surface 
proteins that are being evaluated but  the three most promising ones are the 
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pneumococcal surface protein A (PspA), pneumococcal surface adhesion protein A 
(PsaA), and pneumolysin (37, 45). PspA is a choline binding protein on the surface of the 
S. pneumoniae that blocks the alternative complement pathway (252). Despite its 
antigenic variability among different strains, studies in mice show that it has a broad 
protective effect against invasive infections and nasopharyngeal carriage (44). In a Phase 
I clinical trial it is shown that recombinant PspA from a single strain along with alum as 
an adjuvant can elicit broadly cross reactive antibodies to different antigenic forms and 
that passive immunization with antibodies from the participants can confer protection to 
mice (44). PsaA is a member of the metal binding lipoproteins. Immunization with this 
protein has a greater effect on colonization and nasopharyngeal carriage with little or no 
effect on the invasive disease in mice (37, 42, 45). Pneumolysin is another choline 
binding protein shown to have the best effect in protecting against invasive diseases but 
not colonization in mice (265, 280). As a result of the unique action of each of these 
proteins, the studies show that combining them exploits the synergistic effects and 
induces protection. A combination of PspA and PSaA protects against both colonization 
and otitis media in a mouse model, while a combination of PspA and pneumolysin is 
additive in protecting against invasive disease (42, 265). Some of the advantages of the 
PS protein vaccines using a mixture of different pneumococcal proteins: (1) able to target 
diverse pathogenic mechanisms; (2) useful to both children less than two years and adults 
as the children elicit responses to conjugate vaccines but not polysaccharides; (3) less 
expensive as there is no need for conjugation or polysaccharide purification; and (4)  
totally avoid the problem of serotype replacement (44, 344).  However, there are several 
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challenges to develop a protein based vaccine, not the least of which is finding a suitable 
adjuvant.  
Cytokines as potential adjuvant for PS vaccines  
There are many vaccine adjuvants that have been evaluated in murine models and proven 
to potently enhance the immunogenicity of vaccines response. However, most of these 
adjuvants cannot be used in humans due to their severe side effects. For instance 
complete and incomplete Freund’s adjuvant are potent immunostimulatory adjuvants but 
are not approved for human use due to side effects (27). The approved adjuvant, alum, is 
of very low potency necessitating multiple immunizations (389). As a result of these 
short-comings, there are many attempts to find a potent adjuvant that can still be very 
tolerable in humans. MF-29 is a new vaccine adjuvant approved for use in Europe but not 
in the USA. Monophosphoryl lipid A (MPL) is an adjuvant recently approved for use in 
USA and is thought to work via ligation of TLRs (72). Many researchers have also 
started looking into cytokines as a potential answer due to some of their unique 
properties. Cytokines are endogenous potentiators of immune response; hence enhancing 
the appropriate types of cytokines with antigen can be more highly immunogenic (67) 
(Table 1.1). Luo et al. showed that supplementing Pnu-immune vaccine with IL-10 elicits 
a better immune response than the vaccine alone (213). In a mouse model injecting IL-12 
followed by PPS23 immunization resulted in an enhanced production of both IgG2a and 
IgG3 anti-vaccine antibodies. The IL-12 cytokine activates cell mediated immunity as 
well (49, 271). Physically fusing an antigenic protein with cytokines can elicit potent 
antibody responses consisting of various isotypes like IgG3and IgG1 (67, 383). Systemic 
immunization with PspA protein genetically fused to IL-2 produces higher anti-PspA 
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IgG1 and IgG2a responses compared to PspA adsorbed to alum (383). Another study 
demonstrates that immunizing mice with PspA along with IL-12 enhances sIgA and 
systemic IgG. This combination vaccine delivery strategy results in a dual protection 
against both carriage and fatal bacteremia, thus precluding the need to physically link 
different PPS proteins for different modes of infection and clearance (17). In another 
study recombinant PsaA fused to murine IL-2 or IL-4 is found to induce both IgG1 and 
IgG2a anti-PsaA antibodies, whereas combination with CFA generates only IgG1 
response. Also PsaA plus cytokines confers greater protection to mice challenged with 
virulence strains than pure PSaA antigen. Thus the protection is 30% with PSaA alone as 
opposed to 100% with PSaA plus cytokine (122). 
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Table 1.1:  Some Cytokines and their effects on modulating the humoral response to 
S. Pneumoniae 
 
 
 
 
 
 
Cytokine    Type Function in immune 
response to S. pneumoniae 
IL-10 Anti-inflammatory Suppresses pro-
inflammatory cytokines, 
optimal induction is needed 
for B cell differentiation. 
Enhances S. pneumoniae 
lethality in a mouse lung 
infection model. 
IL-12 Pro-inflammatory Enhances IgG2a and is 
critical for clearance of S. 
pneumoniae via generation 
of opsonic antibodies.  
IL-6 Pro-inflammatory Enhances formation of 
antibody producing cells 
against pneumococcal 
polysaccharide vaccine. 
Plays a crucial role in the 
clearance of S. pneumoniae. 
TNF-α Pro-inflammatory Acute early induction is 
needed for recruitment of 
leukocytes and clearance of 
S. pneumoniae. 
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The  adjuvant properties of –C-phosphote-G- (CpG) oligonucleotide are  due mostly to 
this ability to activate both innate (e.g. macrophages, dendritic cells) and adaptive 
immune cells (e.g. B-cells) to produce cytokines, like IFN-γ, IL-6, IL-12 and TNF-α, that 
are known to modulate antibody production (Table 1.1). Thus, in a study in which mice 
are immunized with conjugate vaccine in the presence of CpG, there is an enhancement 
of polysaccharide specific IgG2A and IgG3, as well as low levels of IgM and IgG1 (69, 
189, 334, 388). As a result, a couple of studies show that CpG can be used in 
combination with DNA vaccine with proteins from S. pneumoniae, or with conjugate or 
polysaccharide vaccines and induces some level of protection against pneumococcal 
infections (109, 316). 
Additional studies show that immunizing mice with TI antigens and subsequently 
inducing endogenous cytokines like IL-1, IL-4, IL-6, IL-12, IL-2, and IFN-γ via TLR 
mediated signaling has the ability to activate B cell proliferation, activation, class 
switching and secretion of Ig (178).  Hence, cytokines are potent providers of signal 2 
needed to work with TI-2 antigens in activation of B cells. Recently it was shown that the 
ability of the PPSV23 vaccine to elicit robust responses in some aged groups is due to its 
contamination with ligands for TLR-2 and 4. This allows the vaccine to mediate 
production of cytokines that are crucial for the enhancement of Ig secretion and class-
switching (178, 317, 331). Another study evaluated the role of monocyte derived 
cytokines, IL-6, IL-10 and TNF-α, in the increased susceptibility of patients with 
common variable immunodeficiency disease (CVID) to infection with Streptococcus 
pneumoniae. The results show that the pneumococcal-23 vaccination of these patients 
produces a less robust response than the normal healthy human controls due to a defect in 
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the vaccine-induced production of monocyte derived cytokines, IL-6, IL-10 and TNF-α 
(153). Thus, the levels of cytokines produced endogenously help to regulate the clearance 
of S. pneumoniae and this can be exploited in the immunocompromised host. Exogenous 
treatment with IL-1 confers protection in mice against lethal challenge with S. 
pneumoniae (167). IL-1 is known to regulate both B-cell expansion and differentiation 
into antibody forming cells (64, 167, 221). 
Challenges with the use of exogenous cytokines  
One of the current drawbacks in exogenous administration of cytokines as adjuvants in 
human studies is due to their pyrogenic properties as  shown with IL-1 and IL-12 (259).  
A human clinical trial that used exogenous recombinant human IL-12 in the presence of 
the polysaccharide vaccine demonstrates that the cytokines elicit a minimal, but non-
significant increase in pneumoccocal IgA, IgM, IgG1 and IgG2 antibodies over the 
placebo group, but have some adverse effects. These adverse effects include fever and 
generalized body pain in the participants resulting in discontinuation of the study (140). 
Another challenge in the use of exogenous cytokines is identifying the route of 
administration that will elicit a protective response and yet be physiologically relevant to 
humans (128, 291, 307). A final challenge in using exogenous cytokines as adjuvant is to 
consider what combinations of cytokines can be given to elicit maximum synergistic 
effects without side effects (7, 8) . 
Endogenous enhancement of cytokines is a biologically relevant alternative adjuvant 
There are still key unanswered questions in the use of the current polysaccharide or 
conjugate vaccines as well as potential challenges with the use pneumococcal protein 
vaccines or exogenous cytokines. Below, we investigate the plausible means for 
44 
 
enhancing endogenous production of macrophage-derived pro-inflammatory cytokines 
that provide the signal 2 needed for potent B cell activation, differentiation and anti-PS 
antibody responses in aged mice. Such an approach is not limited by serotype coverage, 
aging, T-cell dependency, health conditions or cost. In order to address these challenges 
with regards to the impaired antibody response to S. pneumoniae in the aged, there are 
four critical questions that must be answered and investigated with depth: (1) how does 
the age-related cytokine dysregulation in macrophages negatively impinge upon B-cell 
mediated signaling leading to impairment in class switching, affinity maturation and 
activation in response the pathogen; (2) How does aging affect the production of 
opsonizing IgG antibodies for host defense against S. pneumoniae (36, 157); (3) What 
signaling molecules are altered in either B cells, macrophages or both in the elderly that 
can be pharmacologically targeted to restore the impaired B-cell response to S. 
pneumoniae or pneumococcal vaccine;  (4) Can this system be developed as a potential 
vaccine adjuvant? Answers to these questions will provide critical information for the 
development of a more efficacious vaccine for pneumococcal infections (309, 366).   
Hence, in our laboratory, we are studying TLR-MyD88 signaling in the macrophages in 
order to elicit endogenous cytokine production to overcome this cytokine dysregulation 
as a means of enhancing robust B-cell activation, differentiation and anti-PS antibody 
responses (38, 63). We explore the TLR-cytokine mediated signaling pathways between 
the aged and the young as a means to identify specific steps in the pathways downstream 
of the TLR-MyD88 complex  that are dysregulated with aging so that they can be 
pharmacologically exploited to enhance cytokine and anti-capsular antibody response 
(63). In the studies described in this thesis, we attempt to address these questions in the 
45 
 
context of in vitro cultures of SM and BMDM and splenic B cells from aged and young 
adult Balb/c and C57BL/6 mice. We ask if an age-associated increased in PI3K-Akt 
activity plays a role in the cytokine dysregulation in aged splenic and bone marrow 
macrophages. We wonder further if similar heightened PI3K-Akt activities in B cells 
explain the age-related B cell defects (267, 268).  We also investigate the role of GSK-3, 
a downstream target of PI3K-Akt pathway in activating both B cells and macrophages.  
Role of PI3K-AKT-GSK-3 signaling pathway in macrophage activation                                                                               
PI3K enzymes form a group of lipid kinases consisting of Class I, II and III that are 
involved   many fundamental physiological processes and also play a role in modulating 
the activities of phagocytic cells such as macrophages, neutrophils and monocytes that 
are critical for the clearance of S. pneumoniae. PI3K signaling is also important in B and 
T cell survival and activation. The Class IA PI3K consists of regulatory subunits (p85α, 
p85β, p55α, p55γ and p50α) that bind to one of three catalytic subunits (p110α, p110β 
and p110δ) upon activation via a tyrosine-kinase coupled receptor. The Class IB PI3K 
catalytic subunit lacks the p85 binding domain and is activated by G protein coupled 
receptors, (173, 223). The PIP3 generated by PI3K activity serves as a docking site for 
the recruitment of signaling proteins via their pleckstrin homology domains. One of the 
kinases that is recruited to the membrane by PIP3 is the phosphoinositide-dependent 
kinase-1 (PDK-1), which then targets the serine-threonine kinase, Akt, for 
phosphorylation at Thr-308 (361). The activated Akt serves as a master kinase for a 
plethora of downstream substrates including IKK and GSK-3 (173)(Figure 1.4). The 
levels of PIP3 can be down-modulated by PTEN (phosphatase and tensin homolog) and 
SHIP (Src-homology-2 containing inositol 5′-phosphatase), which are phosphatases that 
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respectively target the D3 and D5 positions of PIP3 converting it to PIP2 (223). Recent 
pioneering studies show that PI3K signaling is a negative regulator of TLR-induced 
production of pro-inflammatory cytokines (107). Not only that, but the pharmacological 
inhibition of PI3K results in the suppression of IL-10 in macrophages and monocytes 
(108, 226, 308) (290, 308). Also, MyD88 directly interacts with the p85 subunit of PI3K 
(194).  In phagocytes PI3K modulates chemotaxis, phagocytosis, upregulation of 
activation markers, growth, migration and differentiation (5, 131, 139). The PI3K-Akt 
signaling pathway differentially regulates pro- and anti-inflammatory cytokines in 
macrophages by inhibiting glycogen synthase kinase (GSK-3) (139, 225, 382). 
GSK-3 is a direct downstream substrate of Akt and is phosphorylated on Serine-9 
resulting in its inactivation (225, 382). GSK-3 appears to regulate both the pro- and the 
anti-inflammatory cytokines by controlling the competitive interaction of either CREB or 
p65 NF-κB with the CREB binding protein (CBP)( Figure 1.4). Moreover, inhibition of 
GSK-3 via either siRNA or pharmacological inhibitors results in a cytokine profile that is 
the reverse of the cytokine profile seen when PI3K is inhibited (225, 382, 393). The 
ability of GSK-3 to negatively modulate IL-10 allows the induction of IFN-gamma and 
the associated enhancement in antigen presentation, which has been shown to be critical 
for the control of mycobateria (60). 
 
 
 
 
47 
 
Figure 1.4. The PI3K-Akt-GSK-3 signaling pathway in Macrophages. 
TLR mediated signaling in macrophages results in an interaction of MyD88 and PI3K 
resulting in the phosphorylation of Akt. Akt phosphorylates GSK-3 and the latter is 
inactivated. GSK3 regulates transcription factors like NF-κB and CREB. These 
transcription factors regulate the anti- and the pro-inflammatory cytokines. 
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 Figure 1.4 
 
 
 
 
 
 
 
 
 
  (Modified from D.A. Fruman, Current Opinion in Immunology, 2004)(106) 
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Role of PI3K-AKT in regulating B-cell activation 
 Several previous studies emphasize the ubiquitous role of the Class IA PI3K signaling in 
regulating both the innate and the adaptive  immune responses (188). The crucial role of 
PI3K in B-cell development, differentiation, activation, proliferation and survival is 
amply demonstrated using a combination of both pharmacological inhibitors and 
mutations that are specific for the PI3K pathway in B cells (268, 343). The class IA PI3K 
is downstream of signaling via B cell receptor (BCR), B-cell costimulatory molecules, 
toll like receptors and cytokine receptors. PI3K dependent phosphorylation of Akt is 
crucial for the regulation of B-cell proliferation and survival (81, 268, 333) (Figure 1.5). 
A B cell specific conditional knockout of PTEN, a negative regulator of PI3K-Akt 
signaling, results in enhanced activity of an Akt (343). The hyperactivity leads to a defect 
in expression of activation induced deaminase (AID), class switching and antibody 
responses to both TI and the TD antigens (343). 
 Activated Akt, phosphorylates and inactivates the forkhead transcription factors (Foxo). 
The suppression of the Foxo protein results in a down modulation of class-switch 
recombination. When PI3k is pharmacologically inhibited, using either a generic inhibitor 
like LY294002 or a Class I A (p110δ) specific inhibitor like IC7114, there is an 
enhancement in the expression of the enzyme AID and class switch recombination (267, 
268). Overall, PI3K regulates B cell homeostasis in the periphery, by regulating the 
different types of B cell subsets, their  survival and proliferation (22). On the basis of the 
foregoing, we attempt to first confirm in our hands that there is a defect in IgG3 in the 
aged splenic B cells compared to the young under in vitro conditions, and secondly to 
investigate if  PI3K-Akt signaling pathway plays a causal role in this age-associated 
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defect in IgG3 expression. IgG3 is crucial for the clearance of S. pneumoniae in mouse 
(227). We decided to use HKSP instead of live S. pneumoniae so that we could evaluate 
the cytokine regulatory effects of cell wall component of the bacteria without any lethal 
effects. 
 Role of GSK-3 in modulating B cell responses: GSK-3 is phosphorylated by a PI3K-Akt 
dependent signaling mechanism via BCR signaling. This phosphorylation inactivates 
GSK-3 and results in modulation of several of its downstream targets that are essential 
for B cell function. Two of these transcriptional targets of GSK-3 are NF-AT1c and beta-
catenin (118) (Figure 1.5). NFAT1c is a positive regulator of Ig class switch to IgG3 
upon immunization with Type-II TI antigens in splenic B cells. It is also a positive 
regulator of IgG3 +  plasmablast formation (29). Thus, by regulating NFAT1c, GSK-3 
may play a critical role during B cell immune responses. Beta-catenin accumulates in the 
nucleus of B cells following BCR signaling (391).  Studies in conditional knockout of β-
catenin specific for B cells showed that it is dispensable in terms of B cell response to 
both TI and TD antigen challenge in vivo. Nevertheless, these mice show a significant 
reduction in class switching to IgG1 and plasma cell generation in vitro (391). Under 
normal unstimulated conditions, GSK-3 is active and thus phosphorylates and degrades 
β-catenin. However, following BCR stimulation, GSK-3 is inactivated upon 
phosphorylation which allows β-catenin to accumulate in the nucleus of the B cell and 
regulate the transcription of several genes that are needed for B cell development and 
function (29, 68, 158, 391). Since GSK-3 is downstream of Akt and Akt has a role in 
class switch recombination, we hypothesized that GSK-3 has a role in IgG responses to 
HKSP. 
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Figure 1.5. The PI3K-Akt-GSK-3 signaling pathway in B cells. 
Signaling downstream of BCR, CD19 or TLR in B cells leads to the activation of PI3K 
which in turn leads to the phosphorylation of Akt. Akt phosphorylates and inactivates 
GSK-3 and thus indirectly controls its ability to regulate beta-catenin and NFATc1 that 
play a role in B cell mediated class switching and plasma cell formation. 
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Figure 1.5 
 
 
 
 
      
 
 
 
 
 
 
(Modified from D.A. Fruman, Current Opinion in Immunology, 2004)(106) 
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In vitro mouse model system of macrophage-derived cytokines on B cell response 
We used in vitro model systems to demonstrate that macrophages or macrophage derived 
cytokines enhance B cell response to the typical TI-2 antigen, TNP-Ficoll (63).  
Macrophage derived cytokines provide the critical second signal required for TI-2 
antigen specific response. We are able to further elucidate that the defective B cell 
mediated response to either the polysaccharide vaccine or the synthetic TI-2 antigen in 
the elderly compared to the young adult can be attributed to a defect in macrophage-
derived cytokines. We note an enhancement in the anti-inflammatory cytokine, IL-10, but 
a decrease in the pro-inflammatory cytokines, IL-6, IL-12, and IL-1 in aged macrophages 
triggered via TLR4. This age-associated cytokine profile is considered a “cytokine 
dysregulation”. 
To understand the molecular mechanism of this dysregulation in the aged SM; our 
laboratory performed a microarray analysis of genes expressed in young and aged 
macrophages activated via TLR-4. These studies showed that while the TLR expression 
is similar between the aged and young adult macrophages, there is a decrease in the 
MyD88 adaptor molecule, as well as several signaling molecules in the pathway that 
leads to activation of the transcription factor NF-κB (65).  Also there is an enhancement 
in p38 MAP kinase, as well as PI3K subunits in the aged compared to the young. When 
p38 MAP kinase is pharmacologically inhibited the age-associated cytokine defect is 
partially overcome (65).  
 On the basis of the previous findings, our literature search and preliminary data, we 
advanced the following hypotheses: 
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(1) Cytokine responses of aged splenic macrophages to TLR2 and TLR9 are similar 
to those induced by TLR4 as they all share the MyD88 signaling pathway. 
(2) An age-associated increase in the PI3K-Akt-GSK-3 signaling pathway has a role 
in the cytokine dysregulation in splenic macrophages and that inhibiting PI3K can 
reverse this dysregulation. 
(3) The cytokine dysregulation defect may be intrinsic to macrophages from the aged 
which is tested using BMDM from aged. We further hypothesized that the PI3K 
pathway will be upregulated in BMDM with age. 
(4) We hypothesized that GSK-3, a downstream target of PI3K pathway, will have a 
critical role in TLR responses of macrophages from the aged.  
(5)  The impairment in IgG3 production in the aged splenic B cells compared to 
young B cells may be due to enhancement in the activity of PI3K. 
(6) We hypothesized that inhibiting PI3K or GSK-3 in aged splenic B cells will 
increase IgG3 production by enhancing the expression of AID. 
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CHAPTER TWO: METHODOLOGY 
ANIMALS 
Female young (8-12 weeks old) and aged (18-22 months old) Balb/c and 
C57BL/6 mice were obtained from the National Institute of Aging (NIA), National 
Institute of Health (NIH, Bethesda, MD). The mice were kept in the facility at the 
Department of Laboratory Animal Research (DLAR) at our university on a 12 h daylight 
and 12 h night cycle and given food and water ad libitum. The protocols involving the 
animals were approved by the University of Kentucky Institutional Animal Care and Use 
Committee. 
  REAGENTS 
The TLR-4 agonist LPS (Escherichia coli 055:B5) and the TLR-2 ligands, Pam-3-CSK4 
and the GSK-3 inhibitor, SB216763 were obtained from Sigma Chemical Co. (St. Louis, 
MO), whereas the TLR-2 ligands, Pam2CSK4 and lipoteichoic acid were obtained from 
In Vivogen (San Diego, CA). LY294002 and wortmannin, the inhibitors for PI3K and the 
GSK-3 inhibitor 216763 were obtained from Calbiochem (San Diego, CA). FITC- 
conjugated anti-mouse LY-6G and anti-CD5 antibodies were obtained from BioLegend 
(San Diego, CA), while the FITC-conjugated anti-mouse CD45R (B220), FITC- 
conjugated anti-mouse CD11b, PE-conjugated anti-F4/80, biotin-conjugated anti-IgG3, 
PE-conjugated anti-CD138 antibodies and Strepavidin-conjugated APC were obtained 
from eBioSciences (San Diego, CA). The antibodies to p-Akt (S473), Akt, p-GSK-3αβ 
and GSK-3, were from Cell Signaling Technologies; to anti-PTEN and anti-β-actin were 
from Santa Cruz Biotechnology (Santa Cruz, CA). The immunoreactive proteins were 
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detected using horseradish peroxidase coupled secondary antibodies and the PICO 
Chemiluminescence substrate (Pierce Technology, Rockford, IL). The cytokine OptEIA 
ELISA kits for IL-10, IL-12(p40), IL-12(p70), IL-6 and TNF-α were all from BD 
Biosciences, San Diego, CA. The anti-FITC and the anti-B220 antibody coupled 
microbeads were obtained from Miltenyi Biotec (Auburn, CA). The OptEIA TMB 
peroxidase substrate for the ELISA was acquired from BD Biosciences (San Diego, CA). 
We used sterile RPMI 1640 (BioWhittaker) medium which was made complete by 
supplementing with 25 mM HEPES , 2 mM glutamine  (Invitrogen Gibco), and 
50 µg/ml gentamicin  (Sigma-Aldrich) and 10% Fetal bovine serum (FBS), (Atlanta 
Biologicals, Lawrenceville, GA). The IgG3 or IgA ELISA kits were from Bethyl 
Laboratories, (Montgomery, TX), while the IgM, IgG2a, IgG2b or IgG1 ELISA kits were 
from Southern Biotec (Birmingham, AL).  
HEAT KILLED STREPTOCOCCUS PNEUMONIAE (HKSP) 
Serotype-2 S. pneumoniae bacteria were obtained from Dr. Beth Garvy and plated on 
BBL pre-made blood agar plates (VWR International). Isolated colonies were grown in 
Todd Hewitt broth (BD Biosciences) to mid-log phase and collected for counting. 
Sterility was confirmed by subculture on blood agar plates. After extensive washings the 
bacterial suspension was adjusted with PBS to give an absorbance reading at 630 nm of 
0.59, which corresponded to 1.2 x108 CFU/ml using a turbidity curve. The bacteria were 
then heat killed by incubation at 60°C for 1 h or fixed in 10% formalin. Bacteria were 
then aliquoted at 3.3 x109 CFU/ml and frozen at –80°C until their use as Ag for 
macrophage stimulation.  
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L929 SUPERNATANT 
The L929 fibroblast cell line was obtained from Dr. Don Cohen, University of Kentucky, 
and cultured in 75 mm Flask in 25ml  at 1x106 cells/ml of RPMI complete media for 7 
days. At the end of the seventh day, the supernatant containing M-CSF was aspirated, 
spun down and sterile filtered. Aliquots were made and stored at -800 C for future use in 
the generation of BMDM. 
CELL PREPARATION:  
Splenic Macrophages (SM): Mice were euthanized via carbon dioxide asphyxiation and 
the spleens aseptically removed and crushed into a single cell suspension. After washing 
and erythrocyte lysis with lysing buffer (Sigma, Aldirch, St. Louis, MO) at 2ml/spleen 
for three minutes at room temperature, the FcγR were blocked with normal rat IgG for 15 
minutes. The splenocytes were then incubated with a cocktail of FITC conjugated 
monoclonal antibodies against B220, CD5 and Ly6G in the dark for 30 minutes. This was 
followed by washing with MACS buffer and incubation with anti-FITC microbeads at 4-
8o C for 15 minutes. The purified macrophages were obtained by separating the magnetic 
bead bound and unbound cells using the Miltenyi AUTOMACS Cell Separator using the 
program Deplete-05. The resulting untouched macrophages were found to be 90-95% F4-
80 positive cells (Appendix A). The purified macrophages were cultured at 2.5x105 
cells/ml in 48 well plates (Costar, Corning, NY) and in RPMI fetal calf serum (FCS) at 
370C in a humidified 5% CO2 atmosphere.                                                                                                                                                                                                                             
Bone marrow derived macrophages (BMDM): Mice were euthanized via carbon dioxide 
asphyxiation and bone marrow derived cells were isolated from young (8-12 weeks) and 
aged (18-24 months) Balb/c mice by flushing the bone marrow from the femur and tibia 
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with HBSS media. After washing and erythrocyte lysis with red blood cell lysing buffer 
at 2ml/20x106 cells, the bone marrow cells were cultured at 2 x106 cells/ml in 24 well 
plates. The cells were cultured in RPMI complete media supplemented with 30% L929 
cell supernatant containing M-CSF. On days 4 and 6, the media was completely removed 
and new RPMI complete plus 30% L929 supernatant was added. On day seven the newly 
derived BMDM were isolated by removing the entire old media and adding 2ml of 
trypsin-versene (Lonza Biosceince, Walkersville, MD) per well in a six-well plate and 
incubating the culture for 30 minutes at 370 C. This was followed by adding RPMI 
complete to reduce the toxicity of the trypsin. The cells were then washed twice, 
resuspended, counted and used for different experimental conditions. The resulting 
BMDM were found to be 96% F4-80 and CD11b positive cells. The purified BMDM 
were cultured in RPMI complete at 370C in a humidified 5% CO2 atmosphere at 2 x105 
cells/ml/well. Bone marrow derived macrophages (BMDC) were similarly generated 
except that GM-CSF was used with IL-4 and trysin was not used. The cells were 
harvested on day 8 which expressed CD11c and other phenotypes of BMDC.                     
 Splenic B cells: Mice were euthanized via carbon dioxide asphyxiation and the spleens 
aseptically removed and crushed into a single cell suspension. After washing and 
erythrocyte lysis, the FcγR were blocked with normal rat IgG for 15 minutes. The 
splenocytes were then incubated with anti-B220 microbeads at 4-8o C for 15 minutes. The 
purified splenic B cells were obtained by separating the magnetic bead bound and 
unbound cells using the Miltenyi AUTOMACS Cell Separator using the program Possel-
1. The resulting B cells were found to be 97% B220 positive cells. B220-microbead 
purified splenic B cells were cultured in RPMI complete medium + 10% fetal calf serum 
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(FCS) at 370C in a humidified 5% CO2 atmosphere at 2 x 106 cells in 2 ml of complete 
medium and stimulated in the 24 well plates with LPS (10µg/ml), CpG (5µg/ml), 
Pam3CSK4 (5µg/ml) and HKSP (2 x 108 CFU/ml). The stimulation was done with the 
various ligands alone or together with either the PI3K inhibitors, Wortmannin or 
LY294002 at various concentration or with the GSK-3 inhibitor SB216763 at different 
concentrations for 72 h. Optimal culture conditions were determined in preliminary 
experiments. The supernatants were assayed for IgG3 or IgA as well as IgM, IgG2a, 
IgG2b or IgG1 by ELISA (Southern Biotech, Birmingham, AL).  
FLOW CYTOMETRIC ANALYSES  
 Control and LPS (1μg/ml) or Pam3CSK4 (1μg/ml), Pam2CSK4 (1μg/ml) as well as 
LTA(1μg/ml)  stimulated splenic macrophages were cultured for 24 hours and gently 
removed by scraping them off the plate. The cells were over 80% viable. These 
macrophages from the aged and the young mice were stained for surface expression of 
CD86 and F4/80 using directly conjugated flourochrome antibodies (BD Pharmingen) for 
30 minutes on ice. Newly generated BMDM were stained with anti-CD11b-FITC, anti-
F4/80-PE or anti-TLR-2-biotin and then PE-strepavidin. Also the BMDM were either left 
untreated or stimulated with LPS(1μg/ml), CpG(1μg/ml), P3CSK4(1μg/ml),  or HKSP  
and cultured for 24 hours and gently removed by scraping them off the plate. These 
macrophages from the aged and the young mice were stained with FITC-anti CD86 or 
FITC anti-I-Ek  class-II (BD Pharmingen) for 30 minutes on ice. B cells from the 72 hour 
cultures were collected, washed and resuspended in FACS buffer. They were blocked 
with normal rat IgG to prevent non-specific antigen binding and then biotin-conjugated 
anti-IgG3 and APC-anti-B220 were added and incubated for 30 minutes in the dark. The 
60 
 
cells were then washed two times and were incubated in dark for 15 minutes with PE-
streptavidin.  The cells were stained with B220-PE-Cy5, FITC-anti-IgA, FITC-anti-IgG1, 
FITC-anti-IgG2b, APC-anti-IgM, APC-anti-B220 and PE-anti-CD138. The cells were 
washed once and analyzed on a flow cytometer.  
CYTOKINE ELISA 
Cell free supernatants from either basal or activated purified splenic or bone marrow 
macrophages (2.5x105 cells/ml) were harvested following culture with or without TLR 
ligands or HKSP for 24 hours from predetermined optimal dose concentrations. The 
supernatants were assayed for cytokines, IL-10, IL-12(p40), IL-12(p70), IL-6 and TNF-α, 
by ELISA using OptEIA kits. The dilution of the capture antibody, the biotin-conjugated 
detection antibody and the streptavidin-conjugated horseradish peroxidase (HRP) for IL-
10, IL-12 (p70), IL-12(p40)  and TNF-α was 1:250; while 1: 1000 dilution of the 
detection antibody for IL-12 (p40), t 1:250. For the IL-6, the capture antibody was diluted 
at 1:500, the biotin-conjugated detection antibody was diluted at 1:1000 and the 
strepavidin-conjugated HRP was diluted at 1:2000. All dilutions were done in assay 
diluents, made from 1X PBS with 10% fetal bovine serum (FBS). The optical densities 
(OD) were read on an HTS 7000 plate reader (Perkin Elmer, Norwalk, CT) using the 450 
and 560nM wavelength. The results were expressed as mean +/-SE of triplicate 
determinations of supernatants from duplicate cultures. 
Ig ELISA 
IgG3, IgA, IgM, IgG2a, IgG2b or IgG1 from the 72 hour supernatants were assayed in 
accordance with a sandwich protocol. Briefly, 96-well  flat bottom high binding 
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polystyrene EIA/RIA microtiter plates (Corning Inc., Corning, NY) were coated  with 
100 µl of a purified goat anti-mouse capture Ab  at a concentration of 1 µg/100 µl coating 
buffer and incubated at 1 hour at room temperature for the IgG3 and the IgA ELISA. For 
the  IgM, IgG2a, IgG2b or IgG1 ELISA, the coating was done overnight with the goat 
anti-mouse Ig at 1:2000 dilution in coating buffer (Southern Biotec, #1100-01) in 1x PBS 
at 40 C. Reactions were blocked by adding 200 µl of 1x PBS containing 10% BSA 
(blocking buffer) to each well for 30 min at room temperature. Wells were then washed 
three times with 1x PBS containing 0.05% Tween 20 (washing buffer). Serial dilutions of 
the culture supernatants or of purified mouse IgG3 or IgA, IgM, IgG2a, IgG2b or IgG1, 
at a concentration of 0.5 µg/ml in blocking buffer, were added to each well (100 µl/well) 
and incubated for 2 hours at room temperature. Wells were washed thoroughly three 
times with washing buffer before receiving (100 µl/well) the detecting Ab conjugated 
with HRP, (Bethyl Laboratories), for IgG3 and IgA, and with alkaline phosphatase (AP) 
conjugated for IgM, IgG2a, IgG2b or IgG1, (Southern Biotec) at a concentration of 
1:10,000 to 1:30,000. After 1 h incubation at room temperature, wells were washed five 
times and 100µl of TMB substrate for the IgA and IgG3 and PNPP dissolved in 
phenlylamin buffer (Diethanolamine plusMgCl2, PH9.8) at 1mg of mg/ml for the IgM, 
IgG2a, IgG2b or IgG1 was added. The TMB substrate was stopped with 2M H2SO4. 
Wells containing the TMB substrate was measured for absorbance at 450 nm, while the 
PNPP were measured at 405 nm.  
 WESTERN BLOT 
The SM or BMDM from aged and young adult Balb/c mice were plated at 2 x 106 
cells/well in 500 μl of RPMI 1640 + 2% FCS in 24 well tissue culture plates. These cells 
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are allowed to rest for 4 hours to allow macrophage adherence and recovery from 
handling and then stimulated with 1μg/ml LPS or 1μg/ml Pam-3-CSK4, for 15 or 30 
minutes. These time points and doses were chosen after performing a detailed kinetic 
analysis. For inhibition of PI3 kinase pathway, macrophages were pretreated with 
wortmannin or LY294002. The reaction was stopped by adding 1.0 ml of ice cold 1x 
phosphate buffered saline (PBS). The cells were washed twice with 1.0 ml 1x PBS. The 
macrophages were then lysed in a lysis buffer at 100μL/5x106 cells (Cell Signaling 
Technologies, Beverly, MA), to which was added protease inhibitor cocktail (10x), 
(containing leupetin, EDTA, pepstatin), and phenyl methyl sulfonyl fluoride (PMSF) 
(1mM) (Sigma Chemical Co.  St. Louis, MO).  Nuclear and cytosolic fractions from the 
aged and young BMDM were obtained using the NE-PER nuclear and cytoplasmic 
extraction kit from Thermo Scientific (Rockford, IL) in accordance with the 
manufacturer’s instructions. The total protein content of the sample was determined by 
BCA protein assay (Pierce, Rockford, IL). Equal amounts of protein were separated by 
electrophoresis on sodium dodecyl sulfate-polyacrylamide gels 10% (SDS-PAGE) and 
were transferred to nitrocellulose membranes for Western blot analyses. The membranes 
were blocked with 2% milk and were then probed with  antibodies to: p-Akt (S473), Akt, 
p-GSK-3αβ and GSK-3, all of which were from Cell Signaling Technologies; or to PTEN 
and β-actin from Santa Cruz Biotechnology (Santa Cruz, CA). The immunoreactive 
proteins were then detected using horseradish peroxidase coupled secondary antibodies 
and the PICO Chemiluminescence substrate (Pierce Technology, Rockford, IL) and by 
exposing to Kodak X-omat film. The relative ODs of the protein bands were estimated 
using the Kodak Image Station software (Eastman Kodak, New Haven, CT). Band 
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intensities were determined by dividing the phosphorylated protein by the total protein. 
The blots were stripped with stripping buffer (62.5mM Tris, PH6.8, 2%SDS, 0.1M 2-
mercoptoethanol) for 25 minutes at 500 C and then probed with anti-beta actin (Sigma, St. 
Louis, MO) to correct for differences in protein loading. This was done by comparing the 
protein levels of actin to the various proteins of interest. 
REAL-TIME RT-PCR 
Purified SM or BMDM (3x106 cells/3ml)  were  stimulated with  1 μg/ml LPS  for 
30 minutes and RNA extracted by TriZol extraction kit  and then reverse transcribed to 
cDNA using the High Capacity  cDNA Archive  kit (Applied biosystems, Foster, CA). 
The cDNA was later amplified by real-time PCR in a 25μL reaction volume containing 
SYBR Green (QIAGEN, Valencia, CA) and analyzed using an ABI Prism Sequence 
detection system (Applied Biosystems, Foster City, CA). The experimental cDNA was 
tested in triplicate and normalized to 18S RNA. The RNA levels of p85, p110 and 18S 
were measured with QuantiTect PCR probes obtained from QIAGEN (Alameda, CA). 
 LIGHT MICRSCOPY 
Newly generated BMDM were evaluated under the Olympus light microscope at a total 
magnification of 40X and snap shots taken.  
STATISTICAL ANALYSIS 
Statistical differences between groups were evaluated using an unpaired Student‘s t test, 
or one way ANOVA.  In both tests statistical significance was concluded when p<0.05. 
Copyright © Mosoka Papa Fallah 2011 
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CHAPTER 3:  Role of phosphoinositide 3-kinase – Akt signaling pathway in 
the age-related cytokine dysregulation in splenic macrophages 
stimulated via TLR2 or TLR 4 receptors 
Introduction 
Numerous studies have established the senescence of the immune system in aged human 
and murine populations resulting in reduced effectiveness of both the innate and the 
acquired arms of the immune system of the elderly. As a result, older individuals are 
more susceptible to infections, particularly with Gram positive bacteria such as S. 
pneumoniae, and consistently demonstrate an impaired immune response to 
pneumococcal polysaccharide vaccine (159, 217, 218, 302). Secreted cytokines like IL-
12 and IL-6 help B-cells to produce increased IgG3 or IgA in the absence of help from T-
cells (17, 38, 64, 178, 230).  Both IgA and IgG3 promote opsonization of the bacteria. 
TNF-α is another pro-inflammatory cytokine that is produced by S. pneumoniae activated 
macrophages and also aids in the recruitment of neutrophils and macrophages, which 
phagocytose the opsonized bacteria (176, 201). 
 We have previously  shown that  upon stimulation with LPS, a TLR-4 ligand, 
aged SM secrete lower levels of the pro-inflammatory cytokines, IL-6, IL-12, and TNF-α, 
but  higher levels  of IL-10, resulting in cytokine dysregulation (62, 63, 65). Similar 
defects in TLR-induced pro-inflammatory cytokine secretion by aged splenic 
macrophages are also seen by other investigators (34, 298). As a result, TLR-4 activated 
aged macrophages or their secreted pro-inflammatory cytokines are not able to 
effectively provide support to B-cell mediated anti-capsular polysaccharide antibody 
responses (38, 114). Here we investigated whether or not similar cytokine dysregulation 
is exhibited when aged macropahges are stimulated with different types of TLR-2 ligands 
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that are relevant in the context of pneumococcal infections. Unlike other TLRs that form 
homodimers, the TLR-2 receptor complex is a heterodimer which gives it the ability to 
recognize a broader spectrum of ligands. Gram positive bacteria contain lipoproteins that 
are known to be recognized by TLR-2 resulting in the initiation of inflammation and 
control of bacterial infection (311). We also investigated this phenomenon in the context 
of heat killed S. pneumoniae (HKSP).  
 The lipoproteins or lipopeptides derived from them are differentially recognized 
by either the TLR2/6 heterodimer or the TLR2/1 heterodimer depending on whether the 
cysteine residue is diacylated or triacylated.  TLR2/1 recognizes a variety of bacterial 
lipopeptide/lipoproteins including mycobacterial lipoprotein, meningococcal lipoprotein 
and synthetic Pam3CSK4, while TLR2/6 recognizes mycoplasma lipoprotein, 
peptidoglycan and the synthetic Pam2CSK4 (349, 378). However, some studies show that 
TLR-2 can recognize some bacterial ligands, such as lipoteichoic acids (LTA) 
independent of TLR-1 or 6 (52). LTAs are more restricted to Gram positive bacteria than 
synthetic Pam2CSK4 and Pam3CSK4 like lipopeptides that can be found in both Gram 
positive and Gram negative bacteria (130, 318). LTA is a potent inducer of inflammatory 
cytokines in macrophages and human PBMC and is important for innate responses to 
Gram positive bacteria (97, 318, 378). 
In spite of the critical role of phosphatidyl inositol-3 kinase (PI3K) in modulating 
pro-inflammatory and anti-inflammatory cytokines in macrophages and dendritic cells 
(DC), little research has been done to investigate age-related changes in this important 
signaling molecule and its potential therapeutic value (173, 223).  PI3K is a lipid kinase 
that phosphorylates the inositide ring of PIP2 at the D3 position to generate PIP3.  PIP3 
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generated by PI3K activity serves as a docking site for the recruitment of signaling 
proteins via their pleckstrin homology domains. One of the kinases that is recruited to the 
membrane by PIP3 is the phosphoinositide-dependent kinase-1 (PDK-1), which then 
targets the serine-threonine kinase, Akt for phosphorylation at Thr-308. The activated 
Akt serves as a master kinase for many downstream substrates, including IKK and GSK-
3 (173). The levels of PIP3 can be down-modulated by PTEN (phosphatase and tensin 
homolog) and SHIP (Src-homology-2 containing inositol 5′-phosphatase), which are 
phosphatases that respectively target the D3 and D5 position of PIP3 converting it to 
PIP2 (223).  
Recent studies  show that PI3K signaling also plays a role in most TLR signaling 
as  inhibition of PI3K with pharmacological inhibitors results in differential regulation of  
anti- and  pro-inflammatory cytokines (108, 226, 308). In addition, it has been shown that 
the Class IA PI3K are activated after stimulation via diverse TLRs such as TLR2, 
TLR3,TLR4, TLR5, TLR9 and also the IL-1R signaling pathway (108). However, the 
connection between the TLR signaling and PI3K has recently been elucidated in gene 
knockout studies (215). These resuts show that MyD88 directly interacts with the p85 
subunit of PI3K (194). The PI3K pathway is known to negatively regulate the TLR 
induced production of pro-inflammatory cytokines (108, 226, 284, 308). Moreover, there 
is some evidence that this pathway is required for IL-10 production (290, 308). Hence, 
we questioned if PI3K levels are elevated with aging, and if inhibiting PI3K in aged SM 
restores the production of pro-inflammatory cytokines upon stimulation with either TLR 
ligands or HKSP. We found that there is an age-associated increase in the amount of 
PI3K subunit specific mRNA and its activity as shown by increased phosphorylation of 
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AKT and GSK-3. Inhibition of the PI3K-AKT signaling pathway enhances TLR2 and 
HKSP induced pro-inflammatory cytokines and decreases the anti-inflammatory cytokine 
levels in both the aged and young adult macrophages.  
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RESULTS 
 Age-associated cytokine dysregulation correlates with an enhancement of Class IA PI3K 
activity in TLR-4 stimulated macrophages. 
We have previously shown that LPS activated aged splenic macrophages exhibited a 
cytokine dysregulation with a decrease in the pro-inflammatory cytokines but an increase 
in IL-10, an anti-inflammatory cytokine (63). In these experiments macrophages were 
purified by adherence or by positive selection with anti-CD11b beads. In order to 
establish the role of PI3 kinase in this cytokine dysregulation and to avoid the inadvertent 
activation of splenic macrophages by either adherence or positive selection with CD11b 
magnetic beads, we purified splenic macrophages using negative selection procedures. 
This method involved staining splenocytes with anti-CD5-FITC, anti-B220-FITC and 
anti-LY6G-FITC and using anti-FITC coupled magnetic beads to remove non-
macrophages.   When these negatively selected macrophages from aged mice were 
stimulated with  LPS  they showed an increase in IL-10 secretion (Figure 3.1A) and a 
decrease in production of pro-inflammatory cytokines, IL-12(p40), IL-6 and TNF-α 
(Figure 3.1B)  compared to similar cells from young adult mice. Thus, these negatively 
selected SM continued to exhibit the same cytokine dysregulation that was observed with 
macrophages purified by other methods. 
We questioned if the observed dysregulation of cytokine secretion by the TLR-4 
activated SM was due to the differential expression of PI3 kinase Class I isoform of PI3K  
expressed in leukocytes, B-cells, T-cells, macrophages, and consistently shown to be a 
negative regulator of pro-inflammatory cytokines upon TLR stimulation (139, 188, 194, 
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219, 308). Hence, we examined our previously published microarray data (65) to 
determine if there were differences in the expression of the regulatory and the catalytic 
subunits (p110) of Class I PI3K between the young and the aged. The results indicated 
that there was a statistically significant increase in the expression of p110δ (Figure 3.1C) 
and p85β (Figure 3.1D) in aged compared to young adult murine SM, stimulated with 
LPS for six hours. These findings were confirmed by a quantitative reverse transcriptase 
real time polymerase chain reaction (qRT-PCR) which showed an increase in both p110δ 
(Figure 3.1E) and p85β (Figure 3.1F) in aged compared to  young adult macrophages. 
The increased magnitude of differences between young and aged in qRT-PCR versus 
microarray data could be due to the differences in macrophage isolation between the two 
studies (positive versus negative selection) and the time of stimulation (30 minutes versus 
6 hours). Therefore, we postulated that the age-associated decrease in pro-inflammatory 
cytokines and increase in anti-inflammatory cytokines was due to increased activity of 
PI3K.  
 Age-associated increase in the activity of PI3K as shown by changes in phosphorylation 
of Akt. 
It has been reported that the phosphorylation of Akt was an indirect way to determine the 
activity of PI3K (135, 308, 346) since PI3K activation resulted in phosphorylation of 
Threonine-308 and  serine-473 on Akt in a temporal manner leading to an increase in its 
activity (225, 226, 284). Therefore, levels of p-Akt were measured in young and aged 
SM, as a surrogate measure of PI3K activity. Western blot analysis showed that the 
phosphorylation of Akt was higher in aged compared to young adult SM stimulated with 
LPS. The age-associated increase in p-Akt could be seen as early as 15 minutes of 
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stimulation with LPS and was 2.4 times more in aged than the young adult (Figure 3.2A). 
The total levels of AKT (normalized to actin) were comparable in the elderly and the 
young mouse macrophages. 
GSK-3 is a direct downstream substrate of Akt and has been shown to be mainly 
involved in the differential regulation of the anti- and pro-inflammatory cytokines. GSK-
3 was phosphorylated on Serine-9 resulting in its inactivation (225, 382). An age-
associated increase in the phosphorylation of GSK-3 would provide additional support to 
our hypothesis that the activity of PI3K/Akt pathway was increased in aged splenic 
macrophages.  We employed western blot analysis to determine if the phosphorylation 
status of GSK-3 between the aged and the young correlated with the phosphorylation 
status of Akt. The phospho- GSK-3αβ subunits were normalized to the total GSK-3β 
subunit. GSK-3 phosphorylation was 3-fold more in the aged than the young by 15 
minutes after stimulation with LPS, the TLR-4 ligand (Figures 3.2B). Total GSK-3β 
levels (normalized to actin) were similar between the young and the aged.  
A defect in PTEN can lead to increased levels of PIP3 which in turn can result in 
increased PI3 Kinase activity (51). Tachado et al. have shown that in asymptomatic HIV 
positive patients TNF-α production by TLR-4 stimulated alveolar macrophages was 
suppressed due to a defect in PTEN expression leading to increased PI3K activity (346). 
Hence, we decided to quantify age-associated differences in total PTEN between the aged 
and the young adult splenic macrophages by Western blot. Surprisingly, there were no 
statistically significant differences in the total PTEN at either the basal level or upon 
activation with LPS (Figure 3.3A). We repeated this experiment using Pam2CSK4 as the 
ligand for TLR-2. Again, there were no differences in both the basal level or upon 
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stimulation with the synthetic TLR2/6 ligand (Figure 3.3B).  Thus, there was an increase 
in the activity of PI3K, as demonstrated by increased phosphorylation of AKT and GSK-
3, in aged macrophages stimulated with TLR-4 ligand that is independent of the activity 
of PTEN. 
Cytokine dysregulation in aged macrophages stimulated via TLR-2 and HKSP 
TLR2 was required for protection against S. pneumoniae infection (86, 222). 
Therefore, we tested if age associated cytokine dysregulation could be shown with 
Pam3Csk4, a synthetic ligand for TLR2/TLR1 heterodimer. It was observed that the aged 
splenic macrophages stimulated with Pam-3-CSK4 produced higher levels of IL-10 
compared to young adult macrophages (Figure 3.4A). However, there was a decrease in 
pro-inflammatory cytokines, such as IL-12 (Figure 3.4B) and IL-6 (Figure 3.4C).  
Since, there was an increased incidence of pneumococcal infections in the elderly, 
we inquired if this may be partly due to a similar dysregulation in the cytokine response 
of macrophages to stimulation with S. pneumoniae. To address this question, we 
stimulated aged and young adult purified SM with inactivated S. pneumoniae and assayed 
the cytokine response. The results demonstrated that there was an age-associated defect 
in TNF-α and IL-12(p40) production in the aged compared to the young adult 
macrophages (Figure 3.4D). Thus, age-associated cytokine dysregulation demonstrated 
with LPS can also be seen in both TLR-2 and HKSP activated SM. 
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Cytokine dysregulation in aged macrophages is seen with ligands that stimulate TLR-2 
receptors 
           The lipoproteins or lipopeptides derived from bacteria are differentially recognized 
by either the TLR2/6 heterodimer or the TLR2/1 heterodimer depending on whether the 
cysteine residue is diacylated or triacylated.  TLR2/1 ligands are typified by synthetic 
Pam3CSK4 while the natural ligands include mycobacterial lipoprotein and 
meningococcal lipoprotein.  TLR2/6 recognizes the synthetic ligand Pam2CSK4, as well 
as mycoplasma lipoprotein and peptidoglycan (349, 378). However, some studies show 
that TLR-2 recognized bacterial ligands such as lipoteichoic acid (LTA) independent of 
TLR-1 or 6 (52, 275, 314, 390). Having shown that aged SM have a defect in their ability 
to secrete cytokines upon stimulation with Pam3CSK4, we wondered if their responses to 
Pam2CSK4 and/or LTA were preserved to make them better candidates for adjuvants for 
the aged. Such an analysis wass important since some studies found that different TLR2 
ligands used distinct signaling pathways and had different in vivo effects while others 
found the two ligands use similar signaling pathways (168).  
 We stimulated SM from young and aged with the TLR2/6 ligand, Pam2CSK4 for 24 
hours and assayed for IL-10 (Figures 3.5A) and IL-12(p40) (Figures 3.5B). As shown in 
Figure 3.5A, the aged SM produced higher IL-10 than the young adult SM (almost 
undetectable) when stimulated with Pam2CSK4, but lower levels of IL-12 (p40) than the 
young (Figure 3.5B).   LTA is generally recognized by a TLR2/6 heterodimer (150) in 
macrophages similar to Pam2CSK4. Accordingly, we demonstrated that LTA was able to 
induce higher levels of IL-10 (Figure 3.5C) but lower levels of IL-12(p40) (Figure 3.5C) 
in the SM from aged than young mice. Since TLR4 stimulation induced increased 
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activation of the PI3-Akt-GSK pathway in aged versus the young macrophages, we tested 
if stimulation with the various TLR2 ligands also resulted in greater activation of this 
pathway in the aged. Western blot analysis of lysates from aged and young SM 
stimulated with Pam2CSK4 showed that there was a 2.7 and 3.5 fold increase in p-AKT 
in the aged versus the young adult macrophages stimulated for 15 and 30 minutes 
respectively (Figure 3.6A). We also investigated the effect of age-associated increase in 
the phosphorylation of AKT on phosphorylation of its downstream target, GSK-3, in the 
context of TLR2/6 (Pam2CSK4). The Western blot analysis showed that the levels of P-
GSK-3 were 3.3 and 10 fold more in the aged than in the young SM (Figure 3.6B) at zero 
and 15 minutes of Pam2CSK4 stimulation respectively.  Similarly stimulation of 
macrophages with LTA also demonstrated increased levels of P-GSK-3 in the aged 
compared to the young (Figure 3.6C). Thus PI3K pathway activity was increased in the 
aged SM upon stimulation with both TLR4 and TLR2 ligands. 
 PI3K inhibitors partially rescue the age-associated defect in TLR-4 induced cytokine 
production. 
 We wondered if the increase in the activity of PI3K had a role in the decreased 
production of the pro-inflammatory cytokines and increased IL-10 secretion in the aged 
SM (284, 308).  Hence, SM from aged and young adults were treated with either 
LY294002 or wortmannin, two well characterized PI3K inhibitors, and then stimulated 
with LPS, the TLR-4 ligand to initiate cytokine production. At 2 and 5 μM of LY294002 
there was a reduction in the levels of IL-10 in both aged and young SM stimulated with 
LPS (Figure 3.7A). At 50 nM, wortmannin had a more profound inhibitory effect on IL-
10 production by aged compared to young macrophages (Figure 3.7A). As predicted, 
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treatment with LY294002 resulted in the enhanced production of IL-12(p40) in aged SM, 
but not in the young adult SM (Figure 3.7B). The lack of enhancement in the young SM 
was surprising but was reproducible. However, when wortmannin was used as an 
inhibitor, there was a small but significant increase in IL-12(p40) in both age groups at 5 
nM and 50 nM (Figure 3.7B) but the magnitude of increase in IL-12 with wortmannin 
was smaller in the young than in the aged.  Thus, cytokine dysregulation in the aged 
appears to be linked to a defect in the PI3K-Akt pathway, and this can be partially 
rescued by inhibiting PI3K with either LY294002 or wortmannin. 
To be certain that the PI3K specific inhibitors were indeed blocking the PI3K/Akt 
pathway, Akt activation was evaluated by quantifying p-Akt levels in young 
macrophages treated with wortmannin or LY294002. LPS stimulation increased p-Akt 
levels compared to unstimulated cells. Inhibition of PI3K with wortmannin in the 
presence of LPS resulted in 1.6 fold reduction in the level of p-Akt compared to cells 
activated with LPS in the absence of the inhibitor at the 30 minute time point 
(Figure3.7C; Lanes 3 and 4). Similarly with LY294002, another PI3K inhibitor, there was 
a reduction in LPS induced activation of Akt by 3.7 fold at the 30 minute time point 
(Figure3.7C; Lanes 3 and 5). To demonstrate that phosphorylation of GSK-3 in SM was 
indeed dependent on the PI3K/Akt pathway, we determined if inhibition of PI3K with 
either LY294002 or wortmannin affected p-GSK-3 levels (225). As shown in Figure 3.7D 
stimulation of macrophages with LPS resulted in an increase in GSK-3 phosphorylation 
at 15 and 30 minutes of stimulation. Treatment with wortmannin or by LY294002 
decreased GSK-3 phosphorylation by 2.1 and 2.8 fold compared to untreated group after 
30 minutes of LPS stimulation.  Thus, activation of PI3K with TLR-4 ligand resulted in 
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an increase in phosphorylation of Akt and GSK-3, which was reduced significantly by 
inhibition of PI3K. 
  The ability of LY294002 or wortmannin to modulate the age-associated defect in PI3K 
signaling on cytokine production can also be shown with TLR-2 ligands 
We decided to investigate the possibility that decreased secretion of pro-
inflammatory cytokines in response to TLR2 ligands might also be rescued by PI3K 
inhibitors because TLR2 signaling used the same MyD88 adaptor as the TLR4 receptors 
(86, 134, 332). Purified SM from aged and young adult were pre-treated with LY294002 
or wortmannin and then stimulated with Pam-2-CSK4 (1μg/ml) or LTA. Treatment with 
the LY294002 reduced IL-10 secretion in the presence of both Pam2CSK4 and LTA 
(Figure 3.8A) and increased IL-12(p40) secretion when either Pam2CSK4 (Figure 3.8B) 
or LTA (Figure 3.8C) was used as the TLR-2 agonist in the aged SM. Interestingly, the 
PI3K inhibitor induced very little or no increase in cytokine secretion by young 
macrophages. Similar results were obtained when Pam-3CSK4 was used to stimulate 
macrophages in the presence of the PI3K inhibitor. Thus IL-10 was reduced in both aged 
and young splenic macrophages when PI3K was inhibited, (Figure 3.9A). Moreover, 
treatment with LY294002 resulted in an increase in IL-6 (Figure 3.9B) and IL-12(p40) 
(Figure 3.9C) in aged splenic macrophages, an effect that was not seen in the young adult 
(Figures 3.9 B and 3C).  
 Thus, PI3K inhibition resulted in reduced secretion of IL-10 but increased pro-
inflammatory cytokines in the aged SM when any of the TLR-2 ligands were used to 
stimulate the macrophages. Moreover, PI3K inhibition regulated cytokine secretion more 
in the aged than in the young adult. 
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 PI3K inhibition enhanced the HKSP mediated induction of pro-inflammatory cytokines 
in aged SM 
 As shown in Figure 3.4D, HKSP induced proinflammatory cytokines were decreased in 
aged SM. HKSP had been shown to interact with splenic macrophages via TLR-2, 4 and 
9 and to induce the secretion of both pro- and anti-inflammatory cytokines (85, 86, 201). 
Therefore, we tested if the impairment in HKSP-induced production of pro-inflammatory 
cytokines was also dependent on heightened PI3K activity in aged SM, using LY294002 
and wortmannin. Stimulating aged SM with HKSP in the presence of LY294002 resulted 
in enhanced HKSP induced secretion of IL-6 (Figure 3.10A). Similarly, treatment with 
wortmannin also enhanced secretion of both IL-6 (Figure 3.10B) and IL-12(p40) (Figure 
3.10D) by HKSP stimulated aged macrophages.  IL-12(p70) was measured (Figure 
3.10C) since the p40 subunit was also shared with IL-23. HKSP alone did not induce 
much p70 but treatment with wortmannin dramatically enhanced p70 levels. Similarly, 
induction of IL-12 (p70) by Pam-3-CSK4 was also enhanced by PI3K inhibition (data not 
shown).  
 Age-associated cytokine dysregulation involving TLR-2 and HKSP is due to a defect in 
the Akt-GSK-3 signaling axis 
Here we asked if the ability of the PI3K inhibitors to enhance TLR2 induced 
secretion of pro-inflammatory cytokines was associated with a reduction in the activation 
of p-Akt and p-GSK-3αβ, two downstream targets of the PI3K pathway.  Inhibition of 
PI3K with 20μM of LY294002 in the presence of Pam3CSK4 (1μg/ml) resulted in 40% 
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reduction in P-Akt compared to P3C activation without the inhibitor (Figure 3.11A: lanes 
2 and 3) when the densitometry of P-Akt was compared to total Akt. Since the loading 
was unequal between lanes 2 and lane 3, we also compared the band intensity of p-Akt to 
that of ß-actin band which showed a 76% reduction in p-Akt in LY pretreated cells 
compared to P3C stimulation without the inhibitor (Figure 3.11A: lanes 2 and 3). 
Treatment of Pam3CSK4 stimulated macrophages with wortmannin at 30 minutes 
resulted in a 28% reduction in p-GSK-3αβ (Figure 3.11B: lanes 3 and 4). When 
LY294002 was used, TLR-2 stimulated macrophages at 30 minutes showed a 56% 
reduction in p-GSK-3αβ levels (Figure 3.11B: Lanes 3 and 5). Given the consistency in 
the reduction of p-GSK-3αβ upon stimulation of purified SM with both TLR-2 and TLR-
4 ligands in the presence of PI3K inhibitors, it was of interest to evaluate the effect of 
stimulating aged SM with HKSP in the presence of LY294002.  HKSP was effective in 
activating the PI3K-Akt signaling pathway, as indicated by an increase in the 
phosphorylation of GSK-3 (Figure 3.11C: Lanes 1 and 2). Inhibition of PI3K with 
LY294002 resulted in a 52% reduction in the levels of p- GSK-3αβ (Figure 3.11C: Lanes 
2 and 3). Thus, activation of PI3K with TLR-2 or HKSP resulted in an increase in 
phosphorylation of Akt and GSK-3αβ, which was reduced significantly by inhibition of 
PI3K.  
 Effect of PI3K inhibition on cytokine secretion by SM stimulated with interleukin-1β (IL-
1 β) is similar to TLR induction. 
Thus far we have shown an age associated cytokine dysregulation using ligands 
for TLR1/2, TLR2/6 and TLR4 receptors, all of which use the MyD88/Mal heterodimer 
for signal transduction. One cannot distinguish if signal transduction via MyD88 or Mal 
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was different in the aged compared to the young. Hence, we tested the effect of aging on 
IL-1β induced responses of macrophages, since IL-1β had been shown to use MyD88 but 
not Mal for signal transduction (299). Moreover IL-1β was critical for the clearance of S. 
Pneumoniae via both macrophage activation and anti-polysaccharide antibody production 
by B-cells (64, 167). Very little was known about the role of the PI3K-AKT-GSK-3 
signaling axis in regulating IL-1β-mediated induction of IL-10 and the pro-inflammatory 
cytokines in the context of aged splenic macrophages. Inhibition of PI3K pathway with 
LY294002 resulted in a suppression of IL-1 induced IL-10 secretion (Figure 3.12A) but 
an enhancement of IL-6 secretion (Figure 3.12B) similar to our results with TLR2 and 
TLR4 ligands. This suggested that major target of PI3kinase-Akt-GSK-3 axis was the 
MyD88 pathway in macrophages, which was consistent with the recent findings that the 
p85 subunit of PI3K directly interacts with MyD88 (Laird et al 2009). 
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Discussion 
 
      Immune responses to infection, in particular to encapsulated bacteria, are decreased in 
the aged. Previously, we have shown that antibody responses to polysaccharide antigens, 
one of the protective antigens for infections with pneumococcal bacteria, are decreased in 
the aged, in part due to defects in macrophage function (63). Using TLR-4 activation as a 
model system we now show that the SM from the aged exhibit a cytokine dysregulation 
phenotype with a decrease in pro-inflammatory cytokines required for B cell activation. 
Using gene expression studies we also showed that this is due to a decrease in the 
activation of the MyD88 signaling pathway leading to a decrease in ERK activation with 
an aberrant increase in p38 MAP kinase activation (65).  Since the immune responses to 
Gram positive bacteria, such as S. pneumoniae, are also dependent on TLR2 activation 
(86, 318), and since TLR2 ligands also utilize the MyD88 signaling pathway, we 
hypothesize that SM from the aged would exhibit a cytokine dysregulation phenotype 
with synthetic TLR2 ligands or intact bacteria similar to that seen with TLR4 activation. 
Indeed, studies presented here demonstrate that activation with HKSP or any of the TLR-
2 ligands, Pam3-CSK4, Pam-2-CSK4 or LTA, induces lower levels of pro-inflammatory 
cytokines such as IL-12, but higher levels of anti-inflammatory cytokines such as IL-10 
in SM from the aged macrophages compared to macrophages isolated from young mice. 
Together with our previous studies, these results demonstrate that immunosenescence 
affects responses of SM to both TLR2 and TLR4 ligands.  
To understand the signaling mechanism governing this age-associated cytokine 
dysregulation, we evaluated the activity of PI3K, a well established switch-factor for pro- 
and anti- inflammatory cytokines (108, 290, 308). An analysis of our previous data on 
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gene expression in highly purified SM (65)  reveals that there is an age-associated 
increase in expression of genes encoding both the catalytic (p110δ) and the regulatory 
(p85β) subunits of the Class IA PI3 kinase, which is further validated by qRT real time 
PCR. There is an increase in functionally active PI3-kinase in the aged macrophages as 
shown by an increase in the phosphorylation of its downstream target, Akt, in splenic 
macrophages stimulated by ligands for TLR-2 and TLR-4. Moreover, phosphorylation of 
GSK-3, an immediate downstream target of Akt (139, 225), is also increased in TLR-2 
and TLR-4 stimulated SM from the aged compared to the young. Thus, the PI3K-Akt-
GSK-3 pathway that is known to negatively regulate pro-inflammatory cytokine 
production is upregulated in macrophages from the aged stimulated with TLR2 or TLR4 
ligands, as well as HKSP.  
We next asked if inhibitors of PI3K could restore pro-inflammatory cytokine 
production and decrease IL-10 production by TLR-2 or 4 stimulated macrophages from 
the aged. Accordingly, we show that PI3K inhibitors enhance IL-12(p40) production and 
decrease IL-10 secretion by aged mouse SM stimulated with either TLR-2 or TLR4 
ligands.  However, under these conditions PI3K inhibitors do not have much effect on 
cytokine secretion by young adult SM stimulated with TLR-2 or 4 ligands. Despite 
previous studies demonstrating specificity of wortmannin and LY294002 to Class I 
isoform, more recent studies find that one of the Class II isoforms is also inhibited by 
these reagents, albeit at 50-100 fold higher concentration (135, 238, 335, 338, 367). 
Currently we are devising an RNAi approach to establish the relative importance of PI3K 
isoforms in age-related cytokine dysregulation.     
81 
 
         Our finding that in vitro stimulation of purified SM produced higher IL-10 but 
lower pro-inflammatory cytokines in the aged than in young is consistent with other 
published studies (34, 63, 277, 298). In contrast, there are several reports that IL-6 levels 
are increased in the elderly and contribute to basal inflammation (47, 102). This apparent 
inconsistency between the in vitro and in vivo cytokine profile are attributed to the 
criteria used to select elderly subjects (9). It is known that the frail elderly already have 
predisposing underlying diseases that impact on basal inflammation, whereas, in the 
healthy elderly, the inflammation is controlled by the increase in the levels of IL-10 (9, 
198). Thus, Njemini  and colleagues (2007) show that IL-6 levels in healthy elderly are 
less than in young adults but the levels of IL-6 were more  in elderly than young when 
there is evidence of infection (257). Additionally, work from Kovacs’ laboratory (119)  
further confirms the in vitro defect in production of pro-inflammatory cytokines by LPS 
activated macrophages from the aged. Interestingly, IL-6 knockout mice made more 
TNF-α, IL-1, IL-12 than young wildtype mice suggesting a role for systemic IL-6 in the 
cytokine defect of aged mice. However, IL-6 regulation is complex since young IL-6 
knockout mice makes less IL-1, IL-12 and TNF-α than young wild type mice (119).  
Working with monocyte derived dendritic cells (MDDC) from the elderly 
Agrawal and colleagues (5) show that the age-associated increase in the pro-
inflammatory cytokines is due to a decrease in PI3K activity and increased activity of p38 
MAP Kinase. These discrepant results could be due to the use of SM in our study; while 
human peripheral blood monocyte derived dendritic cells are used by Agrawal and 
colleagues. In contrast to this study with DCs and in agreement with our studies Panda 
and colleagues report that elderly human myeloid and plasmacytoid DC from peripheral 
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blood mononuclear cells exhibit a defect in the production of proinflammatory cytokines 
(277).  
Using Zymosan, yeast derived TLR-2 ligand, to stimulate purified SM, Boehmer 
and colleagues (35) find that IL-6 is decreased in the aged. However, there was no 
difference in the cytokine levels between the aged and the young adult in terms of IL-10. 
This apparent contradiction from our findings that IL-10 is higher in the aged compared 
to the young can be explained by putative differences in the signaling mechanism 
between Zymosan and the other TLR2 ligands used here. Zymosan interacts with dectin-
1 to stimulate production of pro-inflammatory cytokines (84, 87, 90), while Pam-3-CSK4 
is not known to signal via dectin-1 to induce cytokine production (113). A second 
plausible reason for this apparent contradiction could be due to the method by which the 
macrophages are purified. We used negative selection to isolate the splenic macrophages 
and thus keep them unperturbed. Boehmer and colleagues used adherence to isolate 
macrophages, which is known to activate macrophages (80, 175). 
Although, we observed the expected negative effects of PI3K on pro-
inflammatory cytokines in the aged, the effects of PI3K inhibitors on cytokine secretion 
by young SM are very modest and are seen only in certain groups. Interestingly most of 
the studies performed with young macrophages to investigate the role of PI3K and 
cytokine regulation use human monocytes, murine peritoneal macrophages, alveolar 
macrophages or macrophage-derived cell lines like THP-1 and RAW 264.7 cells, but not 
SM (215, 226, 284, 308, 346, 375). It is possible that the PI3K pathway may not have 
major negative effects on TLR signaling in young adult SM, due to the low expression of 
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the PI3K enzyme. More profound effects are seen in the aged due to increased expression 
of PI3K subunits.  
The association between the increased activity of PI3K and a decrease in PTEN 
expression is well established (223). PTEN promotes pro-inflammatory activity of 
macrophages (56). MDDCs from elderly have increased PTEN levels (5). However, we 
do not note any difference in the level of PTEN between aged and young adult SM. This 
apparent contradiction regarding age associated changes in PTEN levels may also be due 
to differences between macrophages and DCs and/or due to differences between human 
and mouse.  
We propose a model (Figure 3.13) in which there is a heightened activity of PI3K 
in the aged macrophages (Figure 3.13A) resulting in increased phosphorylation of Akt. 
The increased activity of Akt results in a further phosphorylation of GSK-3 and reduction 
in its activity. We propose that the reduction in the activity of GSK-3 affects transcription 
factors like CREB, AP-1 and p65NFκB via inhibitory phosphorylation or export from the 
nucleus; resulting in increased IL-10 and a decrease in the pro-inflammatory cytokines 
such as IL-12, IL-6 and TNF-α. Inhibiting PI3K reverses this phenotype to that of a 
young adult (Figure 3.12B) with increases in the pro-inflammatory cytokines over IL-10. 
We are currently investigating the effect of modulating PI3K on transcription factors 
CREB, AP-1 and p65NFκB. Here, we have included TLR2/TLR6 heterodimers and IL-
1R since we find similar results with Pam2CSK4 (TLR2/6 ligand) and IL-1. 
The biological significance of our findings is that these inhibitors can reverse the 
effect of aging on macrophage function. We show that macrophages and macrophage-
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mediated cytokine defects in the aged are critical factors responsible for the impaired 
anti-CPS antibody response in the aged (38, 63). We also show that the humoral response 
of the aged to PS or TNP-Ficoll and TNP-LPS, representative TI antigens, is enhanced if 
aged B-lymphocytes are provided with either young macrophages or macrophage-derived 
cytokines like IL-6 and IL-1β (63, 114). Others show that antibody responses to infection 
with S. pneumoniae are enhanced in the presence of IL-12 (17, 230, 341). We propose 
that PI3K inhibition can enhance the macrophage-derived cytokines that are known to 
provide the signal 2 needed to activate B cells and mount an effective antibody response 
to S. pneumoniae and/or PPS vaccines in the elderly. In conclusion, our novel observation 
that the age-associated increase in PI3K-Akt activity is a signaling defect that contributes 
to the cytokine dysregulation observed in the aged and that PI3K inhibitors may be useful 
as unique adjuvants to enhance immune responses in the aged. 
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Figure 3.1: Age-associated changes in cytokine production and levels of PI3K 
subunits in SM stimulated via TLR4.   
SM (2.5x105 cells/ml) from young (2-4 months) and aged (20-24 months old) mice 
purified by negative selection using an AUTOMACS cell separator were stimulated with 
LPS (1µg/ml) for 24 hours (Panels A and B) and the supernatants were collected and 
analyzed for IL-10 (Panel A) or  pro-inflammatory cytokines, IL-12(p40), IL-6, and 
TNF-α (Panel B) . Panels C and D represent levels of RNA for p110δ and p85β subunits 
derived from microarray analysis performed on gene expression in young and aged 
macrophages. QRT-PCR analysis of mRNA was shown in panels E and F for P110δ and 
p85β subunits respectively of PI3 kinase in purified splenic macrophages from young and 
the aged. The Ct values for each probe were normalized to the 18S RNA. The symbols * 
and #  indicate the statistical significance and was set to p<0.05.  
 
 
 
 
 
 
 
 
 
87 
 
 
Figure 3.2: The age-associated increase in phosphorylation of AKT and GSK-3 in 
TLR-4 stimulated macrophages. 
Purified young adult and aged SM were stimulated with LPS 1μg/ml for 15 minutes. 
Panels A and B show the phosphorylation of Akt and GSK-3 respectively in the aged and 
the young splenic macrophages stimulated with LPS. The blots were stripped and probed 
for total AKT and actin   in panel A and for total GSK-3β and actin in panel B. The 
numbers represent densities of bands normalized to total AKT with the values for 
unstimulated aged macrophages set to one.  
The figure in panel A is a composite of blots for P-Akt, Akt and actin from the same 
membrane that was stripped and reprobed. The same method was employed to assemble 
panel B for P-GSK-3αβ, GSK-3β and actin.  The young and aged cell lysates were 
electrophoresed on the same gel and the membranes were exposed for identical time 
periods. Although a detailed kinetic analysis of LPS stimulation was performed, only the 
lanes representing 0 minutes and 15 minutes time points was shown for clarity. 
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Figure 3.3. Age-associated increase in PI3K activity is not due to changes in the 
levels of PTEN 
Lysates from young and aged SM stimulated with LPS (1µg/ml) for 15 minutes (Panel A) 
or P2C (Panel B) and analyzed by SDS PAGE and Western blots. The blots were first 
probed for PTEN and then for actin after stripping. The graphs showed the arbitrary units 
of band intensities normalized to actin with the values for unstimulated aged 
macrophages set to one.The final figure was a composite of blots for PTEN and actin for 
aged and young samples run on the same membrane that was stripped and reprobed. The 
intervening space, as well as the right end were for the 30 minute time point but were 
deleted for consistency and clarity. 
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Figure 3.4: TLR-2 and HKSP-mediated cytokine dysregulation in young and aged 
splenic macrophages. 
Macrophages (2.5x105 cells/ml) purified from the spleens of young and aged mice were 
stimulated with the TLR-2 agonists, Pam3CSK4 (1µg/ml) (Panels A, B and C) or killed 
S. pneumoniae (2x106 CFU/ml) (panel D) for 24 hours. The supernatants were collected 
and analyzed by a sandwich ELISA for IL-10 (Panels A), IL-12(p40) (Panels B and D), 
IL-6 (Panel C) and TNF-α (Panel D). In panel A, IL-10 levels in unstimulated young and 
aged macrophages were undetectable. Results from one of three experiments were shown 
as Mean + SE values of 8-12 determinations. The statistical significance of differences in 
cytokine secretion between the young and the aged was indicated by the symbols * and 
@ and was set to p<0.05. 
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Figure 3.5: Age-related cytokine dysregulation in response to stimulation of 
macrophages with TLR2 ligands.  
 SM (2.5x105 cells/ml) from young and aged Balb/c mice purified by negative selection 
were stimulated with either Pam2CSK4 (1µg/ml) (Panels A and B) or LTA (1μg/ml) 
(Panel C). Supernatants were collected at 24 hours and analyzed for IL-10 (Panel A and 
C) or IL-12(p40) (Panels B and C). The results were shown as mean +/- SE of duplicate 
determinations from triplicate cultures, and representated three independent experiments. 
The symbols * and ** indicated the statistical significance (Student’s t test) of differences 
in cytokine secretion between the young and the aged and was set to p<0.05.  
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Figure 3.6: Age-related increase in activation of AKT and GSK-3 in splenic 
macrophages stimulated with TLR2 ligands.   
Panel A represents Western blot analysis of levels of P-AKT, total AKT and actin 
loading control; while Panel B represents P-GSK-3, total GSK-3 and actin loading 
control in Pam2CSK4 stimulated purified SM from the aged. The blots were 
stripped and probed for total AKT and actin. The numbers represent densities of 
bands normalized to total AKT with the values for unstimulated aged 
macrophages set to one. Panel C represents levels of P-GSK-3, total GSK-3 and 
actin loading control in LTA stimulated purified splenic macrophages. The final 
figures in both B and C are a composite of blots for P-GSK-3, GSK-3 and actin 
from the same membrane that was stripped and reprobed. The intervening deleted 
space in the middle was for 30 minutes but this was removed for the sake of 
clarity 
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Figure 3.7: PI3K inhibitors partially rescue the age-associated defect in TLR-4 
induced cytokine production by inhibiting phosphorylation of Akt and GSK-3. 
The graphs show cytokine secretion by purified aged and young adult SM pretreated with 
either 2 or 5 μM LY294002 or 5 or 50 nM wortmannin (panels A and B) for 60 minutes 
and then stimulated with LPS (1µg/ml) for 24 hours. Supernatants were collected and 
assayed for IL-10 (panel A) and IL-12 (p40) (panel B) by sandwich ELISA.  Data were 
presented as mean+/-SE values of 6-10 determinations and were representative of three 
independent experiments. The symbols * and # indicated statistical significance of 
differences in responses in groups treated with LPS alone compared to groups treated 
with LPS + PI3K inhibitor and was set to p<0.05. Purified young adult splenic 
macrophages were pre-treated with either LY294002 or wortmannin for 1 hour and then 
stimulated with LPS (Panel C) for 15 or 30 minutes. The blots were probed for p-Akt and 
later probed for total Akt and actin after stripping. The numbers represented densities of 
bands normalized to total AKT with the values for unstimulated aged macrophages set to 
1. Panel D shows relative changes in phosphorylated GSK-3 in young splenic 
macrophages stimulated with LPS in the presence of PI3K inhibitors. The numbers 
represent densities of both GSK-3alpha and GSK-3beta bands normalized to total GSK-
3β with the values for unstimulated aged macrophages set to one. Results were 
representative of two independent experiments. 
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Figure 3.8: Cytokine dysregulation in aged splenic macrophages stimulated with 
TLR2 ligands can be partially rescued by inhibiting PI3K. 
The graphs show cytokine secretion by purified aged and young adult SM pretreated with 
LY294002 for 60 minutes and then stimulated with  Pam2CSK4 (Panels A and B ), LTA 
(1μg/ml) (Panels A and C)  for 24 hours. Supernatants were collected and assayed for IL-
10 (Panel A) or IL-12(p40) (Panels B and C) by sandwich ELISA. Data were presented 
as mean +/- SE of duplicate cultures and duplicate ELISA’s. The symbols * and # 
indicated statistical significance of responses in the aged splenic macrophages treated 
with Pam2CSK4 or LTA with or without the PI3K inhibitor set to p<0.05. 
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Figure 3.9: The cytokine dysregulation in TLR1/2 stimulated aged macrophages can 
also be reversed with PI3K inhibition. 
Macrophages (2.5x105 cells/ml) purified from the spleens of young and aged mice were 
stimulated with the TLR-1/2 agonist, Pam3CSK4 (P3C) (1µg/ml) (Panels A, B and C) for 
24 hours in the presence or absence of LY294002. The supernatants were collected and 
analyzed by a sandwich ELISA for IL-10 (panel A), IL-6 (Panel B) and IL-12(p40) 
(Panel C). Results from one of three experiments were shown as Mean + SE values of 8-
12 determinations. The statistical significance of differences in cytokine secretion 
between the young and the aged macrophage treated with P3C alone compared to groups 
treated with PI3K inhibitors was indicated by the symbols * and #. 
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Figure 3.10.  The inhibition of PI3K by either LY294002 or wortmannin enhanced 
the HKSP-mediated induction of pro-inflammatory cytokines in aged splenic 
macrophages. 
The graphs show cytokine secretion by purified aged SM pretreated with LY294002 
(panel A) or wortmannin (Panels B, C and D) for 60 minutes and then stimulated with 
HKSP (2x 108 CFU/ml) for 24 hours. Supernatants were collected and assayed for IL-6 
(Panels A and B), IL-12(p40) (Panel D) and IL-12(p70) (Panel C) by sandwich ELISA. 
Data were presented as mean +/- SE of duplicate cultures and duplicate ELISA’s. The 
symbol * indicated statistical significance of responses in the aged SM treated with 
HKSP alone compared to the responses obtained by treating with HKSP + PI3K inhibitor 
set to p<0.05.   
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Figure 3.11. Age-associated cytokine defect in TLR-2 and HKSP activated 
macrophages is due to a defect in the AKT-GSK-3 signaling axis.  
Purified aged SM were pre-treated with either LY294002 or wortmannin for 1 hour and 
then stimulated with Pam-3-CSK4 (Panels A and B) or HKSP (2x108 CFU/ml) (Panel C) 
for 15 or 30 minutes, respectively. The blots were probed for p-Akt (Panel A), p-GSK-
3αβ (Panels B and C) and later probed for total Akt (Panel A), total GSK-3β (panels B 
and C) and actin after stripping. The numbers represent densities of bands normalized to 
total AKT, actin or GSK-3 with the values for unstimulated aged macrophages set to 1.  
Results were representative of two independent experiments.The final figure in A was a 
composite of blots for P-Akt, Akt and actin for aged samples run on the same membrane 
that was stripped and reprobed. The intervening space (between second and third lane) 
was for lanes loaded with lysates from other time points or treated with other inhibitors 
but were deleted  to focus on the effect of P3C on Akt activation at 15 minutes, which 
was maximum in this experiment.  
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Figure 3.12.  The effect of PI3K inhibition on IL-1 β induced cytokine production in 
splenic macrophages. 
 Panels A and B respectively showed the levels of IL-10 and IL-6 secreted by IL-1 
(400U/ml) stimulated aged SM pretreated with LY294002 for 60 minutes. Supernatants 
were collected and assayed for IL-10 and IL-6 by sandwich ELISA.  Data represent mean 
+/- SE of duplicate determinations of supernatants from duplicate cultures. The symbol * 
indicated the statistical significance of differences in cytokine levels between cells treated 
with IL-1 alone or IL-1 + the PI3K inhibitor  set to p<0.05.   
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Figure 3.13: Schematic model of differing roles of PI3 Kinase and P38 MAP Kinase 
pathways in cytokine secretion by young and aged splenic macrophages. 
The interaction of aged SM with ligands for TLR-4, TLR-2/1 or TLR2/6 heterodimers, or 
HKSP induces the activity of an already heightened PI3K, as well as p38 MAPkinase via 
MyD88 signaling adaptor molecule (Panel A). The activated AKT and GSK-3, as well as 
the phosphorylated p38 MAP kinase interact with transcription factors like CREB, AP-1 
and p65NκB to suppress the pro-inflammatory cytokines but increase IL-10. The effect of 
this pathway is biased towards pro-inflammatory cytokines in the young due to lower 
levels of PI3 kinase and p38 MAP Kinase activity (Panel B). 
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CHAPTER 4:   Intrinsic defect in the phosphoinositide 3-kinase – Akt                      
pathway plays a role in cytokine dysregulation in aged                      
bone marrow derivedmacrophages stimulated with TLR                   
ligands or heat killed Streptococcus pneumoniae 
Introduction 
The immune system is dysregulated with age resulting in higher susceptibility to 
bacterial and viral infections, as shown with an increase in pneumococcal infections, as 
well as a reduction in the efficacy of pneumococcal and influenza vaccines (236). It has 
been shown in several species (human, rat and mice) that aging affects the innate 
components of the immune system, like macrophages and dendritic cells. These effects 
include impaired antigen presentation and decreased production of critical pro-
inflammatory cytokines that help to induce the adaptive immune response (288). The 
efficacy of the pneumococcal vaccination is low in older adults due to a reduction in 
opsonophagocytosis of the pneumococal bacteria as a result of a decrease in high affinity 
IgM  antibody response (278). 
 Macrophages are known to act in resident tissues to destroy invading pathogens and 
lead to adaptive immunity by expression of co-stimulatory molecules, cytokine 
production and antigen presentation to lymphocytes upon activation by Toll-like 
receptors (TLRs). In a physiological situation, a macrophage sees multiple TLR ligands 
and thus, may produce pro- or anti-inflammatory cytokines depending on the context 
(219). Macrophage-derived cytokines, like IL-1, IL-12 and IL-6, help B-cells to produce 
increased IgG3 and IgA in the absence of help from T-cells (17, 38, 64, 178, 230).  Both 
IgA and IgG3 promote opsonization of many bacteria. TNF-α is another pro-
inflammatory cytokine that is produced by S. pneumoniae activated macrophages and 
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also aids in the recruitment of neutrophils and macrophages, which phagocytose the 
opsonized bacteria (176, 201). IL-12 can directly or indirectly act on B-cells to induce B-
cell proliferation, activation and differentiation, mostly through intermediaries like Th1 
type cells and interferon gamma to enhance production of  IgG2a (12, 350). TNF-α and 
IL-6 play critical roles in the clearance of lung burdens of pneumococcal bacteria (355, 
356). TLR2, TLR4 and TLR9 appear to play an important role in host immunity against 
pneumococcal infections. We have previously shown that upon stimulation with LPS, a 
TLR-4 ligand; in comparison to the young, aged splenic macrophages secrete lower 
levels of the pro-inflammatory cytokines, IL-6, IL-12, and TNF-α, but higher levels of 
IL-10, resulting in cytokine dysregulation (62, 63, 65). We also show a similar cytokine 
dysregulation when SM is stimulated with ligands for TLR-2/1, 2/6 and TLR-2 
homodimer (Fallah et al manuscript in press). Similar defects in TLR-induced pro-
inflammatory cytokine secretion by either aged splenic or peritoneal macrophages 
(resident or thioglycollate induced) are observed in other studies (34, 35, 62, 63, 144, 
298). As a result, TLR-2 or TLR-4 activated aged macrophages or their secreted pro-
inflammatory cytokines are not able to effectively provide support to B-cell mediated 
anti-capsular (CPS) antibody responses. Moreover, the increased IL-10 has a role in 
increased pneumococcal infections in the aged. IL-10 is increased after pneumococcal 
infection in naïve hosts or hosts previously exposed to influenza virus. Prior influenza 
virus infection increases lethality of subsequent pneumococcal infection. Anti-IL-10 
treatment reduces lethality of S. pneumoniae in naïve, as well as influenza in exposed 
hosts (306, 358). 
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While investigating the signaling components associated with the defect in TLR-
induced  activation of aged macrophages, we found that the cytokine dysregulation is  in 
part due to  heightened activity of phosphatidyl inasitol 3-kinase (PI3K).
Current consensus on the effect of aging on hematopoietic stem cells (HSC) points 
to a dual regulation of HSC by intrinsic factors and cues from the bone marrow 
microenvironment or stromal niches. Both of these are altered during aging resulting in 
skewing of the differentiation of HSC towards myeloid lineages. These age-associated 
effects on HSC have a role in narrowing the immune repertoire and blunting the immune 
function in the aged (33, 54, 170, 372, 386). Hence, in this study we attempt to reduce the 
influence of the aging microenvironment by growing a homogenous population of 
macrophages under in vitro conditions (143, 315). 
 Inhibition of the 
PI3K with two well known pharmacological inhibitors (LY294002 and wortmannin) 
partially rescues this age-associated cytokine dysregulation (Fallah et al manuscript in 
press).  Presently, it is unclear whether the cytokine dysregulation is due to intrinsic 
signaling defects or defects in the tissue microenvironment or both in the aged (143, 187, 
212, 315, 339, 354). 
We test the in vitro TLR responses of 
bone marrow derived macrophages (BMDM) from the young and the aged, thus 
eliminating the microenvironment of the aged spleen or peritoneum (315).  
These in vitro generated BMDM exhibit all of the characteristics of mature 
macrophages and are phenotypically similar in the young and the aged. Upon stimulating  
with ligands specific for TLR-4, TLR2/1, TLR2/6 and TLR-9 receptors or HKSP, the 
BMDM from the aged exhibited cytokine dysregulation which are  similar to that  seen 
103 
 
with purified SM (62, 63, 65). Furthermore, BMDM from the aged behave like the SM
 
 in 
having an elevation in the activity of the PI3K-Akt signaling pathway and inhibition of 
this pathway restores pro-inflammatory cytokine production. 
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 RESULTS 
 
 The newly derived BMDM from the aged and young adult exhibit similar purity, 
recovery and activation status. 
We first characterized the newly generated BMDM to ensure that they exhibited 
phenotypes of macrophages and that these phenotypes were similar between the two age 
groups. There was a similar expression of F4/80 and CD11b markers for macrophages 
between the aged and the young BMDM (Figure 4.1A) and in both cases greater than 
96% of the cells expressed both F4/80 and CD11b.. We then showed by light microscopy 
that the morphologies of the newly generated BMDM from the aged and the young were 
similar (Figure 4.1B). Although the absolute recovery of BMDM varied from experiment 
to experiment (Figure 4.1C), the recoveries of BMDM from the bone marrow cell 
cultures from the young and the aged were similar in each experiments. Thus, we 
recovered 0.33+/- 0.06 x 106 BMDM from the young and 0.28+/- 0.05 x 106 BMDM 
from the aged (n=15 experiments and p=0.52) per 1.0x106 bone marrow cells cultured. 
The extent of activation as determined by CD86 expression was not different between the 
aged and the young under basal conditions or after stimulation with LPS (TLR-4) (Figure 
4.1D), Pam3CSK4 (TLR-2) (Figure 4.1E) and HKSP (Figure 4.1F). These results 
provided a basis for us to conclude that the newly generated BMDM from young and 
elderly mice independent of an in vivo microenvironment exhibited similar 
characteristics. 
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Cytokine secretion defects in aged BMDM stimulated with TLR4 and 9. 
We stimulated the newly derived BMDM from the aged and the young mice with LPS, 
Pam3CSK4 and CpG for 24 hours and measured the levels of IL-10, IL-12, IL-6 and 
TNF-α in the supernatants. Similar to our previous data with SM (62, 63), LPS induced 
higher IL-10 and reduced levels of IL-12, IL-6 and TNF-α in the BMDM from elderly 
mice compared to the young (Figures 4.2A, 4.2B, 4.2C and 4.2D). We observed a similar 
age associated increase in IL-10 and decline in IL-12 secretion from BMDM stimulated 
with Pam3CSK4, the TLR2 ligand (Figures 4.2E and 4.2F) similar to our recent results 
with SM (Fallah et al manuscript In Press). The TLR9 ligand, CpG, also induced more 
IL-10 and less IL-6 from the aged than young BMDM (Figures 4.2G and 4.2H). Thus, the 
cytokine phenotype of newly generated BMDM from the aged was similar to the 
previously reported cytokine phenotype of SM from the aged stimulated via different 
TLR receptors suggesting that the splenic microenvironment of the aged was not 
necessary for the age associated cytokine dysregulation in macrophages.  
HKSP-mediated cytokine dysregulation in young and aged BMDM. 
Since whole bacteria can stimulate macrophages via several TLR receptors, we decided 
to test if cytokine response of BMDM to whole pneumococcal bacteria was also affected 
with aging. After 24 hours of stimulation with HKSP, supernatants from young and aged 
BMDM cultures were collected and assayed for IL-10, IL-12 and IL-6. In agreement with 
our previous data on SM activated with HKSP (Fallah et al Manuscript In press) we were 
able to show an age-related increase in IL-10 (Figure 4.3A) but a decrease in both IL-12 
(Figure 4.3B) and IL-6 (Figure 4.3C).  Thus, the intrinsic defects in aged macrophage 
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secretion of pro-inflammatory cytokines observed with individual TLR ligands were also 
demonstrated with the whole bacteria. Just like with the individual TLR ligands, the 
decrease in IL-12 was accompanied by an increase in the anti-inflammatory cytokine, IL-
10.  
The activity of PI3K-Akt pathway is increased in the aged BMDM 
We had earlier shown in SM (Fallah et al Manuscript In Press) that the heightened 
activity of the PI3K/Akt pathway was in part responsible for the cytokine dysregulation 
in the aged. Hence, we decided to determine if the activity of PI3K-Akt pathway was 
altered between the aged and the young BMDM grown in vitro without any 
microenvironmental influences of the aged spleen. The QRT-PCR for the mRNA of the 
p110δ subunit showed that resting young BMDM had higher levels than the aged BMDM 
but the message levels declined rapidly upon LPS stimulation in the young cells. In 
contrast there was no decrease in p110δ mRNA in the LPS stimulated  aged BMDM, but 
there was a small increase with the net result that TLR activated aged BMDM had more 
p110δ message than the young BMDM (Figure 4.4A). We then measured the activity of 
the PI3K in the aged and the young BMDM by way of the phosphorylation status of p-
Akt. Western blot analysis showed that the phosphorylation of Akt was higher in the aged 
compared to young adult BMDM stimulated with LPS. The age-associated increase in p-
Akt was seen as early as 15 minutes of stimulation with LPS and was 2.45+/-0.6 (n=4) 
times more in the aged than the young adult cells treated with LPS (Figure 4.4B). The 
total levels of Akt (normalized to actin) were comparable in the elderly and the young 
mouse BMDM (data not shown).  
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PI3K inhibitors partially rescue the age-associated defect in TLR-4 and TLR-9 induced 
pro-inflammatory cytokine production. 
On the basis of our previous findings that inhibiting PI3Kinase with LY294002 or 
wortmannin could partially reverse the age-related cytokine dysregulation in SM (Fallah 
et al., Manuscript in press), we attemped to recapitulate this phenomenon in the context 
of the BMDM. Hence, BMDM was pretreated with either LY294002 or wortmannin and 
then stimulated them with LPS, the TLR-4 ligand, to initiate cytokine production. Both 
the PI3K inhibitors (Figures 4.5A and 4.5C) reduced LPS induced IL-10 production by 
the aged BMDM. The PI3K inhibitors had similar effects on IL-10 secretion by the 
young BMDM treated with LPS, but the effect of wortmannin was less pronounced. As 
predicted, treatment of BMDM with LY294002 resulted in the enhancement of IL-
12(p40) in the aged but the effect on the young was modest (Figure 4.5B). Treatment of 
aged and young adult BMDM with wortmannin also induced an increase in IL-12 (p40) 
(Figure 4.5D) and TNF-α (Figure 4.5E) in both the aged and young adult. Similar results 
were obtained when aged and young BMDM were stimulated with the TLR-9 ligand, 
CpG in the presence of PI3K inhibitors (data not shown). 
The ability of PI3K inhibitors to rescue the cytokine defect is applicable to aged BMDM 
stimulated via different TLR-2 heterodimers. 
 We have shown that TLR-2 ligands behave like TLR4 ligands in their ability to induce 
high levels of IL-10 and low levels of IL-12-like cytokines from BMDM. Although both 
TLR2 and TLR4 use the same MyD88 molecule, TLR2 utilizes TICAM/MAL while 
TLR-4 uses both TICAM and TRIF for complete signal transduction in macrophages (86, 
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134, 332).  Therefore, it was of interest to know if the PI3K/AKT pathway affects the 
TLR2 mediated cytokine response of aged BMDM similar to the TLR4 response in the 
aged. BMDM from aged adult were pre-treated with LY294002 and then stimulated with 
Pam3CSK4 (1μg/ml), the ligand for the TLR2/1 heterodimer (Figure 4.6A and 4.6B) or 
Pam2CSK4 (1μg/ml), the ligand for the TLR2/6 heterodimer (Figures 4.6C and 4.6D). 
Treatment with both TLR2 ligands in the presence of the PI3K inhibitors, LY294002, 
resulted in reduced IL-10 secretion (Figure 4.6A and 4.6C) and increase in IL-12 
secretion (Figure 4.6B and 4.6D) in BMDM. Thus, despite differences in adaptors used 
by TLR2 and TLR4 receptors, the PI3K pathway appeared to play a role in cytokine 
dysregulation observed in response to both receptors. The reason why P3C induced ten-
fold more IL-10 than P2C was not known but a similar result was obtained with young 
BMDM (data not shown).  
 Age-associated cytokine defect shown with HKSP activated macrophages can be rescued 
by inhibiting PI3K  
Since TLR2 plays a major role in immune response to HKSP, we predicted that 
the PI3K pathway will also regulate HKSP induced macrophage activation. Accordingly, 
we found that PI3K inhibition reduced IL-10 secretion and enhanced IL-12 secretion by 
HKSP treated BMDM from both age groups (Figures 4.7A and 4.7B). The absolute 
quantity of reduction in IL-10 was lower in the aged relative to the young (Figure 4.7A), 
but they had similar enhancement in IL-12 (Figure 4.7B).  
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Effect of PI3K inhibition on Akt and p65Nf-ĸB, downstream targets of the PI3K pathway 
To be certain that the PI3K inhibitors were inhibiting the PI3K-Akt pathway, we 
evaluated the phosphorylation status of Akt upon inhibiting PI3K with LY294002 in TLR 
activated BMDM. The results of the western blot from young BMDM pretreated with 
LY294002 and then stimulated with LPS were shown in Figure 4.8A. There was a 1.9-
fold induction in p-Akt with LPS compared to media treated young BMDM (Figure 4.8A, 
Lanes 1 and 2). When 5 and 20 μM of LY294002 was used in the presence of LPS, there 
was a 9.5-fold and 6.3-fold reduction, respectively, in the levels of p-Akt compared to 
LPS stimulated young BMDM (Figure 4.8A, Lanes 2, 3 and 4).  Thus, we confirmed that 
the proximal signaling defect responsible for the age-related cytokine dysregulation 
involved the PI3K-Akt signaling pathway. 
It was well established in literature that p65N-F-κB was a transcription factor that 
was capable of regulating the pro-inflammatory and the anti-inflammatory cytokines (55, 
219). It was also known that p65NF-κB was regulated by PI3K-Akt signaling at several 
stages including IkB degradation, Ikkα phosphorylation and p65 translocation (13). Akt 
enhanced IκB phosphorylation leading to its degradation enabling increased p65NF-κB 
nuclear translocation. However, inhibition of PI3K in human peripheral blood monocytes 
(PBM) enhanced LPS-induced translocation of p65NF-κB (226). Similarly, PI3K 
inhibition enhanced TRIF-dependent NF-κB activation and production of IFN-β (13). 
When young BMDM were treated with wortmannin in the presence of LPS, there was a 
1.9-fold increase in nuclear p65 NF-κB compared to stimulation with LPS alone (Figure 
4.8B, Lanes 2 and 3). Thus, murine BMDM behave like human PBM in responding to 
LPS by increased NF-κB activation upon inhibition of PI3K pathway.  
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 Discussion 
 
SM in the aged exhibit a cytokine dysregulation which impacts on their ability to support 
antibody responses to polysaccharide antigens that are important for protection against 
encapsulated bacteria like pneumococci. In the aged, there is a decrease in production of 
pro-inflammatory cytokines and an increase in the anti-inflammatory cytokine, IL-10, 
upon stimulation with a variety of TLR ligands that utilize the MyD88 pathway. 
Previously we showed that alteration in cytokine production in the aged is due to a 
decrease in the MyD88 signaling pathway leading to a decrease in ERK activation 
accompanied by an aberrant increase in activation of PI3K/Akt pathway and of p38 MAP 
kinase (65, 95) (Chapter 3). In this study we determined if the imbalance in the 
production of pro- and anti-inflammatory cytokines by SM is an intrinsic defect or is due 
to the exposure of the macrophages to the aged spleen microenvironment. We used 
freshly generated BMDM from both age groups to address this question. We find that the 
BMDM generated from the young and the aged are equally pure and have a similar basal 
state of activation. Interestingly, our studies showed that BMDM from the aged also 
produce less of IL-12 and IL-6, but more of IL-10 than young BMDM upon stimulation 
with TLR2, TLR4 and TLR9 ligands recapitulating the cytokine phenotype of the aged 
SM. Similar results are obtained with HKSP which may utilize both TLR2 and TLR9 to 
activate BMDM but not TLR4, as pneumolysin, a ligand for TLR4 is inactivated in 
HKSP.  Expression of TLR2 is similar between the young and aged BMDM (data not 
shown) which is consistent with the report of Boehmer et al (35) who find that expression 
of TLR2 and TLR4 in peripheral macrophages is not affected by age . Moreover, the 
PI3K-Akt signaling pathway that is previously shown by us to be elevated in the aged 
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SM (95)(Chapter 3) is also found to be elevated in the BMDM. Furthermore, just like in 
the SM, inhibition of the PI3K-Akt pathway enhanced the TLR ligand induced 
production of pro-inflammatory cytokines and decreased IL-10 in the aged BMDM.  
These in vitro generated aged BMDM are a pure homogeneous population of cells 
that are not exposed to other cells that constitute the microenvironment of the aged 
animal, especially the spleen but share many of the phenotypic and functional 
characteristics (secretion of several cytokines in response to stimulation with  different 
TLRs and increased activation of PI3K pathway) of the splenic resident macrophages in 
the aged (143). Thus, the cytokine dysregulation in the aged SM appears to be due to an 
intrinsic defect in the BMDM which also manifests in the SM. However, one cannot rule 
out that bone marrow stromal cells in the aged have some effects on the properties of 
BMDM (145, 372). It should be noted that multiple phenotypes (secretion of four 
different cytokines in response to three different TLR receptors, changes in PI3K, Akt 
and NF-κB and effects of PI3K inhibition) are shared between BMDM and SM.  If the 
macrophage phenotype is due to the microenvironment, then it has to affect similarly 
several of the phenotypes listed above. Nonetheless, there are many studies 
demonstrating that the HSCs are altered by a combination of age-associated defects in the 
bone marrow microenvironment and intrinsic signaling mostly due to epigenetic 
modifications. The genome integrity is lost due to accumulation of DNA damage with 
aging and downregulation of genes involved in the maintaining of the integrity of the 
genome (59, 304, 372). The importance of genetic influence on intrinsic defect in HSC 
has been shown by the differences in the effect of aging on HSCs in aged mice from 
different genetic backgrounds (305). A study by Larsson and colleagues showed that an 
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alteration in the bone marrow microenvironment (niche) may affect the functional 
properties and homeostasis of HSC (199). Aging results in decreased activity of 
osteoblasts and increased infiltration of adipocytes with a concomitant increase in 
osteoclasts which affects the bone marrow microenvironment (303). These age-associated 
alterations in HSCs and progenitors might precede the downstream age-associated defects 
in B-cells, T cells, macrophages and overall immunosenescence (246, 372).  
We note that the recoveries of BMDM are similar in both age groups. This is 
rather surprising considering that several studies report an increase in myeloid precursors 
in the aged bone marrow (25, 208). It is conceivable that despite increased numbers of 
precursors, the burst size of each myeloid progenitor is less in the aged resulting in 
similar numbers of macrophages in both age groups. In this context, Sebastian and 
colleagues show that M-CSF induced proliferation (the assay used does not distinguish 
between increased progenitors and clonal output) is equivalent in young and aged 
BMDM whereas GM-CSF induced growth response is substantially lower in the aged due 
to increased oxidation of Stat-5a transcription factor (315).  Their observation that the 
teleomers are shorter in the aged than in young BMDM is consistent with reduced ability 
to undergo cell division. Our study emphasizes that despite an increase in numbers of 
myeloid lineage stem cells with age, the differentiated macrophages are not as 
immunocompetent as in the young.  
The increased levels of PI3K p110delta and of phospho-Akt in TLR activated 
BMDM with age is consistent with the well known negative regulatory effects of PI3K 
pathway on TLR induced pro-inflammatory cytokine production (107, 308), as we find 
an increase in IL-10 and a decrease in IL-12 like pro-inflammatory cytokines in the aged. 
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Inhibition of Akt pathway with PI3K inhibitors results in a further increase in nuclear p65 
(Fig 8B) which is consistent with the observed increase in pro-inflammatory cytokine 
production. The increase in NF-κB upon inhibition of PI3K pathway could be due to the 
reported positive effects of GSK-3 (an enzyme inhibited by Akt) on NF-κB activation 
(225). This is consistent with similar enhancing effects of PI3K inhibitors on the NF-κB 
activity observed in human embryonic kidney cells lines (HEK293) stimulated via NOD2 
(395). Despite the links between Akt, GSK and NF-κB, it is possible that other pathways 
also modify the TLR induced cytokine secretion. Thus, aging enhances COX-2 mediated 
induction of prostaglandin-2 (PGE2), which is known to enhance IL-10 but suppress pro-
inflammatory cytokines under certain conditions (71, 324, 342, 385). In turn COX-2-
PGE2 pathway is enhanced in aged macrophages via upregulation of NF-κB (71, 239, 
285, 353, 385). Moreover, PI3K-Akt pathway has been shown to positively regulate 
COX-2-PGE2 signaling complex which could in turn enhance IL-10 while suppressing 
pro-inflammatory cytokines (239). The interrelationships between PI3K-Akt pathways 
and the COX-2-PGE2 axis in aged BMDM have not been investigated thus far and will 
be a subject of future efforts.  
Several previous studies including our own observe defects in cytokine secretion 
by TLR activated spleen and thioglycollate elicited peritoneal macrophages and support 
the notion that aged macrophages have intrinsic signaling defects (34, 63, 65, 298). A 
study by Chen et al (66) came to a different conclusion. In this study nitric oxide 
production by BMDM is found to be the same in young and the aged, whereas 
thioglycollate elicited and resident macrophages from the two age groups differ in their 
ability to produce NO suggesting that the microenvironment in the aged affected 
114 
 
macrophage function. Such conclusions are further supported by the studies by Stout et 
al. (339, 340) in which exposure of macrophages to different cytokines prior to TLR 
stimulation altered the cytokine responses. It turns out that Chen and colleagues utilize 
thioglycollate induced macrophages. But Stout and colleagues use only young BMDM, 
young thioglycollate elicited peritoneal macrophages and resident macrophages. These 
studies are unlike ours and other recent studies that focuse on spleen resident 
macrophages. Although one cannot rule out the ability of cytokines like gamma-
interferon to alter the TLR responses to macrophages, the present study establishes that 
BMDM from the aged behave similar to spleen resident macrophages with respect to 
responses to three different TLRs and the increased activity of  PI3K-Akt enzymes, 
strongly supporting the concept that the aged macrophages do have intrinsic defects. As 
noted above aged BMDM have shortened teleomers which is consistent with an intrinsic 
defect hypothesis for the phenotype of splenic macrophages from the aged (315).  
These observations about the ability of PI3K-Akt pathway to modulate cytokine 
production by aged macrophages are relevant in the context of reduced immune 
responses of the aged to S. pneumoniae. The pro-inflammatory cytokines, IL-6, TNF-α 
and IL-12 are all critical for  antibody response to polysaccharide antigen and the 
subsequent clearance of S. pneumoniae infection as depletion of these cytokines by 
antibody treatment or gene knockouts increases bacterial load and overall lethality in 
infected mice (17, 38, 64, 178, 230, 355, 356). Moreover, enhanced IL-10 associates with 
poor clearance, increased lethality and bacterial load in infected mice (357, 358). IL-10 
mediated downregulation of p65NF-κB also correlates with increased susceptibility to S. 
pneumoniae infection (61, 293). Thus, our finding that PI3K inhibition by 
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pharmacological inhibitors not only reduces IL-10 but also increases p65 NF-κB and 
critical cytokines, IL-12, TNF-α and IL-6 upon stimulation with individual TLR ligands 
and HKSP, provides a novel approach to enhance immune responses to pneumococcal 
infections in the aged.  
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Figure 4.1: The purity, recovery, morphology and activation status of BMDM is 
similar between the aged and young. 
 Expression of CD11b and F-4/80 by BMDM from aged and young mice (Figure 1A). 
Photographs of newly generated BMDM from aged and young Balb/c mice seen at 40X 
total magnification with an Olympus microscope (Figure 1B). Bone marrow cells 
(2.5x106 cells/ml) were cultured for seven days with 30% L929 supernatant. The newly 
derived BMDM were enumerated and the number of BMDM recovered per 106 BM cells 
was calculated for the aged and the young (Figure 1C). The graph represented results 
from ten of 15 experiments.  BMDM from young and aged mice were cultured in 
medium or LPS (Figure 1D), or Pam3CSK4 (P3C) (Figure 1E) or HKSP (Figure 1F) and 
then stained with anti- CD86 FITC.  
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Figure 4.2: Cytokine production by young and aged BMDM stimulated with TLR2, 
4 and 9 ligands. 
BMDM (2.5x105 cells/ml) from young and aged mice were stimulated with the TLR 
agonists, LPS (1µg/ml) (Panels A, B, C and D), P3C (1µg/ml) (Panels E and F) or CpG 
(2µg/ml) (Panels G and H) for 24 hours. The supernatants were collected and analyzed by 
a sandwich ELISA for IL-10 (Panels A, E and G), IL-12(p40) (Panels B and F), IL-6 
(Panel C and H) and TNF-α (Panel D). In panels A, C, D, G and H levels of cytokines in 
unstimulated BMDM from one or both age groups were undetectable. The constitutive 
production of IL-12 by aged BMDM seen in panel F was not observed in other 
experiments. Results from one of five experiments were shown as Mean + SE values of 
8-12 determinations. The statistical significance of differences in cytokine secretion 
between the young and the aged was indicated by the symbol *  and it was set at p<0.04. 
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Figure 4.3:  Cytokine production by young and aged BMDM stimulated with HKSP 
The newly derived BMDM from young and aged mice were stimulated with HKSP 
(2x106 CFU/ml) for 24 hours. The supernatants were collected and analyzed by a 
sandwich ELISA for IL-10 (Panel A), IL-12(p40) (Panel B), and IL-6 (Panel C). In panel 
A, IL-10 levels in unstimulated young BMDM were undetectable. Results from one of 
four experiments were shown as Mean + SE values of 8-12 determinations. The statistical 
significance of differences in cytokine secretion between the young and the aged was 
indicated by the symbol * and it wass set at p<0.0003. 
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Figure 4.4: Age-associated changes in expression of mRNA for p110δ subunit of 
PI3K and activation of AKT in TLR4 activated BMDM  
Panel A: mRNA was isolated from young and aged mice BMDM (3x106 cells/ml) after 
stimulation with LPS (1μg/ml) and converted to cDNA. QRT-PCR analysis of mRNA 
was shown in panel A for P110δ subunit of PI3 kinase in the newly derived BMDM from 
young and the aged. The Ct values for each probe were normalized to the 18S RNA. The 
symbols *, ** and *** indicated the statistical significance (p<0.05) of differences in RNA 
expression between the young and the aged at different time points. Panel B: The BMDM 
were stimulated with LPS 1.0 μg/ml for 15 minutes, total cell lysates were isolated and 
immunoblotted for p-Akt. The blots were stripped and probed for total Akt and for beta-
actin. The numbers represent densities of bands normalized to total Akt between aged and 
young with the values for unstimulated cells from both aged and young mice set to one.  
The figure in panel B was a composite of blots for p-Akt and Akt from the same 
membrane that was stripped and reprobed. The young and aged cell lysates were 
electrophoresed on the same gel and the membranes were exposed for identical time 
periods. Although a detailed kinetic analysis of LPS stimulation was performed, only the 
lanes representing 0 and 15 minutes time points were shown for clarity.  Results were 
representative of four experiments.  
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Figure 4.5: PI3K inhibitors partially rescue the age-associated defects in TLR-4 
induced cytokine production. 
The graphs show cytokine secretion by aged and young adult BMDM pretreated with 
LY294002 (Panels A and B) or wortmannin (Panels C, D and E) for 60 minutes and then 
stimulated with LPS (1.0µg/ml) for 24 hours. Supernatants were collected and assayed 
for IL-10 (panels A and C), IL-12(p40) (panels B and D) and TNF-α (Panel E) by 
sandwich ELISA.  Data were presented as mean+/-SE values of 6-10 determinations and 
were representative of three independent experiments. The symbols * and # indicated 
statistical significance (p<0.005) of differences in responses in groups treated with LPS 
alone compared to groups treated with LPS + PI3K inhibitor. 
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Figure 4.6: PI3K inhibitors alter the pattern of cytokine secretion by aged BMDM 
stimulated with ligands for TLR-2 heterodimers. 
The graphs show cytokine secretion by aged BMDM pretreated with LY294002 for 60 
minutes and then stimulated with P3C (Panels A and B) or P2C (Panels C and D) for 24 
hours. Supernatants were collected and assayed for IL-10 (Panels A and C) or IL-12(p40) 
(Panels B and D) by sandwich ELISA and were representative of three experiments. Data 
were presented as mean +/- SE of quadruplicate wells. The symbol * indicated statistical 
significance (p<0.03) of differences in responses in the aged BMDM treated with 
Pam3CSK4 (or Pam2CSK4) with or without the PI3K inhibitor.  
 
123 
 
 
Figure 4.7.  The inhibition of PI3K by either LY294002 or wortmannin differentially 
regulates the HKSP-mediated induction of anti- and pro-inflammatory cytokines in 
BMDM. 
The graphs show cytokine secretion by aged and young BMDM pretreated with 
LY294002 (Panels A and B) for 60 minutes and then stimulated with HKSP (2x 108 
CFU/ml) for 24 hours. Supernatants were collected and assayed for IL-10 (Panel A) and 
IL-12(p40) (Panel B) by sandwich ELISA. Data were presented as mean +/- SE of 
quadruplicate determinations. The symbols * and # indicated statistical significance 
(p<0.03) of differences in responses in the aged BMDM treated with HKSP alone 
compared to the responses obtained by treating with HKSP + PI3K inhibitor.  Results 
were representative of four experiments. 
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Figure 4.8.   PI3K inhibitors reduce activation of Akt but enhance nuclear 
translocation of p65 NF-κB. 
Panel A: The newly derived BMDM from young mice were pre-treated with either 
LY294002 or medium for 1 hour and then stimulated with LPS (1μg/ml) for 15 minutes. 
The blots were probed for p-Akt and total Akt and actin after stripping (panel A). The 
numbers represent densities of bands normalized to total Akt.  The final figure in A was a 
composite of blots for p-Akt, Akt and actin for young samples run on the same membrane 
that was stripped and reprobed.  Panel B: The newly derived BMDM from young were 
pretreated with or without wortmannin and then stimulated with LPS (1μg/ml) at 30 
minutes and the nuclear extract was isolated. The lysate was run on an SDS-PAGE gel, 
transferred to a membrane and then immnoblotted for p65 NF-κB. The numbers represent 
densities of bands normalized to LaminA/C, with the values for unstimulated BMDM set 
to 1.  The final figure in B was a composite of blots for p65NF-κB and Lamin A/C for 
young samples run on the same membrane that was stripped and reprobed. The 
intervening space (between second and third lane) was for lanes loaded with lysates from 
other time points or treated with other inhibitors but were deleted  to focus on the effect 
of LPS on p65 translocation at 30 minutes, which was maximum in this experiment. 
Results were representative of three to five independent experiments.   
Copyright © Mosoka Papa Fallah 2011 
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CHAPTER 5:  Novel role of glycogen synthase kinase-3 in secretion of IL-10 and                                       
  pro-inflammatory cytokines activated via TLR2 and TLR4 receptors 
 
INTRODUCTION 
There are several studies exploring the possibility of modulating macrophages or 
dendritic cells as potential vaccine adjuvants especially for populations like the elderly 
with impaired vaccine response (94, 301). Some studies are beginning to focus on 
modulating glycogen synthase kinase-3 (GSK-3) to enhance  cytokine production by  
myeloid cells such as dendtritic cells, human peripheral blood monocytes and 
macrophages, which are targets for adjuvants (28, 115, 225). GSK-3 is an enzyme that is 
emerging as a prominant pleoitropic kinase in modulating numerous cellular processes. It 
is a focal point for an array of upstream signaling cascades. GSK-3 regulates a diverse 
array of proteins and transcription factors such as CREB and NF-κB (125, 255). It is 
ubiquitously expressed in B-cells, macrophages, T-cells, NK cells and neutrophils which 
play crucial roles in both innate and adaptive immunity (28). It has two isoforms, GSK-
3α and GSK-3β, which are encoded by different genes. Though the two isoforms share 
very high homology in their kinase domain, there are some reports of a lack of 
redundancy between the two isoforms (151).   
Macrophages  upregulate costimulatory molecules and secrete cytokines to modulate the 
shift from innate immunity to adaptive immunity (292). Macrophages can also present 
antigen to T cells in the context of MHC-II and produce cytokines, such as IL-1, which 
help activate T cells.  Macrophages interact with T cells via CD40:CD40 ligands to 
provide critical co-stimulatory signals (362). DCs are even more efficient in antigen 
uptake, transport and presentation to T-cells. They are also known to upregulate 
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costimulatory molecules and secrete some critical pro-inflammatory cytokines that are 
crucial for both innate and adaptive immunity (161, 326, 337). 
Several studies show that inhibition of GSK-3 in either DC or human peripheral blood 
monocytes in the presence of TLR stimulation results in a suppression of the pro-
inflammatory cytokines along with an enhancement in IL-10. While the role of GSK-3 
inhibition on the activation of innate cells likes DC and monocytes are thoroughly 
investigated, there is a conspicuous absence of studies on the role of GSK-3 in cytokine 
regulation in primary splenic or bone marrow derived macrophages (225, 295, 301). To 
fill this gap of knowledge, we investigated the role of GSK-3 in cytokine production in 
SM and BMDM. We earlier established that the PI3K-Akt pathway is more active in 
TLR stimulated aged SM compared to the young. This led to increased phosphorylation, 
and that inhibiting PI3K led to decreased phosphorylation of GSK-3 (Fallah et al., 
manuscript in press). Here we report the surprising result that inhibition of GSK-3 in the 
presence of ligands for TLR-2 or -4, leads to an increase in both IL-10 and the pro-
inflammatory cytokines in macrophages. The increase in cytokines appears to be due to 
an increase in activation of transcription factor NF-κB.  
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Results 
 Inhibition of GSK-3 enhances both pro- and anti-inflammatory cytokines in young and 
aged splenic macrophages  
Purified SM  from aged mice were stimulated with either TLR-2 or TLR-4 ligands in the 
presence of SB216763, a well characterized specific inhibitor of GSK-3, for 24 hours and 
the supernatant was assayed for cytokines by ELISA. Inhibition of GSK-3 enhanced the 
production of IL-10 when TLR-4 or TLR-2 ligands were used for stimulation (Figures 
5.1A and 5.1D) which is in agreement with previous reports that used DCs (225). 
However, inhibition of GSK-3 in the presence of LPS, a TLR-4 ligand, significantly 
enhanced IL-12(p40) and TNF-α production (Figures 5.1B and 5.1C). Similarly, 
inhibition of GSK-3 in the presence of P3C, a TLR2/1 ligand, resulted in enhancement of 
TNF-α (Figure 5.1E) and IL-12 (Figure 5.1D). This result was contrary to what had been 
reported in literature in regards to human blood monocytes or BMDC. Hence, the GSK-3 
signaling pathway could be modulating key transcription factors differently than what 
had been reported in blood monocytes or BMDC (151, 322, 365, 393).  We wondered if 
this effect of GSK-3 inhibition to enhance both the anti- and the pro-inflammatory 
cytokines was unique to macrophages from aged mice. Therefore, we evaluated the 
cytokine response of SM stimulated with LPS or P3C in the presence of GSK-3 
inhibitors. Similar to the result with aged macrophages, there was an increase in IL-10 
and IL-12p40 when young adult SM were stimulated with LPS (Figures 5.2A) or P3C in 
the presence of SB216763 (Figure 5.2B). Thus, the ability of SB216367 to enhance IL-10 
and the pro-inflammatory cytokines in splenic macrophages appeared to be independent 
of the age of the mice. 
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GSK-3 inhibition enhances both pro- and anti-inflammatory cytokines in BMDM 
independent of the age of the mice.  
Previously, we had shown that inhibition of PI3K enhanced the pro-inflammatory 
cytokines but suppressed of IL-10 in either splenic or bone marrow macrophages, 
indicating that the effect of this signaling pathway on macrophages was independent of 
the microenvironment. Hence, it was of interest to evaluate the effect of GSK-3 inhibitor 
on cytokine response of BMDM stimulated with TLR ligands. Interestingly, inhibition of 
GSK-3 in the presence of LPS in aged BMDM enhanced both IL-10 and the pro-
inflammatory cytokines, IL-12 and TNF-α (Table 5.1). When young BMDM were 
evaluated in the presence of LPS and SB216764, there was an increase in IL-10, IL-12 
and TNF-α (Table 5.2). This showed that the ability of GSK-3 inhibition to enhance IL-
10 and the pro-inflammatory cytokines was applicable to different types of primary 
macrophages. 
We next asked if the ability of GSK-3 inhibition to enhance both IL-10 and the pro-
inflammatory cytokines was influenced by the time of stimulation. Hence, we did a time 
kinetics analysis of young BMDM treated with SB216763 in the presence of LPS for 6, 
24 and 48 hours. We found that GSK-3 inhibitor significantly enhanced IL-10 at all 
concentrations and at all time points tested (Figure 5.3A). In the case of IL-12, there was 
a moderate but statistically significant increase at all concentrations of SB216763 at 24 
hours, but only at 10 µM at 48 hours (Figure 5.3B). 
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 Enhancement of pro-inflammatory cytokines upon GSK-3 inhibition is independent of its 
effects on IL-10 production in macrophages 
We asked if the ability of GSK-3 inhibitor to enhance IL12 was influenced by IL-10, 
which was known to inhibit pro-inflammatory cytokines. Accordingly, we cultured young 
BMDM from IL-10 knockout mice in C57BL/6 background with SB216763 in the 
presence of LPS for 6, 24 and 48 hours. We then assayed for IL-12 and found that GSK-3 
significantly enhanced IL-12 at all concentrations of the inhibitor at 24 and 48 hours 
(Figure 5.4).  
The enhancement of pro-inflammatory cytokines with GSK-3 inhibitor is not seen with 
BMDC 
We have shown that the effects of GSK-3 inhibition on both SM and BMDM were 
similar irrespective of the duration of the cultures or IL-10 expression. We decided to 
evaluate the effects of GSK-3 inhibition on the cytokine profile in BMDC. We cultured 
BMDC in the presence of SB216763 and LPS for 24 hours and measured IL-10, IL-
12p40 and IL-12p70 by ELISA. GSK-3 inhibition in the presence of LPS resulted in 
increased IL-10 production (Figure 5.5A) just like in splenic macrophages and BMDM. 
However, inhibition of GSK-3 reduced production of IL-12p40 (Figure 5.5B) and IL-
12p70 (Figure 5.5C) in agreement with the reported results using rodent and human 
monocyte derived dendritic cells (210, 301). Thus, the role of GSK-3 in modulating IL-
10 and the pro-inflammatory cytokines in both splenic macrophages and BMDM was 
unique and different from its role in BMDC. 
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The PI3K-Akt signaling pathway modulates the ability of GSK-3 to regulate cytokines in 
macrophages  
We had shown in SM that Akt phosphorylation via PI3K led to phosphorylation of GSK-
3 which was known to result in inactivation of GSK-3 (Chpater 3 Figure 11A, B and C). 
We asked if the activity of GSK-3 in BMDM was also regulated via PI3K/Akt pathway. 
Upon inhibition of PI3K in BMDM with LY294002, there was a 30% reduction in p-
GSK-3 in the aged BMDM compared to LPS stimulation (Figure 5.6A, lanes 2, 3 and 4). 
Since, the modulatory role of GSK-3 on IL-10 and the pro-inflammatory cytokines was 
independent of the age of the BMDM; we extended this study to BMDM isolated from 
young adult mice.  There was a 45% reduction in GSK-3 posphorylation in BMDM 
treated with LY294002 compared to LPS stimulation at 30 minutes (Figure 5.6B, lanes 3 
and 4).  
Inhibition of GSK-3 enhances activation of p65NF-ĸB  
We next evaluated the effect of GSK-3 inhibition on nuclear translocation of p65 NF-ĸB, 
a known transcription factor that regulates the production of pro-inflammatory cytokines 
(255). In the presence of SB216763, the stimulation of young BMDM with LPS resulted 
in a 2.8-fold increase in nuclear localization of p65NF-ĸB (Figure 7 lanes 2 and 3). Thus, 
in macrophages, the ability of GSK-3 inhibition with SB216763 to enhance the pro-
inflammatory cytokines involved the enhancement of NF-ĸB translocation, a known 
modulator of pro-inflammatory cytokines. 
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Discussion 
Using SM purified by negative selection from both aged and young mice, we 
demonstrated that inhibition of GSK-3 by SB216763 enhanced both IL-10 and the pro-
inflammatory cytokines, IL-12 and TNF-α. We further showed that GSK-3 inhibition 
enhanced these cytokines in vitro generated BMDM from aged and young Balb/c, and 
from young C57BL/6 mice. The current study indicates that this phenomenon is unique to 
macrophages as we are able to demonstrate in BMDC that upon inhibition of GSK-3 in 
the presence of ligand for TLR-4 there is an enhancement in IL-10 with suppression of 
the pro-inflammatory cytokines, IL-12p40 and IL-12p70. This finding in BMDC is 
supported by numerous other findings in both human peripheral blood derived dendritic 
cells and mouse BMDC, which show a reduction in  12p40, IL-6, TNF-α, and  IFN-γ 
with an enhancement in IL-10 (225, 295). 
Macrophages and dendritic cells share many similar functional characteristics. BMDC 
from both Balb/c and C57Bl/6  express CD80, CD86 and produce similar levels of IL-6, 
IL-12p40 and TNF-α upon stimulation with LPS (292). We demonstrated that upon 
stimulation of both BMDM and SM with LPS, IL-12p40, TNF-α and IL-6 are produced. 
Macrophages are able to present antigen and produce relevant cytokines that activate T 
cells and increase CD80 just like dendritic cells (292). 
As a result, one might wonder why we had arrived at seemingly discordant results with 
monocytes and DC. However, there are studies that point to the fact that cytokine-
regulatory capacity of GSK-3 is cell type-specific (166). Thus, Martin and colleagues 
evaluated the effects of GSK-3 inhibitors on cytokine production in the presence of 
132 
 
ligands to several different TLRs in human peripheral blood monocytes. They showed 
enhanced secretion of IL-10 with a suppression of pro-inflammatory cytokines (225). 
Overall, GSK-3 inhibition has anti-inflammatory effects on mature DCS derived from 
human monocytes (MoDC) (225). This cell-specific modulatory role of GSK-3 is also 
seen by Liu et al (211). They showed that immature DCs (iDC) generated from human 
monocytes with GMCSF plus IL-4 in the presence of GSK-3 inhibitor, LiCl, upregulated 
CD86, IL-6, IL-8, TNF-α, IL-1β with a  slight increase in IL-10. However, when these 
very iDCs are matured by LPS stimulation in the presence of LiCl there is an increase in 
IL-10 with a reduction in IL-6, TNF-α and IL-1β (210).   
Several other studies report results similar to ours but different from the Martin group in 
the context of different cell types. Using the ST2 Stromal cell line derived from mouse 
bone marrow, it is shown that IL-17 enhances the production of IL-6 at the mRNA level 
in the presence of GSK-3 inhibitors, indicating an anti-inflammatory property of GSK-3 
(323). It is demonstrated in neonatal cardiomyocytes that GSK-3 is a negative regulator 
of pro-inflammatory cytokines. Upon LPS stimulation of the cells in the presence of 
GSK-3 inhibitor there is an enhancement of TNF-α. Not only that but when a dominant 
negative GSK-3 is over-expressed similar enhancing results are observed, but these could 
be reversed by over-expressing normal GSK-3 (322).  Other studies with fibroblasts and 
human microvascular cells also support an anti-inflammatory role for GSK-3 (151, 365).  
When RAW cells are stimulated with LPS in the presence of GSK-3 inhibitor with or 
without IFN-γ there is a higher production of IL-10 with suppression of INOS and NOS 
(206). Another study shows that activating RAW cells with IFNγ plus GSK-3 inhibitors 
or SiRNA knockdown of GSK-3 results in a suppression of TNF-α, Rantes, INOS and 
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NOS.  The mechanism accounting for this effect is shown to be via phosphorylation of 
GSK-3α at Tyr-279 and GSK-3β at Tyr-216 by the proline rich tyrosine kinase (Pyk2) 
(351). There are two central issues that one can garner from this study; one is that the 
agonist is IFNγ and not LPS. The paper shows that the mechanism involves 
phosphorylation mediated activation of GSK-3. This is contrary to the findings of LPS 
mediated regulation of GSK-3, which is a phosphorylation-mediated inactivation at the 
serine position by the protein kinase family (PKA, PKB, PKC) on the N-terminal serine 
residues. GSK-3α and GSK-3β are inhibited when phosphorylated by protein kinase 
B/Akt on serine -21 and GSK-3β on serine-9 (88, 101, 126, 225). Studies show that 
signaling cascades differ from transformed cell lines and primary macrophages during 
infections or even between cell lines. This is demonstrated in both P388D1 and 
RAW264.7, two macrophage cell lines, stimulated with LPS (23, 112, 294). Hence, the 
findings in RAW cells on the role of GSK-3 on cytokines, though share some similarity 
with our findings in primary splenic and bone marrow macrophages, they are not 
comparable because of the inherent signaling differences between these two categories of 
cells.  
In explaining the paradoxical regulation of anti- and pro-inflammatory cytokines by 
GSK-3 inhibitors in different cell types, one has to take into consideration the uniqueness 
of this multifunctional kinase. The multi-signaling ability of GSK-3 is due to its unique 
ability to target and modulate a plethora of transcription factors which include NF-κB, 
NFATC and CREB (28, 166). Similarly upstream several kinases, such as Akt and 
mTOR, are known to affect GSK-3 activity. Accordingly, we are able to demonstrate in 
aged and young BMDM that GSK-3 is regulated by TLR-4 induced PI3K-Akt signaling 
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pathway. We show in both aged and young groups that inhibition of PI3K results in a 
decrease in the phosphorylation of GSK-3. Similar results are obtained by Wang and 
colleagues in TLR dependent regulation of GSK-3 (371) . 
Since IL-10 is known to inhibit IL-12 like cytokines, we evaluated if GSK-3 dependent 
regulation pro-inflammatory cytokines involves IL-10. We showed that the ability of 
GSK-3 to regulate the pro-inflammatory cytokines is independent of IL-10 using BMDM 
from IL-10-/- mice. This is in agreement with a study by Ohtani and colleagues, who find 
that upregulation of IL-12 upon GSK-3 inhibition is independent of IL-10 (266).  
When we stimulated young BMDM with LPS in the presence of GSK-3 inhibitor, there is 
an increase in the translocation of p65NF-ĸB. The role of GSK-3 in the regulation of 
p65NF-ĸB is multi-faceted and is dependent on the type of cell or its activation status. 
GSK-3 is considered by many studies to be a positive regulator of p65NF-ĸB activity 
(322, 365). On the other hand, studies of human intestinal epithelial cells show that LiCl, 
an inhibitor of GSK-3, enhances p65NF-ĸB binding and transcriptional activities (255). 
Schwabe and colleagues show that in hepatocytes stimulated by TNF-α, GSK-3 
inhibition induces p65 phosphorylation and upregulates its transctivation in agreement 
with our studies (313). However, Martin and colleagues do not find any differences in the 
nuclear translocation of the p50 or p65 subunits in LPS stimulated human monocytes in 
the presence of GSK-3 inhibitors (225). Hence, the ability of GSK-3 inhibition to induce 
the production of the pro-inflammatory cytokines in SM and BMDM could be due to the 
induction of p65NF-ĸB, which is a transcription factor that regulates pro-inflammatory 
cytokines. 
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We can not account for the transcriptional regulation of IL-10 and this will be the focus 
of future experiments. We propose that IL-10 upregulation depends on the transcription 
factor CREB and GSK-3 negatively regulates both CREB and p65NF-ĸB. Hence, 
inhibition of GSK-3 upregulates both pro- and anti-inflammatory cytokines via increased 
activities of p65NF-ĸB and CREB respectively; presently we can not rule out that the 
effects of GSK-3 on these transcription factors are indirect by its ability to modulate other 
regulators of these pathways (Figure 5.8). 
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 Figure 5.1: Pharmacological inhibition of GSK-3 results in increased production of 
IL-10 and the pro-inflammatory cytokines in aged splenic macrophages  
The graphs showed cytokine secretion by purified aged SM pretreated with SB216763 
(Panels A,B, C, D and E)  for 60 minutes and then stimulated with either LPS (1.0µg/ml) 
(Panels A, B and C) or Pam3CSK4 (1.0µg/ml) (Panels D and E) for 24 hours. 
Supernatants were collected and assayed for IL-10 (panels A and D), IL-12(p40) (panels 
B and D) and TNF-α (Panels C and E) by sandwich ELISA.  Data are presented as 
mean+/-SE values of 6-10 determinations and are representative of three independent 
experiments. The symbols * and # indicated statistical significance (p<0.05) of differences 
in responses in groups treated with LPS or P3C alone compared to groups treated with 
LPS (or P3C) + GSK-3 inhibitor. SB in the graphs represents SB216763. 
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Figure 5.2:  GSK-3 inhibition enhances both IL-10 and IL-12 in young splenic 
macrophages 
Young adult purified SM (2.5x105 cells/ml) were pretreated with SB216763 (Panels A 
and B) for 60 minutes and then stimulated with either LPS (1.0µg/ml) (Panel A) or 
Pam3CSK4 (1.0µg/ml) (Panel B) for 24 hours. Supernatants were collected and assayed 
for IL-10 (panels A) and IL-12(p40) (panels A and B) by sandwich ELISA.  Data were 
presented as mean+/-SE values of 6-10 determinations and were representative of three 
independent experiments. The symbols * and # indicated statistical significance (p<0.05) 
of differences in responses in groups treated with LPS or P3C alone compared to groups 
treated with LPS (or P3C) + GSK-3 inhibitor. SB in the graphs represents SB216763. 
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Table 5.1: Inhibition of GSK-3 with SB216763 enhances both pro- and anti-
inflammatory cytokines in aged BMDM  
Aged BMDM (2.5x105 cells/ml) were pretreated with SB216763 (Table 5.1) for 60 
minutes and then stimulated with LPS (1.0µg/ml) for 24 hours. Supernatants were 
collected and assayed for IL-10  and IL-12(p40)  and TNF-α (Table 5.1) by sandwich 
ELISA.  Data are presented as mean+/-SE values of 6-10 determinations and are 
representative of three independent experiments. Statistical significance was indicated by 
p<0.05, which compared the differences in responses in groups treated with LPS alone to 
groups treated with LPS + GSK-3 inhibitor. 
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Table 5.2:  SB216763 upregulates both pro- and anti-inflammatory cytokines in 
young BMDM just like the aged BMDM  
Young adult purified BMDM (2.5x105 cells/ml) were pretreated with SB216763 for 60 
minutes and then stimulated with either LPS (1.0µg/ml) for 24 hours. Supernatants were 
collected and assayed for IL-10, IL-12(p40) and TNF-α (Table 5.2) by sandwich ELISA.  
Data are presented as mean+/-SE values of 6-10 determinations and are representative of 
three independent experiments. The p-values indicate statistical significance (p<0.05) of 
differences in responses in groups treated with LPS alone compared to groups treated 
with LPS + GSK-3 inhibitor. 
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Figure 5.3:  Kinetics of cytokine production in young BMDM treated with GSK-3 
inhibitor. 
 Young adult purified BMDM (2.5x105 cells/ml) from Balb/c mice were pretreated with 
SB216763 (Panels A and B) for 60 minutes and then stimulated with LPS (1.0µg/ml) 
(Panels A and B) for 6, 24 and 48 hours. Supernatants were collected at each of these 
different time points and assayed for IL-10 (panel A) and IL-12(p40) (panel B) by 
sandwich ELISA.  Data are presented as mean+/-SE values of 6-10 determinations and 
are representative of three independent experiments. The p-values indicate statistical 
significance (p<0.05) of differences in responses in groups treated with LPS alone 
compared to groups treated with LPS + GSK-3 inhibitor at the different time points. 
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Figure 5.4:  The ability of GSK-3 inhibitors of GSK-3 to induce higher production 
of pro-inflammatory cytokines is independent of IL-10  
BMDM (2.5x105 cells/ml) from young adult IL-10 knockout mice on a C57BL/6 
background were evaluated for the production of IL-12 at 6, 24 and 48 hours (Panel A). 
The BMDM were   pretreated with SB216763 (Panels A) for 60 minutes and then 
stimulated with LPS (1.0µg/ml) (Panels A) for 6, 24 and 48 hours. Supernatants were 
collected at each of these different time points and assayed for IL-12(p40) (panel A) by 
sandwich ELISA.  Data were presented as mean+/-SE values of 6-10 determinations and 
were representative of three independent experiments. The symbols * , ** and *** indicated 
statistical significance (p<0.05) of differences in responses in groups treated with LPS  
alone compared to groups treated with LPS + GSK-3 inhibitor  at the different time 
points. 
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Figure 5.5:  GSK-3 inhibitors enhance IL-10 but inhibit IL-12 production by BMDC 
BMDC (2.5x105 cells/ml) from young adult C57BL/6 mice were evaluated for the 
production of IL-10, IL-12 (p40) and IL-12(p70) at 24 hours (Panels A, B and C). The 
BMDC were   pretreated with different concentrations of SB216763 for 60 minutes and 
then stimulated with LPS (1.0µg/ml)  for 24 hours. Supernatants were collected and 
assayed for IL-10 (panel A), IL-12(p40) (panel B) and IL-12(p70) (panel C).  Data are 
presented as mean+/-SE values of duplicate cultures and duplicate ELISA of each 
culture. The symbol * indicates statistical significance (p<0.05) of differences in 
responses in groups treated with LPS alone compared to groups treated with LPS + GSK-
3 inhibitor. 
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Figure 5.6.  The PI3K-Akt signaling pathway modulates the ability of GSK-3 to 
regulate cytokine production in macrophages 
 Panels A and B: The newly derived BMDM from aged (Figure 5.7A) and young (Figure 
5.7B) mice were pre-treated with either LY294002 for 1 hour and then stimulated with 
LPS (1μg/ml) for 15 and 30 minutes. The blots were probed for p-GSK and total GSK-3 
and actin after stripping (Figure 5A and B). The numbers represented densities of bands 
normalized to total GSK-3, with the values for unstimulated aged macrophages set to 1.  
Results are representative of three to independent experiments. The final figure in A was 
a composite of blots for P-GSK-3, GSK-3 and actin for young or aged samples run on the 
same membrane that was stripped and reprobed.   
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Figure 5.7.   GSK-3 upregulates cytokine production in macrophages via p65NF-ĸB.  
BMDM from the young were harvested via trypsin-EDTA, washed and allowed to rest 
for three hours and then cultures were set up where some were pretreated with 
SB216763, while others were not treated for one hour. At the end of the hour, the cultures 
were activated with LPS (1μg/ml) at 30 minutes. The nuclear extract was isolated and run 
on an SDS-PAGE gel, transferred to a membrane and then immonoblotted for p65 NFκB. 
The numbers represented densities of bands normalized to LaminA/C, with the values for 
unstimulated BMDM set to 1.  Results were representative of three independent 
experiments. The final figure was a composite of blots for p65NFκB and Lamin A/C that 
were run on the same membrane, stripped and reprobed. The intervening space (between 
second and third lane) was for lanes loaded with lysates from other time points or 
inhibitors but were deleted  to focus on the effect of LPS+ SB216763 on p65 
translocation at 30 minutes, which was maximum in this experiment.  
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Figure 5.8.   Schematic model for GSK-3 inhibition in the regulation of IL-10 and 
pro-inflammatory cytokine production in splenic and bone marrow macrophages 
via p65NF-ĸB and CREB.  
Activated GSK-3 negatively regulates p65Nf-ĸB and CREB: Upon inhibition of GSK-3 
both p65NF-ĸB and CREB functions were enhanced leading to an increase in IL-10, IL-
12 and TNF-α. IL-12 and TNF-α can also be induced independent of GSK-3 via Akt- 
p65Nf-ĸB or p38 MAP Kinase. 
.  
Copyright © Mosoka Papa Fallah 2011 
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CHAPTER 6:  Role of PI3K-AKT-GSK-3 pathway in TLR 
                           Induced B cell activation and differentiation. 
 
Introduction 
During aging, the B cell mediated responses, including affinity and avidity of the 
antibodies, are decreased (40, 103, 220, 327). There is also an age-related decrease in 
antibody responses to the pneumococcal polysaccharide vaccine  in both elderly humans 
and rodents compared to the young leading to an impairment in opsonophagocytosis of 
pneumococci  (278). To effectively eliminate pathogens the humoral response must be 
able to effectively class switch from a predominant IgM to non-IgM isotypes. This defect 
in the elderly is in turn attributed to impairment in class-switch recombination (CSR) to 
other isotypes, such as IgE, IgG1, IgG2a or IgG3 with specific effector functions (103, 
220, 256).  The impaired class switching in the elderly mice is shown to be associated 
with a decrease in the enzyme, activation-induced cytidine deaminase (AID), due to 
defects in signaling molecules that govern the expression of this molecule (103, 379). 
Under normal conditions, B cell receptors sense the capsular polysaccharide of S. 
pneumoniae, which is a TI antigen. In the presence of certain cytokines B cells can 
produce IgG3 via CSR that helps clear the pathogen by opsonophagocytosis (227). 
However, this is impaired in the aged due to a defect in AID and CSR (103, 105, 220).  
 PI3K-Akt signaling plays a crucial role during B cell proliferation, survival, activation 
and differentiation (267, 268). PI3K mediated activation of Akt results in 
phosphorylation and inactivation of the Foxo-1 transcription factor in B cells. 
Inactivation of Foxo-1 results in the impairment of B cell development in the bone 
marrow, fewer lymph node cells in the peripheral and the ability of B cells to undergo 
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class switch recombination and expression of the enzyme AID (53, 83). Overall, PI3K 
also regulates B-cell homeostasis  by regulating B cell development in the bone marrow, 
the different types of B-cell subsets, B-cell survival and proliferation (22). Yet no studies 
have evaluated the PI3K-Akt signaling pathway in the context of the B cells or its role in 
the impaired class switching in the aged. Since we showed earlier that increased activity 
of PI3K-Akt pathway is responsible for age-related cytokine defect in macrophages 
(Chapters 3 and 4), we asked if the PI3K-Akt pathway plays any role in the impaired 
humoral responses of aged B cells. Glycogen synthase kinase-3 (GSK-3) is a direct 
downstream substrate of Akt, but its role in B cell immune function like CSR and plasma 
cell formation is unknown. GSK-3 modulates beta-catenin and NFATc transcription 
factors as well as cyclin D2 that facilitate B cell survival, proliferation and differentiation 
(24, 29, 118, 391). 
Hence, in this chapter we investigated the role of the PI3K-Akt-GSK-3 signaling pathway 
in the impaired humoral response with a future goal of pharmacologically modulating this 
pathway for potent antibody immune responses in the aged. We demonstrate lower 
production of IgG3 in aged mouse compared to the young upon stimulation with TLR2,-4 
and HKSP and that it is in part due to a dysregulation of the PI3K-Akt-GSK-3 pathway.  
 
 
 
 
148 
 
Results 
IgG3 production by splenic B cells activated via TLR2, 4 and HKSP is decreased in the 
aged. 
 Aged and young purified splenic B cells were stimulated with LPS (20 µg/ml) (Figure 
6.1A), P3C (5µg/ml) (Figure 6.1B) and HKSP (2 x 108 CFU/ml) (Figure 6.1C) for three 
days. Total IgG3 levels were quantified by ELISA. There was lower production of IgG3 
in TLR2 (Figure 6.1A), TLR4 (Figure 6.1B) and HKSP (Figure 6.1C) activated aged 
splenic B cells compared to the young.   
 Increased activation of Akt in the aged splenic B cells correlates with the defect in IgG3 
production  
Akt was activated via phosphorylation by the PI3 kinase resulting in  suppression of IgG, 
IgA and IgE production in B cells (269). We inquired if there was an age-related increase 
in p-Akt which could account for the lower production of IgG3.  Levels of p-Akt were 
determined by Western blot analysis of lysates from aged and young adult splenic B cells 
stimulated with LPS (20µg/ml). Under unstimulated conditions, there was a higher level 
(1.5 fold, after normalization to total Akt) of p-Akt in the young compared to the aged, 
which was suppressed strongly after 120 minutes of stimulation with LPS (Figure 6.2 A, 
lanes 1 and 4). Reduction of p-Akt levels in young B cells activated with LPS at early 
time points (15 and 30 minutes, Figure 6.2A, lanes 5, 6 and 7) was very small. In 
contrast, there was no reduction in p-Akt levels in LPS stimulated aged B cells at early 
time points (Figure 6.2A, lanes 1, 2, 3). At 120 minutes of stimulation there was only a 
20% reduction in P-Akt in aged B cells; unlike young B cells where p-Akt was reduced 
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by ~87% (Figure 6.2A, lanes 5, 8). Having established that LPS activated aged B cells 
had higher activated Akt than the young; we next asked if this differential activation of 
Akt was associated with differences in the protein levels of PTEN, an antagonist of the 
PI3 kinase pathway. Surprisingly, there was no change in PTEN levels beteen the aged 
and young B cells (figure 6.2B) at all time points tested. 
 PI3K inhibition leads to increase in production of IgG3 in both the aged and young adult 
splenic B cells 
We asked if the increased levels of p-Akt had a role in decreased IgG3 in the aged since 
Akt pathway was known to inhibit IgG3. Since p-Akt activation was dependent on PI3K 
activity, we tested if inhibition of PI3K enhanced IgG3 expression in aged B cells. We 
stimulated splenic B cells with LPS (20μg/mL) and HKSP in the presence of wortmannin 
or LY294002 for 3 days and the supernatants were assayed by ELISA for IgG3 
production. There was a 2-fold increase in IgG3 production in the young splenic B cells, 
while in aged splenic B cells there was a 6-fold increase with LPS stimulation in the 
presence of wortmannin (Figure 6.3A). When LY294002 was used, there was a two-fold 
increase at 5µM of LY294002 compared to LPS stimulation in a dose dependent manner 
(Figure 6.3B). When wotmannin was used in the presence of HKSP, there was a greater 
increase in IgG3 production in the young B cells at 10 nM of wortmannin compared to 
the aged, yet both were greater than B cells stimulated with HKSP without the inhibitor 
(Figure 6.3 C). At 25 nM of wortmannin, the aged B cells had a greater increase in 
production of IgG3 compared to the young. However, at both concentrations of 
wortmannin there was a higher IgG3 production compared to HKSP stimulated B cells 
without the inhibitor (Figure 6.3C).  In the case of HKSPstimulation, the enhancement of 
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IgG3 by PI3K inhibitor was more in the aged than the young (Figure 6.3D). Finally, we 
asked if the ability of LY294002 to enhance IgG3 production in aged B cells was 
dependent on a specific strain of mouse. Splenic B cells from C57BL/6 mice were 
stimulated with LPS in the presence of LY294002. There was a significant increase in 
IgG3 production in the presence of LY294002 (Figure 6.3 E). Thus, inhibiting PI3 kinase 
partially rescued the age-related defects in IgG3 production.  
Inhibition of PI3K with wortmannin induces AID. 
PI3K-Akt pathway regulates immunoglubulin production by inhibiting the expression of 
the enzyme AID which facilitates class switch recombination (268). On the basis of this 
finding and the fact that wortmannin elicited enhanced IgG3 production by both aged and 
the young B cells at all concentrations evaluated (Figure 6.3 A), we measured the 
expression of AID in young splenic B cells stimulated with Pam3CSK4, a ligand for 
TLR-2/1 that is associated with HKSP lipoproteins, in the presence of different doses of 
wortmannin for 72 hours. There was a 1.3 fold increase in AID levels at 25nM and 1.8-
fold increase at 50nM of wortmannin+ P3C activated B cells compared to P3C 
stimulation alone (Figure 6.4). Thus, PI3K inhibtion induces increased expression of AID 
that plays a role in IgG3 production.  
GSK-3 inhibition in the presence of LPS induces higher production of IgG3 and IgA in 
young splenic B cells. 
Glycogen synthase kinase-3 had been shown to influence B cell survival, proliferation 
and activation (391). Since GSK-3 was an immediate downstream substrate of Akt, we 
evaluated the effect of GSK-3 inhibition on LPS induced IgG3 and IgA secretion. Splenic 
B cells from young mice were stimulated with LPS in the presence of SB216764, a well 
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characterized inhibitor of GSK-3 (Figures 6.5 A and B). There was a 2.6-fold increase in 
IgG3 production in the young splenic B cells at 5 and 10 µM of the inhibitor (Figure 
6.5A), while there was a 3 and 6-fold increase in production of IgA at 5 and 10 µM 
respectively (Figure 6.5B).  
 SB216763 enhances secretion of IgA and surface expression of switched isotypes of 
young mouse B cells stimulated with Pam3CSK4, a TLR2/1 ligand. 
  IgA immunoglubulin conferred protection against S. pneumoniae in aged mice at 
mucosal sites like the lungs (110, 111, 172). Hence, we asked whether GSK-3 inhibition 
enhanced production of IgA if we use Pam3CSK4, the TLR2/1 ligand. We demonstrated 
that SB216763 enhanced the production of IgA (Figure 6.6A) in splenic B cells stimuated 
with Pam3CSK4. We next asked if this effect could be shown via surface expression of 
the IgA. B cells were stimulated with Pam3CSK4 in the presence of SB216763 and 
cultured for 3 days. Figure 6.6 B showed that SB216763 increased the surface expression 
of IgA compared to B cells treated with LPS alone. 
Pharmacologically inhibiting GSK-3 results in increased production of IgA and IgG3 as 
well as enhanced expression of surface IgA in young splenic B cells stimulated with CpG, 
a TLR-9 ligand. 
 TLR9 signal has been implicated in immune response to S. pneumoniae presumably via 
bacterial DNA containing CpG motifs (14). Therefore; it was of interest to know if TLR9 
mediated IgG3 expression was enhanced by GSK-3 inhibition. We demonstrated an 
enhanced production of IgA (figure 6.7A) and IgG3 (Figure 6.7B) at all concentrations of 
the GSK-3 inhibitor tested.  We then asked if this effect could be shown via the surface 
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expression of switched isotypes of IgA. B cells were stimulated with CpG (Figure 6.7 C) 
in the presence of SB216763 and cultured for 3 days. The B cells were collected and 
analyzed by flow cytometry. Figure 6.7C showed that SB216763 increased the surface 
expression of IgA compared to B cells treated with LPS alone. 
Activation of young adult splenic B cells with HKSP in the presence of SB216763 
increase the production of IgG3 as well as surface expression of IgA and IgG3. 
Now that we had shown that synthetic ligands for TLR-2,-4 and -9 which were associated 
with S. pneumoniae enhanced the production and surface expression of different 
immunoglobulin, we decided to approximate as closely as possible the normal host-
bacterial interaction. For this purpose, S. pneumoniae was grown to mid-log phase, heat 
killed and used to activate B cells in the presence of SB216763. We cultured the B cells 
for 3 days and assayed the supernatants by Ig ELISAs. There was enhanced in the 
production of IgG3 (Figure 6.8A) at all concentrations of SB in HKSP stimulated B cells.  
We tested if GSK-3 affected switching to IgA and IgG3 isotypes. Therefore, surface 
expression of IgA and IgG3 was analyzed by flow cytometry. B cells expressing IgA 
(Figure 6.8B) and IgG3 (Figure 6.8C) switched isotypes were enhanced when GSK-3 was 
inhibited. Please note the magnitute of the HKSP induced IgG3 response in these 
experiments was significantly lower than in experiments shown in Figures 6.3. We 
attribute this to a new batch of HKSP which was not as potent as the one used in PI3K 
inhibitor studies. However, the enhancement of IgG3 response by the GSK-3 inhibitor 
was highly reproducible. 
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GSK-3 inhibitor enhances plasma cell formation in TLR-2,-4,-9 and HKSP stimulated 
splenic B-cells  
Previous studies by Omori and colleagues showed that PI3K inhibition enhanced class 
switching at the expense of plasma cell formation via differential regulation of BLIMP 
and FOXO trancription factors (268, 269). Since, GSK-3 was a downstream substrate of 
PI3K-Akt and had multi-factorial roles in regulating B cells we evaluated the effect of 
GSK-3 inhibition on plasma cell formation. We stimulated young adult splenic B cells 
with LPS, P3C, CpG and HKSP in the presence of SB216763 for three days, collected the 
B cells and quantified the expression of the plasma cell marker, CD138 by flow 
cytometry. Surprisingly, there was an increase in plasma cells (B220lo CD138hi ) upon B 
cell activation with LPS (Figure 6.9 A), P3C (Figure 6.9 B, upper panel) and CpG 
(Figure 6.9 B, middle panel) at all concentrations of SB216763 tested. Interestingly, LPS 
and HKSP stimulation induced CD138 expression without reducing B220 levels. Though 
the significance of this difference between P3C and CpG versus LPS and HKSP was 
unclear, B220hi CD138hi cells represented an early stage of plasma cells. 
SB216763 modulates B cell activation and differentiation in the presence of ligands for 
TLR-2, 9 and HKSP without any toxicity.  
Since inhibition of GSK-3 imposed greater metabolic demands on the B cells to both 
class switch and form plasma cells, we wondered if this was at the expense of viability or 
proliferation of the B cells. The viability of the young splenic B cells  was examined by 
trypan blue count following 3 days of culture in the presence of  SB216763 with CpG 
(Figure 6.10 A), Pam3CSK4  (Figures 6.10 B),  and HKSP  (Figure 6.10C). The recovery 
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of viable B cells increased by 3-4-fold upon stimulation with CpG and Pam3CSK4, 
which was further enhanced slightly by GSK-3 inhibition. Stimulation with HKSP had 
only a modest effect on B cell recovery, which was enhanced at one concentration of the 
GSK-3 inhibitor.  
SB216763 enhances the expression of AID in TLR-4 stimulated B cells. 
GSK-3 regulates beta-catenin and NFATc1, transcription factors that play a role in CSR, 
which can be determine by the expression of AID. B cells were stimulated with LPS with 
our without SB216763 for 72 hours and the probed for AID. Our results show that 
SB216763 increased AID expressions at all concentrations (Figure 6.11, lanes 2, 3, 4 and 
5). We conclude that the ability of SB216763 to increase IgG3 and IgA may be via CSR.  
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DISCUSSION 
Our ultimate goal is to establish a possible link between alteration in the PI3K-Akt 
pathway in the aged mice compared to the young that explains the impaired IgG3 
production in aged splenic B cells and whether we can rescue this defect 
pharmacologically. We also wanted to create a proof of principle that pharmacologically 
inhibiting GSK-3, a downstream kinase of the PI3K-Akt signaling induces greater B cell 
differentiation, activation and thus, serves as a potential vaccine adjuvant in the aged 
mice. We demonstrate that aged splenic B cells produce lower levels of IgG3 compared 
to the young and that this is associated with an increase in the activation of Akt, which is 
known to downregulate AID and class switching (268). We establish a causal role of the 
activated Akt in blunting the IgG3 production as we are able to rescue the age-related 
defect in IgG3 production upon inhibition of PI3K in the context of TLR-4 and HKSP. 
We make a notable finding that inhibiting GSK-3 with SB216763 results in an enhanced 
class-switching and plasma cell formation. Inhibitors of PI3K and GSK-3 indicate that 
both signaling molecules are able to upregulate AID expression. 
Aging is associated with impaired humoral  and vaccine responses to pathogens such as 
the Gram positive  S. pneumoniae that is the leading etiological agent for community 
acquired pneumonia (CAP) (278). The impaired humoral response in the aged associates 
with a decrease in AID, class switch recombination and other signaling molecules like 
protein tyrosine kinase (PTK) and protein kinase C isoforms and transcription factors like 
E 47 (105, 379). Hence, these aging markers can be pharmacologically modified to create 
a close approximation of the effective young adult immune responses. 
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We established in vitro conditions which mimicent the defective B cell response to 
pneumococcal polysaccharide vaccine or TNP-Ficoll, a model TI-II antigen and showed 
that the response can be enhanced by macrophage derived cytokines (38, 114). We also 
demonstrated that the age-associated defect in B cell antibody responses to these antigens 
is due to a cytokine dysregulation in the aged macrophages (63). We further showed that 
inhibiting PI3K in aged macrophages rescues this cytokine defect and serves as a 
potential target for providing endogenous cytokines needed for B cells to overcome the 
defective humoral response (Chapter 4). The in vivo use of PI3K inhibitor also affects B 
cells. Hence, we established that PI3K-Akt is also dysregulated in the aged B cells and 
can be rescued by pharmacological inhibition. 
  The Class IA PI3K plays a very important role in modulating B-cell immune functions 
and activities (89). It is one of the key signaling molecules downstream to B cell receptor 
(BCR), B-cell costimulatory molecules, toll like receptors and cytokine receptors and can 
be activated by one or a combination of these receptors. Once activated, it phosphotylates 
Akt, which in turn modulates B-cell proliferation and survival (81, 268). The p110 delta 
(p110δ) catalytic subunit is critical for the phosphorylation of Akt. Phosphorylated Akt 
then phosphorylates and inactivates Forkhead box-1 containing transcription factor, 
Foxo1 (205). Genetic or pharmacological inactivation of p110δ prevents B cells from 
entering the cell cycle by inhibiting upregulation of cyclin D2 (30, 267).   
In this study we show that p-Akt is increased with age and explains the defective IgG3 
production observed in the aged. Our finding is supported by studies showing that 
activation of Akt via a B cell specific PTEN conditional knockout leads to a defect in the 
production of most isotypes of IgG upon B cell stimulation by either TI or TD antigens 
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(343). Though we show a correlation between increased p-Akt and defective IgG3 
production in aged B cells, we still need to establish causation. Hence, we demonstrate 
that inhibition of PI3K-Akt signaling pathway by either LY294002 or wortmannin is able 
to rescue the age-associated defect in IgG3 production. This finding is supported by 
several studies that demonstrate that pharmacological or genetic inhibition of PI3K-Akt 
signaling enhances Ig production (30, 81, 268, 269). AID plays a crucial role in CSR and 
somatic hypermutation which are critical for a potent humoral response to pathogens 
(248). Our studies indicate that inhibition of the PI3K-Akt signaling pathway resultes in a 
higher expression of AID and thus increased production of IgG3.  
Having established that PI3K-Akt can be pharmacologically modulated to shift from a 
decreased AID and IgG3 production, a hallmark of aging, to enhanced AID expression 
and IgG3 production, a marker of young adult mediated immune response, we decided to 
look at downstream of this pathway. A downstream molecule can be modulated under in 
vivo conditions with fewer side effects. Hence, we evaluated the role of GSK-3 in 
enhancing Ig production, AID expression and plasma cell formation in a young splenic B 
cell in vitro model. BCR signaling triggers PI3K-Akt activation resulting in the 
phosphorylation and inactivation of GSK-3 activities. Since GSK-3 negatively regulates 
several of its downstream transcription factors, the phosphorylation mediated inactivation 
of GSK-3 leads to an increase in the activities of transcription factors such as NF-ATc 
and beta-catenin. These transcription factors are important in modulating the immune 
functions of B cell (118, 391).  
We inhibited GSK-3 with SB216763 in B cells that are then activated via TLR-2,4 and 9, 
as well as HKSP and demonstrated an enhanced production of different isotypes of IgG, 
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as well as IgM and IgA. This is the first study to show that GSK-3 inhibition can lead to 
increased production of immunoglobulin. In support of this notion, a conditional 
knockout of beta-catenin, one of the downstream targets of GSK-3 shows a significant 
reduction in class switching to IgG1 and plasma cell generation in vitro (391). Since the 
activity of unphosphorylated GSK-3 is known to phosphorylate and degrade beta-catenin, 
thus inhibiting GSK-3 by SB216763 results in increased beta-catenin which in turn may 
enhance Ig production and plasma cell generation. In the future we will evaluate the role 
of GSK-3 inhibition on beta-catenin in B cells and evaluate its effects on Ig production. 
We wonder if the increased production in IgA and IgG3 is due to class switching or 
expansion of an already class-switched group of B cells. To address this question we 
evaluated the generation of B cells with switched isotypes IgG3 and IgA on their surface 
by FACS. We consistently show that SB216763 enhances the surface expressions of the 
IgG3 and IgA isotypes indicating that this phenomenon is due to class switching. Similar 
results are obtained for surface IgG1 and IgG2b positive B cells (data not shown). We 
further validate that GSK-3 is mostly inducing increased production of the 
immunoglobulin by class switch recombination by Western blot for AID expression. As 
mentioned earlier AID upregulation is a very good indicator of class switch 
recombination (249).  
It is known that plasma cell formation is the terminal and irreversible differentiation state 
of B cells where they lose their B cell characteristics and become potent antibody 
producing cells. This process is aided by antagonistic interactions of transcription factors 
like BLIMP1, BCL6, Pax5 (320). Since switched cells can eventually become  plasma 
cells, the CSR may correlate with plasma cell development in a  sequential manner (270). 
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Recently, Omori and colleagues show that PI3K inhibition leads to increase CSR at the 
expense of plasma cell production (268, 269). Yet in our hands, we show that GSK-3 
inhibition upregulates both CSR and plasma cell formation at the end of three days. This 
is supported by other studies that show that CSR is a prelude to plasma cell formation 
(181). 
In spite of this novel finding with GSK-3, there is a caveat we must point out in our work. 
We have not as of yet clearly delineated the transcription factors that are being regulated 
by either PI3K-Akt or GSK-3 inhibition in our studies. GSK-3 is known to regulate 
transcription factors like NF-κB (p65 and p105), beta-catenin  and NFATc1 that are 
known to regulate CSR or plasma cell formation (166). Hence, a future challenge for us 
will be to clearly delineate the downstream signaling pathway to Akt and GSK-3 that are 
inducing CSR and plasma cell formation, respectively.  Our observation can be 
summarized in a model wherein increased activity of the PI3K-Akt pathway in the aged 
suppresses AID and CSR and resulting in reduction of IgG3 production (Figure 6.12 A). 
Inhibiting PI3K-Akt relieves this suppression and enhances AID, CSR and IgG3 
production (Figure 6.12B). TLR-2, 4 or 9 and HKSP mediated stimulation of B cells in 
the presence of SB216763 reduces p-GSK-3β, leading to increased GSK-3β activity, and 
increased AID, CSR and immunoglobulin production through transcription factors that 
are yet to be charaterized (Figure 6.12B).  
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Figure 6.1. Age-associated decrease in IgG3 production by splenic B cells activated 
via TLR2, 4 and HKSP. 
 Splenic B cells (1.0 x 106 cells/ml) from young (open box) and old (filled black box) 
mice were cultured with LPS (20 µg/ml) (6.1A), P3C (5µg/ml) (6.1B), and HKSP (2 x 
108 CFU/ml) (6.1C), for 3 days. At the end of three days supernatants were collected and 
assayed for IgG3 by ELISA.  Results were expressed as means ± SE which were 
representative of four independent experiments.  The symbol *  indicated  statistical 
significance (p<0.03) of differences in responses of young and  aged B cells. 
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Figure 6.2. Age-associated increase in activation of Akt without changes in PTEN in 
splenic B-cells. 
Purified splenic B cells (2.0 x106 cells/ml) from aged and young adult B cells were 
stimulated with LPS (20 µg/ml) and total cell lysates were isolated and immunoblotted 
for p-Akt (Figure 6.2A) and PTEN (Figure 6.2B). The blots were stripped and probed for 
total Akt and for beta-actin. The numbers represented densities of bands normalized to 
total Akt with the values for unstimulated aged and young B cells set to one.  
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Figure 6.3. Inhibition of PI3K activity increases the production of IgG3 in both the 
aged and young adult splenic B cells 
Splenic B cells (1.0 x 106 cells/ml) from young (open box) and old (filled black box) 
Balb/c mice were pretreated for 1 hour, with the PI3K-inhibitors, LY294002 (Figures 6.3 
B,D and E) or wortmannin (Figures 6.3A and C) at different concentrations that were 
previously tested and optimized. The B cells were then activated with LPS (20 µg/ml) 
(Figures 6.3 A, B and E) or HKSP (2x 108 Cfu/ml) (Figures 6.3 C and D).  After three 
days of culture the supernatant was collected and assayed by ELISA for IgG3. (E) IgG3 
ELISA from splenic B cells of aged C57BL/6 mice activated by LPS in the presence of 
LY294002.  Results were presented as mean ± SE of four independent experiments.  The 
symbol * and # indicated statistical significance (p<0.04) of differences in responses in the 
aged and young B cells treated with LPS (or HKSP) with or without the PI3K inhibitor.  
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Figure 6.4. Wortmannin, a PI3K inhibitor, enhances AID expression in B cells. 
Purified  splenic B cells (2.0 x106 cells/ml)  in  5 ml of RPMI complete from young adult 
mice were stimulated with  P3C (10 µg/ml) for three days and total cell  lysates were 
isolated and immunoblotted for AID  (Figure 6.4A) . The blot was stripped and probed 
for beta-actin. The numbers represent densities of bands normalized to beta-actin with the 
values for LPS stimulated young B cells set to one.  
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Figure 6.5. GSK-3 inhibition induces higher production of IgG3 and IgA in young 
splenic B cells stimulated via TLR-4. 
Splenic B cells (1.06 cells/ml) from young  Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with LPS (20 µg/ml) for 3 days and the supernatant was collected 
and evaluated by sandwich ELISA for IgG3 (Figure 6.5A) and IgA (Figure 6.5B). Results 
were means ± SE of four independent experiments.  The symbol * indicated statistical 
significance (p<0.01) of differences in responses in the young B cells treated with LPS 
with or without the GSK-3 inhibitor.  
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Figure 6.6. Inhibition of GSK-3 enhances secretion of IgA and surface expression of 
IgA in young mouse B cells stimulated with Pam3CSK4. 
Splenic B cells (1.06 cells/ml) from young Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with P3C (5µg/ml) for 3 days and the supernatant was collected 
and evaluated by  ELISA for IgA (Figure 6.6A). Results were means ± SE of four 
independent experiments.  The symbol * indicated statistical significance (p<0.03) of 
differences in responses of young B cells treated with LPS with or without the GSK-3 
inhibitor. (Figure 6.6B) After culture for 3 days B cells are removed, washed and then 
analyzed by FACS for the expression of membrane IgA using PE-Cy5-labeled anti-B220 
Abs and FITC-labelled IgA anti-mouse Ab. Results were representative of five 
independent experiments.  
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Figure 6.7. GSK-3 inhibition leads to increase in production and expression of 
surface IgA and IgG3 in young splenic B cells stimulated with CpG, a TLR-9 ligand. 
Splenic B cells (1.06 cells/ml) from young  Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with CpG (5µg/ml) for 3 days and the supernatant was collected 
and evaluated by  ELISA for IgA (Figure 6.7A) and IgG3 (Figure 6.7B). Results were 
given as means ± SE and are representative of four independent experiments.  The 
symbol * indicated statistical significance (p<0.03) of differences in responses in the 
young B cells treated with LPS with or without the GSK-3 inhibitor.  (Figure 6.6C) 
FACS analysis was done on B cells cultured for 3 days for the expression of membrane 
IgA using PE-Cy5-labeled anti-B220 Abs and IgA FITC-labelled IgA anti-mouse Abs. 
Results were representative of five independent experiments.  
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Figure 6.8. HKSP activates young splenic B cells in the presence of SB216763 to 
increase the production of IgG3 as well as surface expression of IgA and IgG3. 
Splenic B cells (1.06 cells/ml) from young  Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with HKSP (2.0 x 108 CFU/ml) for 3 days and the supernatant 
was collected and evaluated by  ELISA for IgG3 (Figure 6.8A). Results were indicated as 
means ± SE and were representative of four independent experiments.  The symbol * 
indicated statistical significance (p<0.03) of differences in responses in the young B cells 
treated with HKSP with or without the GSK-3 inhibitor. FACS analysis was done on B 
cells cultured for three days  for the expression of membrane IgA (Figure 6.8B) and IgG3 
(Figure 6.8C)  using PE-Cy5-labeled anti-B220 Abs,  FITC-labelled to antibodies to IgA 
and biotin-labelled anti-IgG3  Abs. After incubation for 30 minutes, the biotin-labeled 
cells were washed two times and resupended in APC-strepavidin for additional 15 
minutes. All the cells were finally washed once and were analyzed on FACS Calibur. 
Results were representative of five independent experiments.  
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Figure 6.9. SB216763 induces increased plasma cell formation in TLR-2,-4,-9 and 
HKSP stimulated splenic B-cells  
Splenic B cells (1.06 cells/ml) from young Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with LPS (20 µg/ml) (Panel A), Pam3CSK4 (5µg/ml), CpG 
(5µg/ml) and HKSP (2.0 x 108 CFU/ml) (Panel B) for 3 days.  FACS analysis was 
performed on B cells stained with PE-Cy5-labeled anti-B220 and PE-labelled anti-CD-
138 antibodies. Results were representative of five independent experiments.  
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Figure 6.10. SB216763 is not toxic to young splenic B cells activated via TLR-2, 9 
and HKSP  
Splenic B cells (1.06 cells/ml) from young Balb/c mice were cultured with SB216763 for 
1 hour, then stimulated with CpG (5µg/ml) (Figure 6.10 A), Pam3CSK4 (5µg/ml) 
(Figures 6.10 B),  and HKSP (2.0 x 108 CFU/ml) (Figure 6.10C) for 3 days. The cells 
were harvested and washed twice with 1X PBS and then resuspended in RMPI. The 
viable cells were counted by trypan blue-mediated enumeration. Results were 
representative of three independent experiments. 
 
 
 
 
 
 
 
 
172 
 
 
 
 
 
 
Figure 6.11. SB216763 enhances expression of AID in young splenic B cells activated 
via TLRs.  
Purified  splenic B cells (2.0 x106 cells/ml)  in  5 ml of RPMI complete from  young adult 
mice were were either treated with SB216763 or left untreated  for 1 hour and then 
stimulated with LPS (20 µg/ml) for three days and total cell  lysates were isolated and 
immunoblotted for AID (Figures 6.11) . The blot was stripped and probed for beta-actin. 
The numbers represented densities of bands normalized to beta-actin with the values for 
unstimulated young B cells set to one.  
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Figure 6.12.   Schematic model for PI3K-Akt and GSK-3 inhibition in positively 
modulating B cell immune functions.  
The HKSP or TLR-2,-4 and -9 activation of aged splenic B cells triggers activation of 
PI3K, increased activity of  PI3K-Akt pathway (increased p-Akt, p-GSK-3) leading to 
suppression of AID, CSR and IgG3 production (Figure 6.12A). This age-related defect 
can be rescued by inhibiting PI3K or GSK-3 leading to reduction in p-Akt relieving the 
suppression of AID which then promotes CSR and IgG3 production at levels similar to 
the young (Figure 6.12B).  
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CHAPTER 7: OVERALL DISCUSSION 
Biomarkers of aging- macrophages: Aging has become a challenging global health 
concern as the development in health and technology is giving rise to an ever increasing 
elderly population. This population exhibits a unique aging phenomenon referred to as 
immunosenecence, which is associated with impaired innate and adaptive immune 
functions (197, 220, 228). As a result of these defects, this population is affected with 
pathologies that are neurological, metabolic, plastic and systemic. There is increased 
incidence of dementia, Alzheimer disease, diabetes, cancers and infections resulting in 
higher morbidities, mortalities and costly hospitalization (58, 204). These age-related 
pathologies have led to frantic efforts to identify markers of aging so that effective 
therapeutics can be developed. In any disease entity the identification of biomarkers is 
very relevant as it leads to the ability to (1) predict the disease progression and intensity 
(2) develop effective therapeutics and (3) effectively measure the efficacy of the existing 
and newly developing therapeutics. In the aged humans and rodents, a couple of these 
markers are known and are paving the way to (1) predict the aging population that are 
more susceptible to age-related disease syndromes, (2) develop  therapeutics, such as 
exogenous cytokines, ligands for TLRs such as CpG, that show promises in mouse 
models to rescue these aging defects; and (3) lead the way in measuring intervention in 
age such as increase in CSR and antibody responses that are of higher affinity and avidity 
(78, 196). 
  In the context of immunosenecence, there are still many challenges in adequately 
defining such markers, tailoring patented therapeutics and developing assays that will 
give a good measure of outcomes. One of the challenges is that aging markers are not 
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restricted to one type of cell or tissue as aging is known to affect all innate and adaptive 
immune cells. Hence, a marker in one group of cells may only provide for partial 
therapeutics and outcome measure of disease state and progression. For instance, while 
the level of AID could serve as a very good marker for B cell immunosenescence, it will 
not serve similar purposes in macrophages or T cells (196).  
Macrophage and macrophage-derived cytokines are crucial in modulating both the innate 
and immune responses, and a dysregulation in cytokines is a chief predisposing factor for 
age-abnormalities like Alzheimer’s disease, cancer and increased susceptibilities to 
infectious diseases. Age-related defects in macrophages are a contributing factor to the 
diminished immune responses in the host (186, 282, 288).  The sentinel functions of 
macrophages in the respiratory tract are defective which contribute to mortality from 
pneumonia and influenza among the elderly (186, 397). In the context of immune 
responses to S. pneumoniae, a dysregulation in IL-6, TNF-α, IL-1β in alveolar 
macrophages increases the susceptibility to the disease leading to increased lethality (355, 
357). The age-related decline in vaccine responses has also been attributed to defect in 
macrophage function (58, 186). The prognosis of elderly patients with acute pneumonia 
are very poor if they produce lower TNF-α and IL-1β compared to their young adult 
counterparts (121). IFN-γ has also been shown to cause hypo-responsiveness to S. 
pneumoniae in the post-influenza recovery period. 
If macrophage and macrophage-derived cytokines are crucial biomarkers for aging, and 
modulating their age-related defects could provide effective measurable therapeutics, 
why is there an absence of research to therapeutically modulate macrophage and 
macrophage-derived cytokines to restore immune functions? There are several challenges 
176 
 
such as (1) establishing the dichotomy between cytokine dysregulation and 
“inflammaging”; (2) uniform characterization of aged macrophages in terms of 
phenotypes and signaling molecules; and (3) evaluating age-related impairment in terms 
of intrinsic and extrinsic defects. 
Cytokine-dysregulation and inflammaging:In this thesis, we report in chapter 3 that upon 
stimulating negatively selected splenic macrophages with  ligands for TLR-4, TLR2/1 
and TLR2/6 there is a reduction in pro-inflammatory cytokines, IL-12, IL-6 and TNF-α, 
but an increase in IL-10. We repeat this with a ligand for the IL-1 receptor and heat killed 
Streptococcus pneumoniae (HKSP) that contain ligands for TLR2 and TLR9. This is 
established in literature as “cytokine dysregulation”, and is reported in both peritoneal 
and splenic macrophages by many other investigators (34, 63, 277, 298). However, this 
finding runs contrary to the concept of “inflamm-aging” which indicates increased basal 
inflammation is the norm in the elderly.  IL-6 and TNF-α are the two common cytokines 
that gave rise to this basal inflammation and predispose such individuals to several 
inflammatory disease such as atherosclerosis (47, 102). This low grade inflammation has 
several contributing factors including: frailty of the elderly, obesity, lack of exercises and 
prior infections among others  (9). The frail elderly already have predisposing underlying 
diseases that impact on basal inflammation, whereas, in the healthy elderly, the 
inflammation is controlled by the increase in the levels of IL-10 (10).  For instance IL-6 
is less in normally healthy elderly than the young adult, but this is reversed in elderly 
having infections (257).  
A recent study shows that the apparent discrepancies in age-related macrophages in terms 
of cytokine-dysregulation and to age-related inflammation are due to differences in 
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strains, sex, site and methods of macrophage collection and experimental conditions 
(186). But we are able to show in chapter 4 that cytokine dysregulation can also be 
demonstrated in in vitro generated BMDM stimulated with several TLR ligands and 
HKSP. Since two different groups of macrophages (spleen and BMDM) are isolated 
under different conditions and treated similarly to yield cytokine-dysregulation, we 
conclude the method of macrophage isolation or the site of macrophages does not explain 
this deviation in cytokine prolife. If cytokine dysregulation represents an aging marker 
for effective therapeutics, there must be a careful selection of healthy elderly candidates 
to account for other co-morbidities.  
Another issue with the use of cytokine dysregulation in macrophage as a marker for aging 
for the development of effective therapeutics is the fact that there are differences in 
macrophages in terms of phenotype, function and effects on the surrounding cells (245). 
Thus, human intestinal macrophages do not produce inflammatory cytokines and do not 
express complement receptor (CR/CD11b) (330).  There is a classification of M1 and M2 
macrophages, in which the M1 macrophages are associated with the Th1 strain of mice 
(C57BL/6) and produce high levels of nitric oxide (NO) in response to LPS or interferon 
gamma (IFN-γ), while the M2 are associated with Balb/c, the Th2 strain and produce 
arginase which converts arginase to L-Ornithine in response to LPS alone (237). The 
most commonly identified macrophages are the classically activated macrophages 
(CAM/M1) and the alternatively activated macrophages (AAM/M2) (123). The CAM 
and the AAM are relevant to our studies as each of these classes of macrophages is 
influenced by different cytokines and they in turn produce different cytokines. Not only 
that, they can each respond to different classes of pathogens and thus the appropriate 
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microenvironment must be created to tailor a response for a specific pathogen. In our 
case, the goal is to design therapeutics that precisely orchestrate a particular phenotype of 
macrophages that  target extracellular pathogens like S. pneumoniae;  as in the case of the 
CAM which  are effective against intracellular pathogens like Mycobacterium 
tuberculosis (245, 258). 
The  CAM are activated by a dual signaling involving first a priming by IFN-γ, produced 
by Th1 cells, and then  a subsequent signal by microbial LPS, but the AA macrophages 
don’t need a priming as IL-4 and/or IL-13 produced by Th2 cells can activate these cells 
(123). The CAM have higher phagocytic and antigen presentation functions than AAM. 
They produce chemokines like IL-8 and Rantes that help in the recruitment of NK cells, 
neutrophils, T cells and even immature DCs.  In addition, they produce pro-inflammatory 
cytokines like IL-1β, IL-6 and TNF-α (245, 258).  However, they have a tendency to 
produce massive inflammation and  uncontrolled activation that can result in tissue 
damage, type I autoimmunity and tumors (123). The AAM also upregulate MHC-II and a 
distinct set of chemokines like CCL-17, 18 and 22, which help in the recruitment of 
leukocytes. Unlike CAM, AAM do not produce NO from L-arginine (247).  Once 
activated they can pinocytose antigens via their mannose receptor (MR), which are 
specific to the AAM, and present these antigens to T cells in the context of MHC-II. They 
also upregulate the enzyme arginase-I, a hallmark of AAM, that help produce proline 
required for rebuilding of extracellular matrix that is destroyed by the overly activated 
CAM (123, 247). AAM can down-modulate the massive pro-inflmmatory cytokines 
produced by the CAM via the production of anti-inflammatory cytokines like IL-10, 
TGF-β and IL-1Ra. They are also involved in would healing, angiogenesis and tissue 
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repairs (245, 258). The AAM like the CAM, have beneficial and pathological effects. 
While the AAM are involved in mediating humoral immunity and anti-parasitic 
responses, such as Shistosomiasis, they are associated with common pathologies like 
allergy and asthma (123). 
In this thesis we demonstrated that both in splenic and bone marrow derived 
macrophages inhibiting PI3K-Akt signaling pathway orchestrates a macrophage 
population that is specifically producing the pro-inflammatory cytokines, while 
suppressing IL-10, one of the anti-inflammatory cytokines used by the AAM to down-
modulate pro-inflammatory cytokines. We could probably say that PI3K-Akt inhibition 
produces a macrophage population that is closer to CAM in terms of the cytokines 
profile. A recent study indicates that PI3K is needed for the development of AAM, where 
a deficiency of SHIP, a negative regulator of PI3K, leads to the production of AAM, but 
that SHIP-mediated negative regulation of PI3K had a propensity for CAM  (296).  
Hence, by modulating PI3K-Akt we can drive the AAM or CAM dichotomy for rescuing 
the age-related defects in macrophage and macrophage-derived cytokines for potent 
immune response to specific type of infections. However, we cannot clearly identify 
whether these pharmacological inhibitors are able to produce either CAM or AAM. We 
will need additional assays to determine NO and arginase-I for CAM and AAM 
respectively under these conditions.  Our microarray shows that neither iNOS nor 
arginase is selectively increased in the aged versus young macrophages (65). 
Finally, for the use of cytokine-dysregulation in macrophages as a marker for aging in the 
development of therapeutics, there is the challenge of clearly establishing the contribution 
of the intrinsic and extrinsic factors (186). Until these can be resolved, it becomes 
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difficult to develop effective therapeutics and to rely on reversing cytokine-dysregulation 
as treatment marker. In the context of viral infection, it is known that macrophages can 
exert both intrinsic (limiting viral growth in vivo) and extrinsic (preventing viral 
production in other cells via the induction of interferons or TNF-α) modulatory effects 
(229, 243, 381).  Macrophage function in terms of cytokine production and antiviral 
resistance can be positively modulated by exercise, which is an extrinsic modulatory 
effect (146, 186). To address this important question, we used negatively selected SM 
and BMDM that are grown under in vitro conditions and treated them with ligands for 
TLR-2, 4 and/or -9 as well as HKSP with or without PI3K inhibitors. By demonstrating 
similar signaling mechanisms and cytokine profile in BMDM and SM we showed that the 
age-related defect in macrophages is most likely due to intrinsic signaling defects. We 
also demonstrated that PI3K-Akt inhibition can rescue this cytokine dysregulation in 
macrophages from either of these sources. Thus, we established that the cytokine 
dysregulation can be considered an aging marker, which can be treated in the context of 
intrinsic signaling defect in the PI3K-Akt pathway (17, 38, 64, 178, 230, 355, 356). We 
further show that inhibiting GSK-3, a downstream kinase of Akt, can potently activate 
macrophages to secrete IL-10 and pro-inflammatory cytokines needed for B cell 
mediated humoral responses to S. pneumoniae, as well as co-stimulatory molecues that 
are necessary for activation of the adaptive immunity (213, 325). Our studies do not 
address the reasons for elevation of PI3 kinase subunits in the aged SM and BMDM. 
Presently little is known about how genes for the p85 and p110δ are regulated (116). It is 
conceivable that epigenetic changes have a role in increased expression with ageing. 
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Future studies will have to address the kinetics and mechanism of regulation of such 
genes with increasing age. 
  Biomarkers of aging-B cells: Even, if we assume that AID levels are a very significant 
all-encompassing marker for aging, there is the additional challenge to establish whether 
the B cell immunosenescene is due to age-related intrinsic defects or extrinsic 
environmental defects or a combination. If it is possible to show that both intrinsic and 
extrinsic defects are affecting B cells in the aged it will be difficult to develop a unified 
therapeutics that modulates both the intrinsic and the extrinsic defects simultaneously. 
One group of studies  show that over expressing transcription factors like E47 or 
genetically down-modulating Akt  increases AID, CSR and upregulates antibody 
production and thus serves as a potential method to rescue the age-related intrinsic 
defects in B cells. We and others show that providing an extrinsic microenvironmental 
support like macrophage-derived cytokines could similarly rescue B cells in terms of 
antibody production under in vitro conditions (38, 63, 114, 196, 268). 
Our laboratory has been studying the effect of  aging  on B cell response in the context of 
S. pneumoniae, a Gram positive bacterium that affects the elderly more than any other 
pathogen and is responsible for very long expensive hospitalization, morbidity and 
mortalities (218). We show that B cells from the aged Balb/c mice have an impaired 
response to both pneumococcal polysaccharide vaccine (Pnu-Immune) and the TNP-
Ficoll, a typical TI-2 antigen. These age-related defects can be rescued by macrophages 
or macrophage-derived cytokines from young adult mice. We further demonstrate that the 
age-related defects in B cell responses are due to extrinsic defects due to cytokine 
dysregulation in aged macrophages (38, 63, 114). However, these studies still have some 
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unanswered questions, such as (1) is the increase in antibody responses due to CSR and 
to what extent is AID involved?  (2) are there intrinsic signaling pathways that are 
defective in the aged B cells that are contributing to the B cells defect? (3) is the 
modification of the extrinsic cytokines  that positively upregulate the B cell antibody 
response also regulate a signaling pathway in B cell? (4) can we modify B cell responses 
by modifying the age-related cytokine dysregulation in macrophages? (5) is cytokine-
dysregulation a good aging biomarker that can be used to design therapeutics and to 
reverse immunosenence in B cells and thus enhance immunity to S. pneumoniae and 
other pathogenic infections?  and (6) can we correlate this cytokine dysregulation with a 
signaling pathway that can be pharmacologically modulated to reverse age-related B cell 
defects? 
As alluded to earlier, the immunsenescence markers in B cells include impaired AID and 
CSR leading to a decrease in the quality and quantity of antibodies that are needed for the 
clearance of infections (196). These defects have been shown to be both intrinsic and 
extrinsic by us and many other laboratories and can be potentially rescued by modulating 
either the intrinsic factors or the extrinsic factors like the cytokine milieu (38, 114, 196). 
On the basis of literature on the role of the PI3K-Akt-GSK-3 pathway in modulating B 
cell immune function (103, 105, 268, 269), we investigated this pathway. We showed in 
Chapter 6 that the age-related heighted activity of the PI3K-Akt pathway correlates with 
a defect in the production of IgG3 in the aged splenic B cells and that inhibiting this 
pathway can rescue this pathway. We further show that inhibiting this pathway can 
enhance the AID marker for CSR. The finding that PI3K-Akt is an inhibitor of AID and 
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that this pathway is crucial to pathway for humoral responses including CSR is supported 
by many studies (22, 30, 81, 343). 
Finally, we show that GSK-3 has comparable effects to the PI3K-Akt pathway in young 
adult splenic B cells. Inhibiting GSK-3 pharmacologically induces higher production of 
different isotypes of IgG, IgA and IgM, as well as increased production of plasma cells. 
The inhibition also leads to the induction of AID and CSR. The transcriptional factors 
responsible for these effects are not presently known, but on the basis of previous studies 
we are postulating that β-catenin, NFATc1 and NF-κβ may be involved and will be 
included in future studies (29, 82, 391). 
In conclusion, we show in this thesis that the age-asscociated cytokine dysregulation in 
macrophages and impaired humoral response of B cells when activated via TLR-2, 4 and 
9 and HKSP are crucial biomarkers for aging. We showed that PI3K pathway plays a 
critical role in both macrophages and B cells. We will have to test the effect of the 
inhibitors in models of challenge with live S. pneumoniae. Also, these biomarkers and the 
effects of PI3K and GSK-3 inhibitors have to be further validated in aged humans. We 
propose an overall model in Figure 7.1 to summarise the findings from the work of this 
thesis. We demonstrate that the cytokine dysregulation in aged macrophage is a factor 
that can possibly account for the inability of macrophages to provide extrinsic support to 
the already intrinsically defective aged B cell resulting in overall impaired B cell function 
which may have a role in the clearance of S. pneumoniae.   
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Figure 7.1: Age-related cytokine dysregulation provides a less robust support for B 
cell humoral response to S. pneumoniae. This can be overcome by inhibiting the 
PI3K-Akt-GSK-3 pathway. 
Upon inhibiting the PI3K-Akt pathway in the presence of TLR-2, 4, and 9 or HKSP the  
cytokine dysregulation in macrophages is reversed and B cells are able to induce AID and 
CSR that may be more effective in pathogen clearance. 
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Appendices 
Appendix A – Purity of splenic macrophages: (A) FACS staining by PE-conjugated 
F4/80 on the Y-axis and X-axis is CD11b  negative. (B) Average purity of 
macrophages from seven experiments. 
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Appendix B - Abbreviations 
AID              activation-induced cytidine deaminase  
AP-1   Activator protein-1 
AAM   alternatively activated macrophages  
BMDM  bone marrow derived macrophages 
BCR    B cell receptor 
BAFF               B cell activating factor 
BLyS                B lymphocyte stimulator 
BAFFR              B cell activating factor receptor 
COX-2  cycloxyenase-2  
CSR    class switch recombination 
CR    complement receptor  
CAM   classically activated macrophages  
CBP   choline binding protein 
CVID   common variable immunodeficiency disease  
CREB   cAMP-response element-binding protein 
DCs   dendritic cells 
DTH              Delayed type hypersensitivity 
ERK   extracellular-signal-regulated kinase 
ELISA   enzyme-linked immunosorbent assay 
FOXO3a   forkhead transcription factor/Forkhead box 3a  
FcγR    Fc γ receptor  
FITC   Fluorescein isothiocyanate (FITC)  
GM-CSF  granulocyte-macrophage colony stimulating factor 
GSK-3   Glycogen synthase kinase-3 
HSC                         Hematopoietic stem cell 
HKSP   Heat killed Streptococcus pneumoniae     
IPD   Invasive pneumococcal disease 
IRAK-4  Interleukin-1 receptor-associated kinase 4 
 IRAK1   Interleukin-1 receptor-associated kinase 1 
IL-1β   Interleukin -1 beta 
IKK   Inhibitor of nuclear factor kappa B kinase 
IRF3   Interferon regulator factor 3 
IFN- γ   Interferon-gamma 
LPS   Lipopolysaccharide 
LY   LY294002  
LTA   Lipoteichoic acid (LTA) 
LRR   leucine-rich repeats 
MyD88   Myeloid differentiation primary response gene 88 
MAPK   Mitogen activated protein kinase 
MDDC  Monocyte derived dendritic cells 
MZ   Marginal zone  
MHC-II   Major histocompatibility complex II 
MPL   Monophosphoryl lipad A sIgA 
NF-ATc   Nuclear factor of activated T cells 
NF-κB                 Nuclear factor kappa B 
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Pam-3-CSK4 N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-C-S-
Lys4  
PMSF    phenyl methyl sulfonyl fluoride 
PBP   penicillin binding protein  
PCV-7   the seven valent conjugate vaccine  
PI3K    phosphatidyl inositol 3-kinase (PI3K)  
PTEN   phosphatase and tensin homolog  
PspA   pneumococcal surface protein A  
PsaA    pneumococcal surface adhesion protein A  
PRR   pattern recognition receptors  
PPS-23   23-valeent pneumococcal polysaccharide vaccine 
PTK              Protein tyrosine kinase   
PKC             Protein kinase C 
pDC   plasmacytoid dendritic cells  
PGE2   prostaglandin E2  
PPS    polysaccharide capsule 
PH   pleckstrin homology domain  
PDK-1                         phosphoinositide-dependent kinase-1                                                           
PAMPs   pathogen associated molecular patterns  
PBM   peripheral blood monocytes 
qRT RT-PCR quantitative real time reverse transcriptase polymerase chain 
reaction 
RPMI    Roswell Park Memorial Institute media 
SAC              Staphylococcus aureus cowan 
SM   splenic macrophages 
S. pneumoniae  Streptococcus pneumoniae  
TCR                   T cell receptor 
TLR   Toll like receptor 
Treg                 regulatory T cells 
TIR     Toll/interleukin-1 (IL-1) receptor homology  
TIRAP   TIR domain containing adaptor protein 
TRIF   TIR domain containing adaptor -inducing interferon-β 
TNP-Ficoll  trinitrophenol conjugated to Ficoll 
 TNP-LPS  trinitrophenol conjugated to LPS  
TICAM1  TIR domain containing adaptor molecule likes MyD88                                                                                                                                         
TRAM   TRIF-related adaptor molecule 
TRAF-6  TNF receptor associated factor-6 
TD   T-cell dependent  
TGF-β    transforming growth factor beta 
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